

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 51/00, A61M 36/14		A1	(11) International Publication Number: WO 97/14445
			(43) International Publication Date: 24 April 1997 (24.04.97)
(21) International Application Number: PCT/US96/16908		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 21 October 1996 (21.10.96)		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(30) Priority Data: 08/545,327 19 October 1995 (19.10.95) US 08/649,782 17 May 1996 (17.05.96) US			
(71) Applicant (for all designated States except US): THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; Suite 300, 3700 Market Street, Philadelphia, PA 19104 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): KUNG, Hank, F. [US/US]; 525 Foxglove Lane, Wynnewood, PA 19096 (US). MEEGALLA, Sanath [LK/US]; 80-7 Drexel Brook Drive, Drexel Hill, PA 19206 (US). KUNG, Mei-Ping [US/US]; 525 Foxglove Lane, Wynnewood, PA 19096 (US). PLÖSSL, Karl [DE/US]; 1406 Hamilton Street, Wilmington, DE 19806 (US).			
(74) Agents: ELDERKIN, Dianne, B. et al.; Woodcock Washburn Kurtz Mackiewicz & Norris, 46th floor, One Liberty Place, Philadelphia, PA 19103 (US).			
(54) Title: DOPAMINE AND SEROTONIN TRANSPORTER LIGANDS AND IMAGING AGENTS			
(57) Abstract <p>This invention presents a series of novel tropane-based derivatives complexed with either technetium or rhenium that are specific for central nervous system receptors, in particular, dopamine or serotonin receptors. The compounds of the invention have utility, <i>inter alia</i>, as imaging agents for CNS receptors. Methods of using these novel compounds as imaging agents are presented, as are intermediates and methods for making these novel compounds.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

DOPAMINE AND SEROTONIN TRANSPORTER LIGANDS AND IMAGING AGENTS

RELATED CASES

This patent application is a continuation-in-part application of United States
5 patent application serial number 08/545,327 filed on October 19, 1995.

FIELD OF THE INVENTION

This invention relates to novel tropane-based ligands that display selective
binding to central nervous system receptors, such as dopamine and serotonin
transporters (reuptake sites), and have utility, *inter alia*, as imaging agents for the
10 central nervous system. Also within the scope of this invention are methods for
utilizing these ligands as diagnostic agents. Methods for preparing the novel ligands of
the invention and intermediates useful in their preparation are also presented.

GOVERNMENT SUPPORT

The work reported herein was supported in part by National Institute of Health
15 NS-18509 and NS-24538.

BACKGROUND

Neural transmitters are chemicals in the brain that are used to send messages
from one brain cell to another. Neurotransmitters bind to special receptor proteins in
the membranes of nerve cells, like a lock in a key, triggering a chemical reaction
20 within the cell. Dopamine is an example of a central nervous system (CNS)
neurotransmitter.

Dopamine is a catecholamine belonging to a class of biogenic amine
neurotransmitters, along with norepinephrine, serotonin, and histamine. The

- 2 -

catecholamines (particularly dopamine and serotonin) are involved in the control of movement; mood; attention; and possibly, certain endocrine, cardiovascular, and stress responses. Imbalances in neurotransmitter production have been implicated in a variety of mental and physical disorders, such as Parkinson's disease (PD). It is thus desirable
5 to diagnose and monitor such imbalances and to monitor the effectiveness of drugs and substances that affect brain chemistry.

New and powerful imaging methods that enable one to assess the living brain *in vivo* and thereby monitor brain chemistry and the effectiveness of drugs and substances that affect brain chemistry have been developed. Methods such as positron
10 emission tomography (PET) and single photon emission computed tomography (SPECT) involve administering to a patient a radioactive tracer substance comprising a ligand that binds to the presynaptic or postsynaptic neuroreceptors in the patient's brain. Emissions (primarily gamma rays are emitted from the positrons or photons from the radioactive tracer) are measured. These emissions are indicative of the
15 number and degree of occupancy of blocking of the neuroreceptors. The number of neuroreceptors and the degree of occupancy or blocking is calculated utilizing a mathematical model, and compared with an intra-person or inter-person control to determine the degree of drug response. Further treatment of the patient with drugs is based on the comparisons made. For these methods to be useful, however, a ligand
20 that has a high specificity and affinity for the desired receptor is required.

It is believed that certain radioactive ligands may be selective for dopamine transporters and are thus potentially useful in evaluating changes in dopamine function *in vivo* and *in vitro*, especially for patients with Parkinson's disease (PD), which is characterized by a selective loss of dopamine neurons in the basal ganglia and
25 substantia nigra. Recently, a large number of dopamine transporter imaging agents based on cocaine or its closely related congeners, tropane derivatives, have been reported. (Carroll, F. I., *et al*, *Med. Res. Rev.* 1995, 15, 419-444; Carroll, F. I., *et al.*, *J. Med. Chem.* 1994, 37, 2865-2873; Carroll, F. I., *et al.*, *J. Med. Chem.* 1995, 38, 379-388). The regional brain distribution of cocaine is largely concentrated in the
30 basal ganglia, where the dopamine neurons are located. [¹¹C]-N-methyl labeled cocaine (Yu, D.-W., *et al.*, *J. Med. Chem.* 1992, 35, 2178-2183; Fowler, J. S., *et al.*, *Synapse* 1992, 12, 220-227) is a very useful PET (positron emission computed

- 3 -

tomography) ligand for studying the pharmacology and drug effects of cocaine itself; however, additional modifications on the cocaine molecule have led to development of positron emission tomography (PET) imaging agent, CFT (WIN35,428) (Clarke, R.L. *et al. J. Med. Chem.* 1973, 16, 1260-1267; Clarke, R.L. *et al. J. Med. Chem.* 1978, 21, 1235-1242; Frost, J. J., *et al., Ann. Neurol.* 1993, 34, 423-431; Wong, D. F., *et al., Synapse* 1993, 15, 130-142), and single photon emission computed tomography (SPECT) imaging agents β -CIT (Innis, R. B., *et al., Proc. Natl. Acad. Sci. U.S.A.* 1993, 90, 11965-11969; Seibyl, J. P., *et al., J. Nucl. Med.* 1996, 37, 222-228; Kuikka, J. T., *et al., Eur. J. Nucl. Med.* 1995, 22, 682-686; Neumeyer, J. L., *et al., J. Med. Chem.* 1994, 37, 1558-1561.), IPT (Goodman, M. M. *et al. J. Med. Chem.* 1994, 37, 1535-1542; Mozley, P. D., *et al., J. Nucl. Med.* 1996, 37, 151-159), and other related derivatives that display much higher binding affinity and selectivity to dopamine reuptake sites. Both of the agents for PET and SPECT imaging displayed excellent specific uptake in the striatum (basal ganglia) area and are more suitable than GBR12,935 in imaging dopamine reuptake sites (dopamine transporters). (Kilbourn, M. R., *Life Sci.* 1988, 42, 1347-1353). The dopamine reuptake site ligands are useful in evaluating changes in dopamine reuptake sites *in vivo* and *in vitro*, especially for patients with PD. Recent publications describing the use of [^{11}C]-CFT (WIN35,428) (Frost, J. J., *et al., Ann. Neurol.* 1993, 34, 423-431) and [^{123}I]- β -CIT (Innis, R. B., *et al., Proc. Natl. Acad. Sci. U.S.A.* 1993, 90, 11965-11969; Innis, R. B., *Eur. J. Nucl. Med.* 1994, 21, 1-5) suggest a strong correlation between the decrease in localization of dopamine transporters in the anterior putamen area and PD symptoms.

Currently, PET and SPECT imaging studies of dopamine transporters are under investigation. Recent publications using [^{11}C]-CFT and [^{123}I]- β -CIT suggest a strong correlation between the decrease in localization in the anterior putamen area and PD symptoms. See Innis, R. B. *et al. Proc. Natl. Acad. Sci. U.S.A.* 1993, 90, 11965-11969; Innis, R. B. *Eur. J. Nucl. Med.* 1994, 21, 1-5; Frost, J. J. *et al. Ann. Neurol.* 1993, 34, 423-431, the disclosures of which are herein incorporated by reference in their entirety.

Central nervous system (CNS) receptor function has also been successfully evaluated *in vivo* using C^{11} ($T_{1/2}$ = 20 minutes, β +) or F^{18} ($T_{1/2}$ = 120 minutes, β +) labeled agents for positron emission tomography (PET) imaging and ^{123}I ($T_{1/2}$ = 13

- 4 -

hours, 159 KeV) labeled agents for single photon emission computed tomography (SPECT) imaging. See Eckelman, W. C. *Nucl. Med. Biol.* 1992, 18, iii-v; Fowler, J. S. et al. *Ann. Rep. Med. Chem.* 1989, 24, 277-286; Fowler, J. S. et al. *Ann. Rep. Med. Chem.* 1990, 25, 261-268, the disclosures of which are herein incorporated by reference in their entirety.

A ligand that is being widely investigated as an agent for diagnosing and treating PD patients is [^{123}I]-CIT. However, one of the drawbacks of [^{123}I]- β -CIT is the length of time (> 18 hours) required for reaching optimal uptake ratio in the target area (semi-equilibrium state) (the basal ganglia (BG)) versus the nontarget area (the frontal cortex (CTX)). Because of the need for agents with faster equilibrium times, new ligands such as [^{123}I]-IPT (N-(3-iodopropen-2-yl)-2 β -carbomethoxy-3 β -(4-chlorophenyl)tropane) and [^{123}I]- β -CIT-FP are under investigation, both of which reach equilibrium in less than one hour. See Kung, M.-P. et al. *Synapse* 1995, 20, 316-324; Malison, R. T. et al. *J. Nucl. Med.* 1995, in Press; Mozley, P. D. et al. *J. Med. Chem.* 1994, 37, 1558-1561, the disclosures of which are herein incorporated by reference in their entirety.

Despite the success in developing such new techniques using PET and SPECT for imaging CNS receptors, their use in routine procedures is hampered by the cost ([^{123}I] costs about \$30/mCi) and the limited supply of the three isotopes mentioned above, ^{123}I , ^{11}C , and ^{18}F , all of which are produced by cyclotron.

A radionuclide that is widely used in diagnostic nuclear medicine is technetium [$^{99\text{m}}\text{Tc}$] ($T_{1/2} = 6$ hours, 140 KeV). It is well established that when Tc-99m pertechnetate (TcO_4^-), the most commonly available starting material, is reduced in the presence of a reducing agent, such as stannous chloride, and a "soft" chelating ligand, including N_2S_2 and NS_3 , a [$\text{Tc}^{\text{IV}}\text{O}$] $^3+\text{N}_2\text{S}_2$ or [$\text{Tc}^{\text{IV}}\text{O}$] $^3+\text{NS}_3$ center core is formed. Technetium [$^{99\text{m}}\text{Tc}$] is readily produced by a [$^{99\text{m}}\text{Tc}$]/Mo-99 generator, and its medium gamma-ray energy emission (140 KeV) is suitable for gamma camera detection with a far less cost (\$1/mCi). In the past ten years, significant progress has been made in defining technetium chemistry using the chemical level of [^{99}Tc] ($T_{1/2} = 2.1 \times 10^5$ yr), and non-radioactive rhenium as a surrogate substitute, that will potentially benefit millions of patients who receive [$^{99\text{m}}\text{Tc}$] agents for routine nuclear medicine diagnosis. Over 85% of the routine nuclear medicine procedures currently performed use

radiopharmaceutical methodologies based on [^{99m}Tc]. In addition, comparable rhenium complexes labeled with [^{186}Re] ($T_{1/2} = 90$ hours) or [^{188}Re] ($T_{1/2} = 17$ hours) may also be potentially useful for *in vivo* imaging of dopamine transporters.

The potential of developing [^{99m}Tc] labeled agents for CNS receptor imaging is well recognized. Several recent reports demonstrate that it is possible to incorporate [TcVO] $^3 + \text{N}_2\text{S}_2$ (bisaminoethanethiol, BAT) into potential receptor selective imaging agents for muscarinic receptors, vesamicol sites, and steroid hormone receptors. See Del Rosario, R. B. *et al. Nucl. Med. Biol.* 1994, 21, 197-203; Chi, D. Y. *et al. J. Med. Chem.* 1994, 37, 928-935; DiZio, J. P. *et al. Bioconj. Chem.* 1991, 2, 353-366; DiZio, J. P. *et al. J. Nucl. Med.* 1992, 33, 558-569; O'Neil, J. P. *et al. Inorg. Chem.* 1994, 33, 319-323; O'Neil, J. P. *et al. Bioconj. Chem.* 1994, 5, 182-193; Jurisson, S. *et al. Chem. Rev.* 1993, 93, 1137-1156; Jurisson, S. S. *et al. Nucl. Med. Biol.* 1995, 22, 269-281; Jurisson, S. *et al. Chem. Rev.* 1993, 93, 1137-1156; Steigman, J. *et al. National Academy Press: Washington, D.C.* 1992; Lever, S. Z. *et al. Nucl. Med. Biol.* 1994, 21, 157-164; Chi, D. Y. *et al. Am. Chem. Soc.* 1993, 115, 7045-7046, the disclosures of which are herein incorporated by reference in their entirety. However, these [^{99m}Tc] imaging agents have demonstrated limited success in *in vivo* studies, this is believed to be attributable to the low initial brain uptake and poor selective binding to the receptor after attaching the molecules with [^{99m}Tc].

Recently, a series of neutral and lipophilic conjugated complexes, containing N-alkylthiolatotropane, aminobisethylthiolato and a [^{99m}Tc]TcO $^3+$ center core, were prepared and evaluated as CNS dopamine transporter imaging agents in rats (Meegalla, S. K., *et al., J. Am. Chem. Soc.* 1995, 117, 11037-11038). One of the compounds, [^{99m}Tc] technetium, [methyl 3-(4-chlorophenyl)-8-(2-mercaptoethyl)-8-azabicyclo [3.2.1]octane-2-carboxylato-S][[2,2'-(methylimino) bis[ethanethiolato]](2-)-N,S,S']oxo, displayed low initial uptake in rat brain (0.1% at 2 minutes post intravenous injection), but the striatal/cerebellar (ST/CB) ratio reached 3.50 at 60 minutes after an intravenous injection. The Rhenium complexes were also discussed. These neutral [^{99m}Tc] labeled three plus one complexes designed for brain imaging, as well as mixed-ligand, aminothiol plus aminothiol complexes (two plus two complexes) designed as [^{99m}Tc] steroid analogs are quite stable *in vivo* and *in vitro*. However, since these agents are

- 6 -

not designed to cross the blood-brain barrier, they are inferior for imaging CNS receptors, such as dopamine and serotonin.

Technepine compounds containing technetium and rhenium have been investigated as potential dopamine transporter agents. Madras, B. K., *et al.*, *Synapse* 5 1996, 22, 239-246. These compounds showed poor biodistribution, which is believed to be a result of the amide moiety present on the N_2S_2 ligand.

Despite its attractive physical properties, technetium is a difficult element for designing suitable SPECT ligands. Technetium is a transition metal and requires a complexing agent to stabilize it at different valence states. Steigman, 1992, *supra*. 10 Valance states can vary from plus 7 (as pertechnetate) to zero (0), depending on the reaction conditions and chelating agents used during preparation. After complexation, the molecules invariably become big and bulky, which is the limiting factor in designing a molecule targeted to a specific biological process(es). Additional requirements for Tc-99m labeled complexes as CNS receptor imaging agents are: i) 15 small (molecular weight < 750), with good lipophilicity (partition coefficient ~ 50-1,000); ii) high binding affinity (K_d < 10 nM) and high selectivity; iii) minimum brain uptake in rats should be 0.5% dose/organ at 2 minutes post intravenous injection.

The [^{99m}Tc] brain imaging agents that have been developed thus far have been aimed at measuring perfusion or its changes due to a particular disease state, and not as 20 diagnostics directed to evaluating neuronal functions, such as the biochemistry of dopamine or serotonin receptors. See Mastrostamatis, S. G. *et al.*, *J. Med. Chem.* 1994, 37, 3212-3218; Spies, H. *et al.*, *Technetium and Rhenium in Chemistry and Nuclear Medicine*, 1995, 4, 243-246; S. G. Editoriali, Ed.: Padova, Italy 1995, 4, 243-246; Spies, H. *et al.* *Angew. Chem. Int. Ed. Engl.* 1994, 33, 1354-1356; Chi, D. 25 Y. *et al.* *J. Amer. Chem. Soc.* 1993, 115, 7045-7046; Chi, D. Y. *et al.* *J. Med. Chem.* 1994, 37, 928-935, the disclosures of which are herein incorporated by reference in their entirety.

Thus, there remains a need for new imaging agents, such as CNS receptor-based imaging agents, for evaluating neuronal functions that do not present the 30 problems associated with prior agents, as discussed above. These agents should have good selectivity, affinity, and specific activity for the target. Several additional factors are also of importance such as radiochemistry (preparation time for short-lived labeled

- 7 -


agents), suitable modeling for kinetics of receptor uptake and retention, and metabolism. The imaging agents should also be economical and readily available.

The present invention addresses these, as well as other needs, by providing novel tropane-based technetium- or rhenium- labeled imaging agents useful, *inter alia*, for imaging the CNS, in particular dopamine and serotonin receptors, to diagnose CNS abnormalities. It is also expected that the novel compounds of the invention possess pharmacological activity. It is believed that the compounds of the invention are the first imaging agents of their kind displaying specific regional uptake directly proportional to dopamine neuronal distribution in the brain.

10 SUMMARY OF THE INVENTION

This invention presents, *inter alia*, a novel class of technetium- or rhenium-labeled dopamine or serotonin transporters imaging agents based on a tropane core. The compounds of the invention transfer through the blood brain barrier, which makes them good candidates for diagnostic and therapeutic agents for the central nervous system.

In one aspect of this invention, the compounds of the invention have the following general formula (I):




I

wherein X is selected from the group consisting of H, C₁-C₄ alkyl, F, Cl, Br, and I; Q is selected from the group consisting of H, C₁-C₅ alkyl, A₁, A₂, A₃, A₄, A₅, A₆, A₇, and A₈; Z is selected from the group consisting of R, CONRR₁, COR₁, CO₂R₁, CO₂R₂, CO₂A₁, CO₂A₂, CO₂A₃, CO₂A₄, CO₂A₅, CO₂A₆, CO₂A₇, CO₂A₈, COA₁, COA₂, COA₃, COA₄, COA₅, COA₆, COA₇, COA₈, C OO2, CH₂OA₃, CH₂OA₄, CH₂OA₅, CH₂OA₆, CH₂OA₇, CH₂OA₈, CH₂NHA₁, CH₂NHA₂, CH₂NHA₃, CH₂NHA₄, CH₂NHA₅, CH₂NHA₆, CH₂NHA₇, CH₂NHA₈, A₁, A₂, A₃, A₄, A₅, A₆, A₇, and A₈; Y is -(CH₂)_n; R is H, C₁-C₅ alkyl; R₁ is H, C₁-C₅ alkyl; R₂ is a heterocyclic amine;


- 8 -

CH_2NHA_5 , CH_2NHA_6 , CH_2NHA_7 , CH_2NHA_8 , A_1 , A_2 , A_3 , A_4 , A_5 , A_6 , A_7 , and A_8 ; Y is $-(\text{CH}_2)_n$; R is H, C_1 - C_5 alkyl; R_1 is H, C_1 - C_5 alkyl; R_2 is a heterocyclic amine;


A_1 is




A_2 is




5 A_3 is




A_4 is




A_5 is




A_6 is



A_7 is




10 A_8



E is C_1-C_2 alkyl; n is 0, 1, 2, 3, 4, 5; M is selected from the group consisting of Tc and Re; R_3 is selected from the group consisting of H, CR_4 , substituted or unsubstituted C_1-C_3 alkoxy, substituted or unsubstituted C_6-C_{24} aryl, and substituted or unsubstituted phenylalkoxy; and R_4 is selected from the group consisting of H and C_1-C_3 alkyl, optionally substituted with a substituted or unsubstituted phenyl group; provided that, one of Q and Z, and only one of Q and Z, includes a moiety selected from the group consisting of A_1 , A_2 , A_3 , A_4 , A_5 , A_6 , A_7 , and A_8 .

The compounds of the invention include compounds that comprise an N_2S_2 ligand (bis-aminoethanethiol) in which the ligand complexes with either the technetium or rhenium, or "three plus one complexes" (NS_3) where a tropane thiolate and an aminobisethanethiolate ligand are involved in complexation. In one series of the N_2S_2 complexes, the N_2S_2 ligand is attached to the 2β position of the tropane core, at the Z position of Formula I. In another series of the N_2S_2 complexes, the N_2S_2 ligand is attached to the bridge head nitrogen of the tropane core. The "three plus one complexes" may have the ligand attached to either the 2β position of the tropane core or the bridge head nitrogen of the tropane core.

This invention further relates to compounds that are useful, *inter alia*, as intermediates for preparing the compounds of the invention. For example, compounds having the following general Formula II, are useful, *inter alia*, as intermediates for preparing certain three plus one complexes of the invention. A compound of Formula II has the following general formula:



II

wherein E is C_1-C_2 alkyl.

A compound of Formula II can be used in combination with a compound of Formula I wherein X is C_1-C_4 alkyl, F, Cl, Br, or I; Q is A_8 , wherein Y is $-(CH_2)_n-$ and n is 0, 1, 2, 3, 4, or 5; and Z is CO_2R_1 or CO_2R_2 , wherein R_1 is C_1-C_3 alkyl and R_2 is a heterocyclic amine.

The compounds of Formula I, where A_n is A_8 , and the compounds of Formula II are useful, *inter alia*, as intermediates for preparing certain three plus one complexes

- 10 -

of the invention, and further useful as kit components. Kits comprising these compounds and kits comprising other Formula I compounds are also within the scope of this invention.

In other aspects of the invention, methods of utilizing the novel ligands of the invention in diagnostic imaging techniques are presented.

Test results indicate that the novel ligands of the invention are highly selective for CNS receptors, particularly dopamine receptors, which make these compounds useful, when appropriately labelled, as imaging agents for the evaluation of such receptors. The compounds of the invention should also have pharmacological activity associated with such CNS receptors as a result of their high selectivity.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts a general reaction scheme that may be used for synthesizing compounds of Formula I comprising a two plus one complex and where the N_2S_2 ligand is attached to the 2β position of the tropane ring via an amide linkage.

Figure 2 depicts a general reaction scheme that may be used for synthesizing compounds of Formula I comprising two plus one complexes and having the N_2S_2 ligand in the 2β position of the tropane ring and two plus one complexes having an amide on the N_2S_2 ligand.

Figure 3 depicts general reaction schemes that may be used for synthesizing two plus one complexes containing either rhenium or technetium and two plus one complexes having an amide moiety on the N_2S_2 ligand.

Figure 4 depicts an HPLC chromatogram of a racemic mixture of a technetium containing compound of the invention.

Figure 5 depicts the ratios of regional brain uptakes at 60 minutes post intravenous injection of [^{99m}Tc]TRODAT-1 (1.19a) in control rats and rats pretreated with haldol (1 mg/kg, iv) or β -CIT (1 mg/kg, iv) 5 minutes prior to radiotracer injection. Values shown are means \pm SD ($n=3-4$, $p < 0.05$, student t-test). ST: striatum; HP: hippocampus; CX: cortex; CB: cerebellum. The ST area, where dopamine transporters are located, displayed selective regional brain uptake, with the highest concentration ratio (ST/CB = 2.6). Pretreatment with β -CIT, which competes

with dopamine transporter binding, showed blocking of the specific uptake of [99mTc]TRODAT-1 (1.19a) in the ST area.

Figure 6 depicts a transaxial, coronal and sagital SPECT images (1.34 mm thick) of monkey brain at 60-90 post-intravenous injection of 9 mCi of [99mTc]TRODAT-1 (1.19a). SPECT images were acquired by a Picker T3000 scanner. The SPECT images were co-registered with the same sections of MRI of the same baboon. A high accumulation of [99mTc]TRODAT-1 (1.19a) was observed in caudate and putamen, areas of the brain where dopamine transporters are concentrated.

Figure 7 depicts a time course of regional brain uptakes as measured by SPECT imaging following intravenous injection of [99mTc]TRODAT-1 (1.19a) in a baboon. Regions of right and left caudat and putamen, cerebellum (CB) is expressed as counts/pixel/minute.

Figure 8 depicts a general reaction scheme that may be used for synthesizing two plus one complexes where the N_2S_2 ligand is connected to the bridge head nitrogen of the tropane core.

Figure 9 depicts a general reaction scheme that may be used for radiolabelling an N_2S_2 ligand.

Figure 10 depicts a reaction scheme that may be used for preparing a rhenium-containing compound of the invention.

Figure 11 depicts HPLC chromatograms of a racemic mixture of an N_2S_2 compound of the invention where the N_2S_2 ligand is attached to the bridge head nitrogen of the tropane core and an HPLC chromatogram of the resolved isomers.

Figure 12 depicts a reaction scheme that may be used for synthesizing a tridentate ligand that is useful as an intermediate for preparing three plus one complexes of the invention.

Figure 13 depicts a reaction scheme that may be used for synthesizing a monothiol compound that is useful as an intermediate for preparing three plus one complexes of the invention.

Figure 14 depicts a reaction scheme for the synthesis of a three plus one complex from Formula II and Formula III intermediates.

Figure 15 depicts an X-ray crystallographic structure of rhenium complex containing a tropane moiety, 3.23. Meegalla, 1995, *supra*.

- 12 -

Figure 16 depicts ratios of regional brain uptakes at 60 minutes post-intravenous injection of 3.25 in control rats and rats pretreated with haldol (1 mg/kg, iv) or β -CIT (1 mg/kg, iv) at 5 minutes prior to radiotracer injection. Values shown are means \pm SD (n=3-4, p < 0.05, student t-test). ST: striatum; HP: hippocampus; 5 CX: cortex; CB: cerebellum. The ST area, where dopamine transporters are located, displayed selective regional brain uptake, with the highest concentration ratio (ST/CB = 2.6). Pretreatment with β -CIT, which competes with dopamine transporter binding, showed blocking of the specific uptake of 3.25 in the ST area, where dopamine transporters are located.

10 Figure 17 depicts an *in vitro* autoradiogram of 3.25 binding to dopamine transporters in a rat brain section demonstrated that it localized in caudate putamen and olfactory tubercle, areas known to have a high dopamine transporter density. A comparable section labeled with [125 I]IPT, a known iodinated dopamine transporter ligand, Kung, 1995, *supra*, showed an almost identical regional labeling pattern. The 15 coronal section of rat brain shown corresponds to Plate 17 in the atlas by Paxinos and Watson. Paxinos, G. *et al.* The Rat Brain In Stereotaxic Coordinates (New York, Academic Press 1986).

Figure 18 is a comparison of HPLC traces of 3.23 (UV) and 3.25 (radio trace) on a C-18 column (Partisil 10-ODS-3, 250 x 4.6 mm) with MeOH/NH₄HCO₃ (0.1M, 20 pH 7, ratio 8:2, flow rate 1 ml/min).

Figure 19 depicts a reaction scheme where the Z moiety of Formula I is an ester moiety.

Figure 20 depicts a reaction scheme where the Z moiety of Formula I is an ether moiety.

25 Figure 21 depicts a reaction scheme where the A moiety of Formula I is in the Z position and the Z moiety is COA₂.

Figure 22 depicts a reaction scheme where the A moiety is in the Z position and the Z moiety is CO₂A₂.

30 Figure 23 depicts a reaction scheme where the A moiety is in the Z position and is connected to the tropane core by an amide linkage.

- 13 -

Figure 24 depicts a reaction scheme where a compound of Formula I is prepared from a direct linkage reaction by eliminating an ester moiety at the Z position.

Figure 25 depicts a reaction scheme for the synthesis of a compound of Formula I using cocaine as a starting material.

DETAILED DESCRIPTION OF THE INVENTION

The term "ligand," as used herein, refers to compounds chelating with a central atom in a complex compound, and may be used generally to refer to the compounds of the invention. It is contemplated that certain of the compounds of the invention may be chiral or have chiral centers and form R and S isomers (enantiomers), which may be resolved, for example, using a chiral HPLC column. The racemic mixtures as well as the resolved isomers of the ligands are within the scope of this invention.

A "complex compound," as used herein, refers to any group of chemical compounds in which part of the molecular bonding is of the coordination type. In the context of this invention, "coordination compound" refers to compounds having a central atom or ion and a group of ions or molecules surrounding it.

In the context of this invention, "tridentate ligand" refers to a chelating agent having three groups capable of attachment to a metal ion. As used herein, the terminology "chelating agent" refers to organic compounds in which atoms form more than one coordinate bond with metals in solvent.

As used herein, the term "alkyl" refers to radicals that are formed from the loss of a hydrogen from an alkane (C_nH_{2n+2}). The alkyl compounds may be straight or branched chain compounds, cyclic or acyclic, and further substituted with hetero atoms (*i.e.*, O, S, N). Also included within this definition are structural isomers (*i.e.*, chain isomers, position isomers, and functional isomers) and stereoisomers (*i.e.*, enantiomers and diastereomers).

In the context of this invention, the term "aliphatic" refers to any carbon-hydrogen containing compounds having either saturated or unsaturated bonds (alkanes, alkenes, alkynes). Such compounds may be cyclic or acyclic, straight or branched chains, and may further be substituted with hetero atoms (*i.e.*, O, S, N). The term

- 14 -

"aromatic," as used herein, refers to any compound that contains at least one benzene ring. The term "aryl," as used herein refers to a compound having at least one benzene radical or benzene ring, and may be substituted with other aliphatic compounds.

5 The terminology, "heterocyclic amines," refers to aliphatic compounds having a ring structure that incorporates other atoms in addition to carbon atoms.

Heterocyclic amines include, without limitation, pyrrole and its derivatives, imidazole and its derivatives, pyridine and its derivatives, pyrimidine and its derivatives, quinioline and its derivatives, piperidine and its derivatives, pyrrolidone and its
10 derivatives, purine and its derivatives, pyrrolidine and its derivatives, and morpholine and its derivatives. Derivatives refers to compounds having the core heterocyclic structure (*e.g.*, pyrrole) substituted with one or more of an aliphatic moiety, aromatic moiety, alkoxy moiety, phenoxy moiety, amine moiety, nitro moiety, nitrile moiety, halogens, or hetero atoms.

15 As used herein, the term "phenoxy" is used in its conventional sense and refers to, generally, phenyl radicals attached to a molecule through an oxygen. It is contemplated that the phenoxy compounds of the invention may be further substituted. Also included within this definition are structural isomers (*e.g.*, chain isomers, position isomers, and functional isomers) and stereoisomers (*e.g.*, enantiomers and
20 diastereomers).

The term "alkoxy," as used herein, is used in its conventional sense and refers to, generally, alkyl radicals attached to a molecule through an oxygen. Alkyl radicals are generally derived from an aliphatic hydrocarbon by removal of one hydrogen atom. It is contemplated that the alkoxy compounds of the invention may be further
25 substituted with, for example, other aliphatic compounds. Also included within this definition are structural isomers (*i.e.*, chain isomers, position isomers, and functional isomers) and stereoisomers (*i.e.*, enantiomers and diastereomers).

The term "substituted," as used herein refers to single or multiple substitutions of a molecule with a moiety or moieties distinct from the core molecule. Substituents
30 include, without limitation, halogens, hetero atoms, nitro moieties, amine moieties, nitrile moieties, hydroxy moieties, alkoxy moieties, phenoxy moieties, other aliphatic

- 15 -

or aromatic moieties. Substituted compounds may be referred to as derivatives of the core structure.

As used herein, the terminology "radionuclide-containing" compound refers to any compound that contains at least one atom of a compound capable of being used in radiopharmaceutical techniques, such as technetium or rhenium. As used herein, "technetium-containing compound" refers to any compound that contains at least one atom of technetium (Tc). In the context of this invention, the term "rhenium-containing compound" refers to compounds having at least one atom of rhenium (Re).

The terminology "protecting group," as used herein, is used in its conventional sense and refers to compounds that are used for blocking reactive sites on a multifunctional molecule to prevent such reactive sites from taking part in a chemical reaction.

In one series of compounds the N_2S_2 ligand is in the 2β position of the tropane core. These compounds may be synthesized by the general reaction schemes shown in Figures 1-3. For example, a ligand, such as 1.16a, 1.16b or 1.17, is dissolved in ethanol and hydrochloric acid. To this is added hydrochloric acid and a reducing agents, such as Sn-glucosheptonate (containing 136 micrograms $SnCl_2$ and 200 micrograms Na-glucosheptonate, pH 6.67) and 50 microliters EDTA solution. [^{99m}Tc]Pertechnetate in saline is then added to the reaction mixture, which is then heated for about 30 minutes at $100^\circ C$. After cooling to room temperature, the reaction mixture is neutralized with a saturated sodium bicarbonate or phosphate buffer solution. It is possible that tropane derivatives containing a bis-aminoethanethiol group will form stereoisomers.

Other methods for preparing these kinds of compounds are depicted in Figures 21-24, but any such methods known to those skilled in the art may be used without departing from the spirit of the invention.

Another series of the two plus one complexes has the N_2S_2 ligand attached to the bridge head nitrogen of the tropane core. These compounds may be prepared according to the general reaction schemes depicted in Figures 8-10. Radiolabeling was achieved by a method similar to that disclosed above in connection with the compounds having the N_2S_2 ligand in the 2β -position of the tropane core. The tropane derivatives

- 16 -

(2.6a) containing a bis-aminoethanethiol group are believed to form stereoisomers. (Table 2.1 a, b, c).

Other methods for preparing these kinds of compounds are depicted in Figures 19, 20, and 25, but any such methods known to those skilled in the art may be used without departing from the spirit of the invention.

The three plus one complexes (NS_3) (those containing, for example, an A_7 moiety) may generally be made from two key intermediates -- a tridentate ligand aminodithiol (Formula II) and a monothiol ligand (Formula I, where Z is A_8), which is particularly applicable when the A_n moiety is in the Q position of Formula I. These intermediates may be prepared by using methods analogous to those in the reaction schemes set forth in Figures 12 and 13. The monothiol intermediate compound can be prepared according to the reaction scheme of Figure 13 or reactions analogous thereto.

Generally, a demethylated tropane derivative is prepared from cocaine in 4 steps, as previously reported. See Meltzer, P. C. *et al. J. Med. Chem.* **1993**, *36*, 855-862, the disclosure of which is herein incorporated by reference in its entirety. N-alkylation of the tropane derivative is achieved by reacting it with a triphenylmethyl thioether (S-trityl) protected 2-bromoethanethiol and 3-bromopropanethiol. Dhar, T. G. M. *et al. J. Med. Chem.* **1994**, *37*, 2334-2342. The protecting group (trityl) may then be cleaved by acid hydrolysis or with heavy metal ions to yield the monothiol ligand of Formula II. See Ohmomo, Y. *et al. J. Med. Chem.* **1992**, *35*, 157-162; Kolb, U. *et al. Inorg. Chem.* **1994**, *33*, 4522-4530; Dhar, 1994, *supra*, the disclosures of which are herein incorporated by reference in their entirety. Any protecting groups known to those skilled in the art may be used without departing from the spirit of the invention.

For example, the particular tropane derivatives of formulas 3.19-3.22 may be prepared as follows: a halogenated nortropane derivative is refluxed with a triphenylalkyl mercapto (trityl) compound to form a protected mercapto halogenated nortropane intermediate. The tritylated nortropane derivative is then dissolved in a suitable solvent system, such as trifluoromethyl carboxylic acid and anisole, followed by the addition of a mercury oxide, such as $Hg(OAc)_2$, to cleave the protecting group. The resultant mixture is stirred at 0°C for 30 minutes. The reaction mixture is then concentrated *in vacuo* to obtain a brownish red oil, which is then dried under high vacuum for 1 hour. Anhydrous ether is then added to the above oil and the mixture is

then sonicated for 15 minutes, followed by magnetic stirring for an additional 30 minutes. This results in the formation of a colorless precipitate, which is then collected by suction filtration. The collected precipitate is then dried under a high vacuum for 15 minutes and then redissolved in ethanol. Hydrogen sulfide gas is then bubbled throughout the ethanol solution for 15 minutes, forming a black precipitate. The resultant black precipitate is then filtered through a thick pad of celite. The resultant filtrate is then concentrated *in vacuo* to obtain a colorless oil, which is then dried in a high vacuum for 30 minutes. An aqueous solution of hydrochloric acid and an aqueous solution of ether is then added to the dried oil and the resulting mixture is vigorously stirred for 15 minutes. The mixture is then transferred to a separating funnel where the aqueous layer is separated and basified with concentrated ammonium hydroxide and the resulting colorless product is extracted with methylene chloride (20 x 2 mL). The methylene chloride layer is then dried with sodium sulfate and concentrated *in vacuo* to yield the desired tropane derivative. Other tropane derivatives of Formula II may be made by analogous methods that would be known to those skilled in the art.

This invention presents a novel series of compounds based on a tropane core, which compounds comprise N_2S_2 ligands and three plus one complexes that comprise an NS_3 ligand.

Tridentate ligand aminodithiol intermediates, Formula II, can be synthesized according to the reaction scheme of Figure 12 or reactions analogous thereto.

In certain preferred embodiments the aminobisethanethiol ligand has gem-dimethyl groups, 3.6, and can be synthesized according to methods known in the art, as shown in Figure 12. See, e.g., Ohmomo, 1992, *supra*, the disclosures of which are herein incorporated by reference in their entirety. The aminobisethanethiol ligand without gem-dimethyl groups, 3.7, can be synthesized according to methods known in the art. Kolb, 1994, *supra*, the disclosures of which are herein incorporated by reference in their entirety. The N-ethyl substituted aminobisethylthiols, 3.8, may be prepared according to the procedure employed for the synthesis of 3.7, using N-ethyl bischloroethyl amine as the starting material. The other N-substituted bisethanethiols, 3.9 to 3.12, may be prepared by bis-alkylation of benzyl-, iso-butyl-, morpholinoethyl- and (N,N-bisethylamino)ethyl-amine with ethylene sulfide, respectively, as disclosed in

Corbin, 1984, *supra*, the disclosures of which are herein incorporated by reference in their entirety.

In certain preferred embodiments the tridentate ligand aminodithiol (Formula II) will be N,N-di[(2-(4'-methoxybenzylthio)-2-methylpropyl)] amine (3.4). This can
5 be prepared by adding a solution of $\text{BH}_3 \cdot \text{THF}$ to a solution of N-[(2-(4'-methoxybenzylthio)-2-methylpropyl)] 2-(4'-methoxybenzylthio)-2-methyl-propionamide (3.3), and heating the resultant mixture at reflux under nitrogen gas for 12 hours. The reaction mixture is then cooled in an ice bath, and water is carefully added. The resulting solution is then concentrated *in vacuo* to obtain a viscous oil that is suspended
10 in hydrochloric acid. This mixture is then heated at reflux for 1 hour. The reaction mixture is then cooled in an ice bath and then basified with concentrated ammonium hydroxide. The product (3.4) is then extracted with methylene chloride and purified on silica.

In other preferred embodiments the tridentate ligand aminodithiol (Formula II)
15 is N,N-di[(2-(4'-methoxybenzylthio)-2-methylpropyl)]-methyllamine (3.5). This can be prepared by adding NaBH_3CN to a solution of compound 3.4 and methanol in acetonitrile. The resulting mixture is then stirred for 15 minutes and glacial acetic acid is added dropwise until the solution tests neutral. The mixture is then stirred for 45 minutes and the solvents are removed. Potassium hydroxide is then added to the
20 residue, and the resulting mixture is extracted with ether (3 x 10 mL). The ether extracts are combined and washed with potassium hydroxide and then extracted with hydrochloric acid. The acid extracts are combined and neutralized with solid potassium hydroxide and then re-extracted with ether (3 x 10 mL). The ether layers are combined and concentrated *in vacuo* to obtain a viscous oil (3.5), which is purified on silica.

25 In certain other preferred embodiments, the tridentate ligand aminodithiol (Formula II) is N,N-di[(2-mercapto)-2-methylpropyl)]-methyllamine (3.6). This compound can be prepared by mixing the amine compound 3.5 and anisole in trifluoroacetic acid and cooling to 0°C . Then $\text{Hg}(\text{OAc})_2$ is added and the mixture stirred at 0°C for 15 minutes and concentrated *in vacuo* at room temperature. The
30 residue is then dried under a high vacuum for 30 minutes and dry ether is added. The resulting solid is then collected by suction filtration and redissolved in ethanol. Hydrogen sulfide gas is then bubbled through the ethanol solution for 15 minutes and

the black precipitate that forms is then filtered through a thick pad of celite. The filtrate is concentrated *in vacuo* to obtain a colorless oil that is then dried under a high vacuum for 30 minutes. Hydrochloric acid and ether are added to the oil, and the resulting mixture is vigorously stirred for 15 minutes and then transferred to a separating funnel. The aqueous layer is separated and is then basified with concentrated ammonium hydroxide, and the resulting colorless product is then extracted with methylene chloride (20 x 2 mL). The methylene chloride layer is then dried in sodium sulfate and then concentrated *in vacuo* to obtain a viscous oil (3.6) which is then stored under a blanket of argon.

10 Other tridentate ligand aminodithiols of Formula II for use as intermediates in preparing other compounds of Formula I, may be prepared by analogous methods that would be known to those skilled in the art.

The dithiols seem to have only moderate stability and tend to produce a white solid, presumably disulfides, over time. However, the monothiols, 3.15-3.18, seem to have fairly good stability when stored at a low temperature under N₂. The X-ray crystallographic structure of the Re-complex 3.23 (Figure 15), shows that none of the reaction conditions employed in preparation of the monothiols 3.15-3.18 and the Re complex altered the stereochemistry at the C-2 position of tropane ring.

The compounds of Formula I comprising a three plus one complex may be synthesized by using the monothiol intermediate and tridentate aminodithiol intermediate (Formula II) in methods analogous to those illustrated in the general reaction scheme of Figure 14.

Other compounds of Formula I where Z is an ester moiety and the A_n moiety is in the Q position may be synthesized according to the general reaction scheme depicted in Figure 19 or ones analogous thereto.

Other compounds of Formula I where Z is an ether moiety and the Aⁿ moiety is in the Q position may be synthesized according to the general reaction scheme depicted in Figure 20 or ones analogous thereto.

In other embodiments of the invention, Z is COA₂ and may be prepared according to the general reaction scheme depicted in Figure 21 or methods analogous thereto.

- 20 -

Generally, methods of making compounds of the invention having an ether linkage couple an alcohol and a halide using NaH.

In certain other embodiments, Z is CO_2A_2 and may be prepared according to the general reaction scheme depicted in Figure 22 or ones analogous thereto. In addition to the ester linkage described above and in Figure 22, amide linkages are also contemplated and may be synthesized according to the general reaction scheme depicted in Figure 12 or ones analogous thereto.

Other illustrative synthetic methods include those using a direct linkage and elimination of the ester functional group as depicted in Figure 23. See, e.g., Kung, H. F. *et al.*, *Nucl. Med. Biol.*, 1991, 18, 215-226 (Reference A); and Kozikowski, A. P. *et al.*, *J. Med. Chem.*, 1995, 38, 3086-3093 (Reference B), the disclosures of which are herein incorporated by reference in their entirety.

Persons skilled in the art, once armed with the present disclosure, will be able to select the appropriate starting materials and prepare any of the claimed compounds of the invention.

The compounds of this invention lend themselves easily to the formation from materials that may be assembled in kit form and provided to users. When the novel compounds of the invention are to be used as diagnostic tools, such as imaging agents, the compounds are labeled with a radionuclide, such as technetium. Kits for forming the three plus one complex imaging agents of the invention may contain, for example, a lyophilized composition comprising the tridentate ligand aminodithiol (Formula II) and the monothiol ligand (Formula I, where Z is A_3), a reducing agent, preferably the lyophilized composition is a powder. A user would dissolve the lyophilized composition comprising the tridentate ligand aminodithiol and the monothiol ligand in saline and hydrochloric acid. A reducing agent, such as stannous glucoheptonate, and sodium [$^{99\text{m}}\text{Tc}$] pertechnetate, in saline solution is then added to the mixture. The mixture is then kept at room temperature for about 30 minutes. This is followed by neutralizing the reaction mixture with sodium carbonate. The resulting compounds are extracted into ethyl acetate and the compounds are purified by HPLC.

Preferred compounds of Formula II for inclusion in the kits of the invention are those where, independently or in combination, A is Cl or FI; B is A_6 ; and D is CO_2R_5 , wherein R_5 is $\text{C}_1\text{-C}_5$ alkyl, or CO_2R_2 , wherein R_2 is a heterocyclic amine.

- 21 -

Preferred compounds of Formula II for inclusion in the kits are those where E is C₁-C₂ alkyl.

Reducing agents suitable for practicing this invention include, but are not limited to, stannous glucoheptonate, stannous chloride, sodium bisulfite, or combinations thereof, with stannous glucoheptonate being preferred. Any other reducing agents known to those skilled in the art may be used without detracting from the spirit of the invention.

Radionuclide-containing compounds suitable for practicing this invention include, but are not limited to, sodium [^{99m}Tc] pertechnetate (Na^{99m}TcO₄), and sodium 10 pertechnetate (NaReO₄), with sodium [^{99m}Tc] pertechnetate (Na^{99m}TcO₄) being preferred. Other radionuclide-containing compounds known to those skilled in the art may be used without detracting from the spirit of the invention.

Kits containing N₂S₂ (bis-aminoethanethiol) complexes are also within the scope of the invention. These kits would generally comprise a lyophilized powder of a 15 N₂S₂ compound, stannous chloride, sodium glucoheptonate, EDTA, hydrochloric acid, and ethanol. A user would dissolve the lyophilized compound ethanol and hydrochloric acid. A reducing agent, such as stannous glucoheptonate, and sodium [^{99m}Tc] pertechnetate, and EDTA is added to the mixture. The mixture is then autoclaved for about 30 minutes. After the autoclaving, the mixture is allowed to cool 20 to room temperature. The amount of the solution necessary for analysis is mixed with sodium phosphate before use. The information discussed above in connection with the three plus one complexes is applicable here.

For dopamine transporter imaging agents, the target area of the brain is the striatum, where dopamine transporters are highly concentrated. The cerebellum region 25 is suitable for use as the background region, because it has no dopamine transporters. The specific uptake is measured by the ratio of % dose/gram of striatum divided by % dose/gram of cerebellum (ST/CB ratio)--the higher the value, the better the specific uptake, and the more promising as a dopamine transporter imaging agent.

When using the compounds of the invention as diagnostic agents (such as in 30 imaging techniques) or as therapeutic agents, it is preferable to keep the Tc or Re complex core of the compounds of the invention small. There are stringent structural requirements for achieving both neutral-lipophilicity and dopamine transporter binding

- 22 -

affinity for this series of tropane derivatives. The addition of gem-dimethyl groups to a compound of Formula I, dramatically enhances lipophilicity and significantly reduces specific binding to the striatal regions of the brain, where dopamine reuptake sites are located. Fine tuning of size and lipophilicity of technetium or rhenium complexes appears to be important for brain uptake and receptor binding. It is also important that the compounds of the invention have a neutral charge for them to be able to cross into the brain, and therefore, it is preferable that only one nitrogen on the tropane core be substituted. It is also preferable that the CO_2R moiety (Z) and the halogenated phenyl moiety (X) be in the beta position. The examples show that substitution of the N_2S_2 moiety (A_n moiety) with gem-dimethyl groups destroys the specificity of the compound (Table 3.1), same is true when the N of the A_n moiety is substituted with groups larger than C_3 or with additional amino groups (Table 3.1). Both of these observations are not readily predictable by simple estimation of partition coefficient or molecular weight or size. The partition coefficient value is also very important for the evaluation of potential brain imaging agents, because they must be neutral and lipophilic in order to penetrate the intact blood-brain barrier. Generally, the optimal range of partition coefficient values for good brain uptake are between 100-1000. Apparently, the *in vivo* biodistribution and receptor binding site for dopamine transporters place unique and highly selectively requirements on this novel groups of agents.

Certain preferred Formula I compounds useful as imaging agents are those comprising a three plus one complex as the ligand and where, independently or in combination, Q or Z includes a compound selected from the group consisting of an A_7 or A_8 moiety or groups including an A_7 or A_8 moiety; X is Cl or Br; Z is CO_2R_1 or CO_2R_2 ; and E is C_1 - C_2 alkyl. A preferred compound is one where X is Cl; Q is A_7 or A_8 and n is 2; M is Tc; and Z is CO_2CH_3 . Other preferred compounds are those where X is Cl; Q is A_7 or A_8 and n is 2; M is Tc; and Z is CO_2R_2 , wherein R_2 is piperidine, pyrrolidine, or morpholine. Still other preferred compounds are those where X is Br; Q is A_7 or A_8 and n is 2; M is Tc; and Z is CO_2CH_3 . Other preferred compounds are those where X is Br; Q is A_7 or A_8 and n is 2; M is Tc; and Z is CO_2R_2 , wherein R_2 is piperidine, pyrrolidine, or morpholine.

In other preferred embodiments the Formula I compounds useful as imaging agents are those comprising an N_2S_2 ligand in which the ligand is attached to the

bridgehead nitrogen of the tropane core, and where X is C₁-C₄ alkyl, F, Cl, Br, or I; Q is A₁, A₂, A₃, or A₄; Z is CO₂R₁, or CO₂R₂. In other preferred embodiments X is Cl or Br; Q is A₂ and n is 2; Z is CO₂CH₃; and M is Tc. Other preferred
5 embodiments are those where X is Cl or Br; Q is A₁ and n is 2; Z is CO₂CH₃; and M is Tc. In still other preferred embodiments, X is Cl or Br; Q is A₂ and n is 2; Z is CO₂R₂, wherein R₂ is piperidine, pyrrolidine, or morpholine; and M is Tc. In still other preferred embodiments, X is Cl or Br; Q is A₁ and n is 2; Z is CO₂R₂, wherein R₂ is piperidine, pyrrolidine, or morpholine; and M is Tc. The Tc-99m labeled tropane derivative, 2.6a, displayed a significant brain uptake and specific uptake to the striatum
10 area of the rat brain. This compound showed a distinctive difference from both the prior art, technepine, and 3.25.

Particularly preferred Formula I compounds are those comprising an N₂S₂ ligand (bis-aminoethanethiol) where the ligand is attached to the 2β position of the tropane core, and where X is C₁-C₄ alkyl, F, Cl, Br, or I; Z is A₁, A₂, A₃, or A₄; Y is
15 -(CH₂)_n; R₃ is H; and Q is H or C₁-C₄ alkyl; and M is Tc. A particularly preferred compound is one where Q is CH₃, X is Cl; Z is A₃ or A₄; and Y is CH₂. A particularly preferred compound is one where Q is CH₃, X is Br; Z is A₃ or A₄; and Y is CH₂. Another preferred compound is one where Q is CH₃, X is Br, Z is A₁ or A₂, and Y is CH₂. Another preferred compound is one where Q is CH₃, X is Cl, Z is A₁
20 or A₂, and Y is CH₂. Experimental data, as discussed in Example 12, demonstrates that chemical compounds 1.19a, and 1.20a having an A₂ moiety are particularly useful dopamine transporter imaging agents.

This novel series of N₂S₂ compounds differ from those previously reported in that the substitution of the bis-aminethanethiol ligand is attached at the 2β-position of
25 the tropane core structure. The corresponding Tc-99m labeled agent displayed a three- to fourfold increase in initial brain uptake (0.1% for N-substituted compound (Meegalla, *supra*) vs. 0.3-0.4% in brain at 2 minutes post-injection) and concomitantly retained the specific uptake in the striatum area of the brain. This observation suggests that, in this series of compounds, the 3β-p-fluoro- is slightly less favorable than the
30 corresponding 3β-p-chlorophenyl derivative. As previously reported for the same series of tropane derivatives, the 3β-p-fluoro- derivative displayed a lower brain uptake,

- 24 -

which may be due to its lower binding affinity to dopamine transporters. Carroll, 1995, *supra*.

Pharmaceutical formulations of the novel ligands of the invention are also within the scope of this invention. Pharmaceutically acceptable diluents suitable for practicing this invention include, but are not limited to, non-pyrogenic physiological saline, and water, with saline being preferred. Any other suitable diluents known to those skilled in the art may be used without departing from the spirit of the invention.

Pharmaceutically accepted salts of the novel compounds of the invention are also within the contemplated scope of the invention. Pharmaceutically acceptable salts suitable for practicing this invention include, but are not limited to, hydrochloride and tartrates.

Another aspect of this invention relates to methods for utilizing the compounds of the invention as CNS imaging agents. Imaging techniques are non-invasive diagnostic techniques that generally involve administering a compound with marker atoms that can be detected externally to the mammal. Generally, these methods comprise administering to a mammal a compound of the invention, dissolved or dispersed in a suitable pharmaceutical carrier or diluent. The compound of the invention selectively binds to CNS receptors, such as dopamine, thus permitting the imaging of CNS receptors and the ability to, *inter alia*, evaluate brain chemistry, the effectiveness of drugs, and neuronal functions. Imaging techniques suitable for practicing the present invention include, but are not limited to, single photon emission computed tomography (SPECT) and positron emission tomography (PET).

The compounds of the invention are the first receptor specific imaging agents, in particular, the first technetium [^{99m}Tc] labeled CNS and are believed to provide a convenient source of short-lived imaging agents for routine diagnosis of CNS abnormality, in conjunction with, for example, single photon emission computed tomography (SPECT). The technetium [^{99m}Tc] isotope has better physical properties than those that are currently available in the art. For example, [^{99m}Tc] has a half-life of 6 hours versus a half-life of 13 hours for iodine [^{123}I]. Also, [^{99m}Tc] is more readily available than [^{123}I]. The [^{123}I] is a cyclotron produced isotope and is believed to be available from only two commercial sources -- Irdion, located in Canada, and Emencia, located in Great Britain. By contrast, [^{99m}Tc] is generated using [^{99m}Tc]/Mo-

- 25 -

99, which is a generator that is used in nuclear medicine techniques and is virtually in all hospitals. Another advantage to the use of [^{99m}Tc] is its cost. Using the generator described above, [^{99m}Tc] can be made at a cost of \$1 per millicurie while the cost of preparing the same amount of iodine would be 30 to 50 times greater. It is also
5 possible to follow the same radiochemistry reactions using radionuclide-containing compounds containing rhenium, which has similar advantages.

The following tables (A-R) provide examples of compounds of Formula I and are intended only for illustrative purposes and in no way limit the scope of the invention. The examples are also illustrative of the invention and are not intended to
10 limit the scope of the invention. The examples illustrate the preparation of compounds within the scope of this invention as well as compounds used for comparison.

TABLE A

	Q	n	X	Z	R ₁	E'	M
5	A ₁ , A ₄ , A ₆ , or A ₇	2	F	CO ₂ R ₁	CH ₃	CH ₂	Tc ^{70a}
	A ₁ , A ₄ , A ₆ , or A ₇	2	Cl	CO ₂ R ₁	CH ₃	CH ₂	Tc ^{70a}
	A ₁ , A ₄ , A ₆ , or A ₇	2	Br	CO ₂ R ₁	CH ₃	CH ₂	Tc ^{70a}
	A ₁ , A ₄ , A ₆ , or A ₇	1	F	CO ₂ R ₁	CH ₃	CH ₂	Tc ^{70a}
	A ₁ , A ₄ , A ₆ , or A ₇	1	Cl	CO ₂ R ₁	CH ₃	CH ₂	Tc ^{70a}
	A ₁ , A ₄ , A ₆ , or A ₇	1	Br	CO ₂ R ₁	CH ₃	CH ₂	Tc ^{70a}
10	A ₁ , A ₄ , A ₆ , or A ₇	3	F	CO ₂ R ₁	CH ₃	CH ₂	Tc ^{70a}
	A ₁ , A ₄ , A ₆ , or A ₇	3	Cl	CO ₂ R ₁	CH ₃	CH ₂	Tc ^{70a}
	A ₁ , A ₄ , A ₆ , or A ₇	3	Br	CO ₂ R ₁	CH ₃	CH ₂	Tc ^{70a}
	A ₁ , A ₄ , A ₆ , or A ₇	4	F	CO ₂ R ₁	CH ₃	CH ₂	Tc ^{70a}
	A ₁ , A ₄ , A ₆ , or A ₇	4	Cl	CO ₂ R ₁	CH ₃	CH ₂	Tc ^{70a}
	A ₁ , A ₄ , A ₆ , or A ₇	4	Br	CO ₂ R ₁	CH ₃	CH ₂	Tc ^{70a}
15	A ₁ , A ₄ , A ₆ , or A ₇	2	F	CO ₂ R ₁	CH ₂ CH ₃	CH ₂	Tc ^{70a}
	A ₁ , A ₄ , A ₆ , or A ₇	2	Cl	CO ₂ R ₁	CH ₂ CH ₃	CH ₂	Tc ^{70a}
	A ₁ , A ₄ , A ₆ , or A ₇	2	Br	CO ₂ R ₁	CH ₂ CH ₃	CH ₂	Tc ^{70a}
	A ₁ , A ₄ , A ₆ , or A ₇	1	F	CO ₂ R ₁	CH ₂ CH ₃	CH ₂	Tc ^{70a}
	A ₁ , A ₄ , A ₆ , or A ₇	1	Cl	CO ₂ R ₁	CH ₂ CH ₃	CH ₂	Tc ^{70a}
	A ₁ , A ₄ , A ₆ , or A ₇	1	Br	CO ₂ R ₁	CH ₂ CH ₃	CH ₂	Tc ^{70a}
20	A ₁ , A ₄ , A ₆ , or A ₇	3	F	CO ₂ R ₁	CH ₂ CH ₃	CH ₂	Tc ^{70a}
	A ₁ , A ₄ , A ₆ , or A ₇	3	Cl	CO ₂ R ₁	CH ₂ CH ₃	CH ₂	Tc ^{70a}
	A ₁ , A ₄ , A ₆ , or A ₇	3	Br	CO ₂ R ₁	CH ₂ CH ₃	CH ₂	Tc ^{70a}
	A ₁ , A ₄ , A ₆ , or A ₇	4	F	CO ₂ R ₁	CH ₂ CH ₃	CH ₂	Tc ^{70a}
	A ₁ , A ₄ , A ₆ , or A ₇	4	Cl	CO ₂ R ₁	CH ₂ CH ₃	CH ₂	Tc ^{70a}
	A ₁ , A ₄ , A ₆ , or A ₇	4	Br	CO ₂ R ₁	CH ₂ CH ₃	CH ₂	Tc ^{70a}

Applies when A is A₇

TABLE B

	Q	n	X	Z	R ₁	E'	M
5	A ₁ , A ₄ , A ₆ , or A ₇	2	F	CO ₂ R ₁	CH ₃	CH ₂ CH ₃	Tc ^{99m}
	A ₂ , A ₄ , A ₆ , or A ₇	2	Cl	CO ₂ R ₁	CH ₃	CH ₂ CH ₃	Tc ^{99m}
	A ₁ , A ₄ , A ₆ , or A ₇	2	Br	CO ₂ R ₁	CH ₃	CH ₂ CH ₃	Tc ^{99m}
	A ₂ , A ₄ , A ₆ , or A ₇	1	F	CO ₂ R ₁	CH ₃	CH ₂ CH ₃	Tc ^{99m}
	A ₂ , A ₄ , A ₆ , or A ₇	1	Cl	CO ₂ R ₁	CH ₃	CH ₂ CH ₃	Tc ^{99m}
	A ₂ , A ₄ , A ₆ , or A ₇	1	Br	CO ₂ R ₁	CH ₃	CH ₂ CH ₃	Tc ^{99m}
10	A ₁ , A ₄ , A ₆ , or A ₇	3	F	CO ₂ R ₁	CH ₃	CH ₂ CH ₃	Tc ^{99m}
	A ₂ , A ₄ , A ₆ , or A ₇	3	Cl	CO ₂ R ₁	CH ₃	CH ₂ CH ₃	Tc ^{99m}
	A ₂ , A ₄ , A ₆ , or A ₇	3	Br	CO ₂ R ₁	CH ₃	CH ₂ CH ₃	Tc ^{99m}
	A ₁ , A ₄ , A ₆ , or A ₇	4	F	CO ₂ R ₁	CH ₃	CH ₂ CH ₃	Tc ^{99m}
	A ₂ , A ₄ , A ₆ , or A ₇	4	Cl	CO ₂ R ₁	CH ₃	CH ₂ CH ₃	Tc ^{99m}
	A ₂ , A ₄ , A ₆ , or A ₇	4	Br	CO ₂ R ₁	CH ₃	CH ₂ CH ₃	Tc ^{99m}
15	A ₁ , A ₄ , A ₆ , or A ₇	2	F	CO ₂ R ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc ^{99m}
	A ₂ , A ₄ , A ₆ , or A ₇	2	Cl	CO ₂ R ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc ^{99m}
	A ₂ , A ₄ , A ₆ , or A ₇	2	Br	CO ₂ R ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc ^{99m}
	A ₂ , A ₄ , A ₆ , or A ₇	1	F	CO ₂ R ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc ^{99m}
	A ₂ , A ₄ , A ₆ , or A ₇	1	Cl	CO ₂ R ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc ^{99m}
	A ₂ , A ₄ , A ₆ , or A ₇	1	Br	CO ₂ R ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc ^{99m}
20	A ₁ , A ₄ , A ₆ , or A ₇	3	F	CO ₂ R ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc ^{99m}
	A ₂ , A ₄ , A ₆ , or A ₇	3	Cl	CO ₂ R ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc ^{99m}
	A ₁ , A ₄ , A ₆ , or A ₇	3	Br	CO ₂ R ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc ^{99m}
	A ₂ , A ₄ , A ₆ , or A ₇	4	F	CO ₂ R ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc ^{99m}
	A ₂ , A ₄ , A ₆ , or A ₇	4	Cl	CO ₂ R ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc ^{99m}
	A ₂ , A ₄ , A ₆ , or A ₇	4	Br	CO ₂ R ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc ^{99m}
25	A ₁ , A ₄ , A ₆ , or A ₇	4	F	CO ₂ R ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc ^{99m}
	A ₂ , A ₄ , A ₆ , or A ₇	4	Cl	CO ₂ R ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc ^{99m}
	A ₂ , A ₄ , A ₆ , or A ₇	4	Br	CO ₂ R ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc ^{99m}

Applies when A is A₇

TABLE C

	Q	n	X	Z	R ₂	E ⁺	M
	A ₁ , A ₄ , A ₆ , or A ₇	2	F	CO ₂ R ₁	piperidine, pyrrolidine, or morpholine	CH ₂	Tc ^{99m}
	A ₁ , A ₄ , A ₆ , or A ₇	2	Cl	CO ₂ R ₁	piperidine, pyrrolidine, or morpholine	CH ₂	Tc ^{99m}
5	A ₁ , A ₄ , A ₆ , or A ₇	2	Br	CO ₂ R ₁	piperidine, pyrrolidine, or morpholine	CH ₂	Tc ^{99m}
	A ₁ , A ₄ , A ₆ , or A ₇	1	F	CO ₂ R ₁	piperidine, pyrrolidine, or morpholine	CH ₂	Tc ^{99m}
	A ₁ , A ₄ , A ₆ , or A ₇	1	Cl	CO ₂ R ₁	piperidine, pyrrolidine, or morpholine	CH ₂	Tc ^{99m}
	A ₁ , A ₄ , A ₆ , or A ₇	1	Br	CO ₂ R ₁	piperidine, pyrrolidine, or morpholine	CH ₂	Tc ^{99m}
	A ₁ , A ₄ , A ₆ , or A ₇	3	F	CO ₂ R ₁	piperidine, pyrrolidine, or morpholine	CH ₂	Tc ^{99m}
10	A ₁ , A ₄ , A ₆ , or A ₇	3	Cl	CO ₂ R ₁	piperidine, pyrrolidine, or morpholine	CH ₂	Tc ^{99m}
	A ₁ , A ₄ , A ₆ , or A ₇	3	Br	CO ₂ R ₁	piperidine, pyrrolidine, or morpholine	CH ₂	Tc ^{99m}
	A ₁ , A ₄ , A ₆ , or A ₇	0	F	CO ₂ R ₁	piperidine, pyrrolidine, or morpholine	CH ₂	Tc ^{99m}
	A ₁ , A ₄ , A ₆ , or A ₇	0	Cl	CO ₂ R ₁	piperidine, pyrrolidine, or morpholine	CH ₂	Tc ^{99m}
15	A ₁ , A ₄ , A ₆ , or A ₇	0	Br	CO ₂ R ₁	piperidine, pyrrolidine, or morpholine	CH ₂	Tc ^{99m}

Applies when A is A₇

TABLE D

	Q	n	X	Z	E	R ₁	M
5	A ₂ , A ₄ , A ₆ , or A ₇	2	F	COR ₁	CH ₂	CH ₃	Tc ^{nm}
	A ₂ , A ₄ , A ₆ , or A ₇	2	Cl	COR ₁	CH ₂	CH ₃	Tc ^{nm}
	A ₂ , A ₄ , A ₆ , or A ₇	2	Br	COR ₁	CH ₂	CH ₃	Tc ^{nm}
	A ₂ , A ₄ , A ₆ , or A ₇	1	F	COR ₁	CH ₂	CH ₃	Tc ^{nm}
	A ₂ , A ₄ , A ₆ , or A ₇	1	Cl	COR ₁	CH ₂	CH ₃	Tc ^{nm}
	A ₂ , A ₄ , A ₆ , or A ₇	1	Br	COR ₁	CH ₂	CH ₃	Tc ^{nm}
10	A ₂ , A ₄ , A ₆ , or A ₇	3	F	COR ₁	CH ₂	CH ₃	Tc ^{nm}
	A ₂ , A ₄ , A ₆ , or A ₇	3	Cl	COR ₁	CH ₂	CH ₃	Tc ^{nm}
	A ₂ , A ₄ , A ₆ , or A ₇	3	Br	COR ₁	CH ₂	CH ₃	Tc ^{nm}
	A ₂ , A ₄ , A ₆ , or A ₇	0	F	COR ₁	CH ₂	CH ₃	Tc ^{nm}
	A ₂ , A ₄ , A ₆ , or A ₇	0	Cl	COR ₁	CH ₂	CH ₃	Tc ^{nm}
	A ₂ , A ₄ , A ₆ , or A ₇	0	Br	COR ₁	CH ₂	CH ₃	Tc ^{nm}
15	A ₂ , A ₄ , A ₆ , or A ₇	2	F	COR ₁	CH ₂	CH ₂ CH ₃	Tc ^{nm}
	A ₂ , A ₄ , A ₆ , or A ₇	2	Cl	COR ₁	CH ₂	CH ₂ CH ₃	Tc ^{nm}
	A ₂ , A ₄ , A ₆ , or A ₇	2	Br	COR ₁	CH ₂	CH ₂ CH ₃	Tc ^{nm}
	A ₂ , A ₄ , A ₆ , or A ₇	1	F	COR ₁	CH ₂	CH ₂ CH ₃	Tc ^{nm}
	A ₂ , A ₄ , A ₆ , or A ₇	1	Cl	COR ₁	CH ₂	CH ₂ CH ₃	Tc ^{nm}
	A ₂ , A ₄ , A ₆ , or A ₇	1	Br	COR ₁	CH ₂	CH ₂ CH ₃	Tc ^{nm}
20	A ₂ , A ₄ , A ₆ , or A ₇	3	F	COR ₁	CH ₂	CH ₂ CH ₃	Tc ^{nm}
	A ₂ , A ₄ , A ₆ , or A ₇	3	Cl	COR ₁	CH ₂	CH ₂ CH ₃	Tc ^{nm}
	A ₂ , A ₄ , A ₆ , or A ₇	3	Br	COR ₁	CH ₂	CH ₂ CH ₃	Tc ^{nm}
	A ₂ , A ₄ , A ₆ , or A ₇	0	F	COR ₁	CH ₂	CH ₂ CH ₃	Tc ^{nm}
	A ₂ , A ₄ , A ₆ , or A ₇	0	Cl	COR ₁	CH ₂	CH ₂ CH ₃	Tc ^{nm}
	A ₂ , A ₄ , A ₆ , or A ₇	0	Br	COR ₁	CH ₂	CH ₂ CH ₃	Tc ^{nm}

Applies when A is A₇

TABLE E

	Q	n	X	Z	E'	R ₁	M
5	A ₂ , A ₄ , A ₆ , or A ₇	2	F	COR ₁	CH ₂ CH ₃	CH ₃	Tc [™]
	A ₂ , A ₄ , A ₆ , or A ₇	2	Cl	COR ₁	CH ₂ CH ₃	CH ₃	Tc [™]
	A ₂ , A ₄ , A ₆ , or A ₇	2	Br	COR ₁	CH ₂ CH ₃	CH ₃	Tc [™]
	A ₂ , A ₄ , A ₆ , or A ₇	1	F	COR ₁	CH ₂ CH ₃	CH ₃	Tc [™]
	A ₂ , A ₄ , A ₆ , or A ₇	1	Cl	COR ₁	CH ₂ CH ₃	CH ₃	Tc [™]
10	A ₂ , A ₄ , A ₆ , or A ₇	1	Br	COR ₁	CH ₂ CH ₃	CH ₃	Tc [™]
	A ₂ , A ₄ , A ₆ , or A ₇	3	F	COR ₁	CH ₂ CH ₃	CH ₃	Tc [™]
	A ₂ , A ₄ , A ₆ , or A ₇	3	Cl	COR ₁	CH ₂ CH ₃	CH ₃	Tc [™]
	A ₂ , A ₄ , A ₆ , or A ₇	3	Br	COR ₁	CH ₂ CH ₃	CH ₃	Tc [™]
	A ₂ , A ₄ , A ₆ , or A ₇	0	F	COR ₁	CH ₂ CH ₃	CH ₃	Tc [™]
15	A ₂ , A ₄ , A ₆ , or A ₇	0	Cl	COR ₁	CH ₂ CH ₃	CH ₃	Tc [™]
	A ₂ , A ₄ , A ₆ , or A ₇	0	Br	COR ₁	CH ₂ CH ₃	CH ₃	Tc [™]
	A ₂ , A ₄ , A ₆ , or A ₇	2	F	COR ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc [™]
	A ₂ , A ₄ , A ₆ , or A ₇	2	Cl	COR ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc [™]
	A ₂ , A ₄ , A ₆ , or A ₇	2	Br	COR ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc [™]
20	A ₂ , A ₄ , A ₆ , or A ₇	1	F	COR ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc [™]
	A ₂ , A ₄ , A ₆ , or A ₇	1	Cl	COR ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc [™]
	A ₂ , A ₄ , A ₆ , or A ₇	1	Br	COR ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc [™]
	A ₂ , A ₄ , A ₆ , or A ₇	3	F	COR ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc [™]
	A ₂ , A ₄ , A ₆ , or A ₇	3	Cl	COR ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc [™]
25	A ₂ , A ₄ , A ₆ , or A ₇	3	Br	COR ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc [™]
	A ₂ , A ₄ , A ₆ , or A ₇	0	F	COR ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc [™]
	A ₂ , A ₄ , A ₆ , or A ₇	0	Cl	COR ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc [™]
	A ₂ , A ₄ , A ₆ , or A ₇	0	Br	COR ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc [™]
	A ₂ , A ₄ , A ₆ , or A ₇	0	Br	COR ₁	CH ₂ CH ₃	CH ₂ CH ₃	Tc [™]

Applies when A is A₇

TABLE F

	Q	n	X	Z	E	M
5	CH ₃	2	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
	CH ₃	2	Cl	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
	CH ₃	2	Cl	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
	CH ₃	1	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
	CH ₃	1	Cl	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
10	CH ₃	1	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
	CH ₃	3	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
	CH ₃	3	Cl	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
	CH ₃	3	Cl	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
	CH ₃	0	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
15	CH ₃	0	Cl	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
	CH ₃	0	Cl	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
	CH ₃	2	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
	CH ₃	2	Cl	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
	CH ₃	2	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
20	CH ₃	1	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
	CH ₃	1	Cl	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
	CH ₃	1	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
	CH ₃	3	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
	CH ₃	3	Cl	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
25	CH ₃	3	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
	CH ₃	0	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
	CH ₃	0	Cl	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
	CH ₃	0	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}
	CH ₃	0	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂	Tc ^{99m}

Applies when A is A₁

TABLE G

	Q	n	X	Z	E'	M
5	CH ₃	2	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
	CH ₃	2	Cl	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
	CH ₃	2	Cl	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
	CH ₃	1	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
	CH ₃	1	Cl	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
10	CH ₃	1	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
	CH ₃	3	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
	CH ₃	3	Cl	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
	CH ₃	3	Cl	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
	CH ₃	0	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
15	CH ₃	0	Cl	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
	CH ₃	0	Cl	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
	CH ₃	2	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
	CH ₃	2	Cl	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
	CH ₃	2	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
20	CH ₃	1	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
	CH ₃	1	Cl	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
	CH ₃	1	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
	CH ₃	3	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
	CH ₃	3	Cl	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
25	CH ₃	3	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
	CH ₃	0	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
	CH ₃	0	Cl	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
	CH ₃	0	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}
	CH ₃	0	F	COA ₂ , COA ₄ , COA ₆ , or COA ₇	CH ₂ CH ₃	Tc ^{7m}

Applies when A is A₁

TABLE H

	Q	Z	n	E'	X	M
5	CH ₁	CH ₂ NHA ₁	1	CH ₂	Cl, F, or Br	Tc ^{nm}
	CH ₂ CH ₁	CH ₂ NHA ₁	1	CH ₂	Cl, F, or Br	Tc ^{nm}
	CH ₂ CH ₂ CH ₁	CH ₂ NHA ₁	1	CH ₂	Cl, F, or Br	Tc ^{nm}
	CH ₂ CH ₂ CH ₂ CH ₁	CH ₂ NHA ₁	1	CH ₂	Cl, F, or Br	Tc ^{nm}
10	CH ₁	CH ₂ NHA ₁	2	CH ₂	Cl, F, or Br	Tc ^{nm}
	CH ₂ CH ₁	CH ₂ NHA ₁	2	CH ₂	Cl, F, or Br	Tc ^{nm}
	CH ₂ CH ₂ CH ₁	CH ₂ NHA ₁	2	CH ₂	Cl, F, or Br	Tc ^{nm}
	CH ₂ CH ₂ CH ₂ CH ₁	CH ₂ NHA ₁	2	CH ₂	Cl, F, or Br	Tc ^{nm}
15	CH ₁	CH ₂ NHA ₁	3	CH ₂	Cl, F, or Br	Tc ^{nm}
	CH ₂ CH ₁	CH ₂ NHA ₁	3	CH ₂	Cl, F, or Br	Tc ^{nm}
	CH ₂ CH ₂ CH ₁	CH ₂ NHA ₁	3	CH ₂	Cl, F, or Br	Tc ^{nm}
	CH ₂ CH ₂ CH ₂ CH ₁	CH ₂ NHA ₁	3	CH ₂	Cl, F, or Br	Tc ^{nm}
	CH ₁	CH ₂ NHA ₁	0	CH ₂	Cl, F, or Br	Tc ^{nm}
	CH ₂ CH ₁	CH ₂ NHA ₁	0	CH ₂	Cl, F, or Br	Tc ^{nm}
	CH ₂ CH ₂ CH ₁	CH ₂ NHA ₁	0	CH ₂	Cl, F, or Br	Tc ^{nm}
	CH ₂ CH ₂ CH ₂ CH ₁	CH ₂ NHA ₁	0	CH ₂	Cl, F, or Br	Tc ^{nm}

Applies when A is A.

TABLE I

	Q	Z	n	E'	X	M
5	CH ₃	CH ₂ NHA ₁	1	CH ₂ CH ₃	Cl, F, or Br	Tc ^{99m}
	CH ₂ CH ₃	CH ₂ NHA ₁	1	CH ₂ CH ₃	Cl, F, or Br	Tc ^{99m}
	CH ₂ CH ₂ CH ₃	CH ₂ NHA ₁	1	CH ₂ CH ₃	Cl, F, or Br	Tc ^{99m}
	CH ₂ CH ₂ CH ₂ CH ₃	CH ₂ NHA ₁	1	CH ₂ CH ₃	Cl, F, or Br	Tc ^{99m}
10	CH ₃	CH ₂ NHA ₁	2	CH ₂ CH ₃	Cl, F, or Br	Tc ^{99m}
	CH ₂ CH ₃	CH ₂ NHA ₁	2	CH ₂ CH ₃	Cl, F, or Br	Tc ^{99m}
	CH ₂ CH ₂ CH ₃	CH ₂ NHA ₁	2	CH ₂ CH ₃	Cl, F, or Br	Tc ^{99m}
	CH ₂ CH ₂ CH ₂ CH ₃	CH ₂ NHA ₁	2	CH ₂ CH ₃	Cl, F, or Br	Tc ^{99m}
15	CH ₃	CH ₂ NHA ₁	3	CH ₂ CH ₃	Cl, F, or Br	Tc ^{99m}
	CH ₂ CH ₃	CH ₂ NHA ₁	3	CH ₂ CH ₃	Cl, F, or Br	Tc ^{99m}
	CH ₂ CH ₂ CH ₃	CH ₂ NHA ₁	3	CH ₂ CH ₃	Cl, F, or Br	Tc ^{99m}
	CH ₂ CH ₂ CH ₂ CH ₃	CH ₂ NHA ₁	3	CH ₂ CH ₃	Cl, F, or Br	Tc ^{99m}
	CH ₃	CH ₂ NHA ₁	0	CH ₂ CH ₃	Cl, F, or Br	Tc ^{99m}
	CH ₂ CH ₃	CH ₂ NHA ₁	0	CH ₂ CH ₃	Cl, F, or Br	Tc ^{99m}
	CH ₂ CH ₂ CH ₃	CH ₂ NHA ₁	0	CH ₂ CH ₃	Cl, F, or Br	Tc ^{99m}
	CH ₂ CH ₂ CH ₂ CH ₃	CH ₂ NHA ₁	0	CH ₂ CH ₃	Cl, F, or Br	Tc ^{99m}

Applies when A is A₁

TABLE J

	Q	Z	n	X	E'	M
5	CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A ₅	1	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	1	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	1	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₂ CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	1	Cl, F, or Br	CH ₂	Tc ^{nm}
10	CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	2	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	2	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	2	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₂ CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	2	Cl, F, or Br	CH ₂	Tc ^{nm}
15	CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	3	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	3	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	3	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₂ CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	3	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	0	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	0	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	0	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₂ CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	0	Cl, F, or Br	CH ₂	Tc ^{nm}

Applies when A is A₁.

- 36 -

TABLE K

	Q	Z	n	X	E'	M
5	CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	1	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	1	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	1	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₂ CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	1	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
10	CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	2	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	2	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	2	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₂ CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	2	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
15	CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	3	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	3	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	3	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₂ CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	3	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	0	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	0	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	0	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₂ CH ₂ CH ₃	CO ₂ A ₂ , CO ₂ A ₃ , CO ₂ A ₄ , or CO ₂ A	0	Cl, F, or Br	CH ₂ CH ₃	Tc [™]

Applies when A is A₁.

TABLE I

Q	Z	n	X	E	M
CH ₃	COA ₂ , COA ₃ , COA ₄ , or COA ₅	1	Cl, F, or Br	CH ₂	Tc ^{III}
CH ₂ CH ₃	COA ₂ , COA ₃ , COA ₄ , or COA ₅	1	Cl, F, or Br	CH ₂	Tc ^{III}
CH ₂ CH ₂ CH ₃	COA ₂ , COA ₃ , COA ₄ , or COA ₅	1	Cl, F, or Br	CH ₂	Tc ^{III}
CH ₂ CH ₂ CH ₂ CH ₃	COA ₂ , COA ₃ , COA ₄ , or COA ₅	1	Cl, F, or Br	CH ₂	Tc ^{III}
CH ₃	COA ₂ , COA ₃ , COA ₄ , or COA ₅	2	Cl, F, or Br	CH ₂	Tc ^{III}
CH ₂ CH ₃	COA ₂ , COA ₃ , COA ₄ , or COA ₅	2	Cl, F, or Br	CH ₂	Tc ^{III}
CH ₂ CH ₂ CH ₃	COA ₂ , COA ₃ , COA ₄ , or COA ₅	2	Cl, F, or Br	CH ₂	Tc ^{III}
CH ₂ CH ₂ CH ₂ CH ₃	COA ₂ , COA ₃ , COA ₄ , or COA ₅	2	Cl, F, or Br	CH ₂	Tc ^{III}
CH ₃	COA ₂ , COA ₃ , COA ₄ , or COA ₅	3	Cl, F, or Br	CH ₂	Tc ^{III}
CH ₂ CH ₃	COA ₂ , COA ₃ , COA ₄ , or COA ₅	3	Cl, F, or Br	CH ₂	Tc ^{III}
CH ₂ CH ₂ CH ₃	COA ₂ , COA ₃ , COA ₄ , or COA ₅	3	Cl, F, or Br	CH ₂	Tc ^{III}
CH ₂ CH ₂ CH ₂ CH ₃	COA ₂ , COA ₃ , COA ₄ , or COA ₅	3	Cl, F, or Br	CH ₂	Tc ^{III}
CH ₃	COA ₂ , COA ₃ , COA ₄ , or COA ₅	0	Cl, F, or Br	CH ₂	Tc ^{III}
CH ₂ CH ₃	COA ₂ , COA ₃ , COA ₄ , or COA ₅	0	Cl, F, or Br	CH ₂	Tc ^{III}
CH ₂ CH ₂ CH ₃	COA ₂ , COA ₃ , COA ₄ , or COA ₅	0	Cl, F, or Br	CH ₂	Tc ^{III}
CH ₂ CH ₂ CH ₂ CH ₃	COA ₂ , COA ₃ , COA ₄ , or COA ₅	0	Cl, F, or Br	CH ₂	Tc ^{III}

Applies when A is A₁

- 38 -

TABLE M

	Q	Z	n	X	E'	M
5	CH ₁	COA ₂ , COA ₃ , COA ₄ , or COA ₅	1	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₁	COA ₂ , COA ₃ , COA ₄ , or COA ₅	1	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₂ CH ₁	COA ₂ , COA ₃ , COA ₄ , or COA ₅	1	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₂ CH ₂ CH ₁	COA ₂ , COA ₃ , COA ₄ , or COA ₅	1	Cl, F, or Br	CH ₂ CH ₂ 3	Tc [™]
10	CH ₁	COA ₂ , COA ₃ , COA ₄ , or COA ₅	2	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₁	COA ₂ , COA ₃ , COA ₄ , or COA ₅	2	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₂ CH ₁	COA ₂ , COA ₃ , COA ₄ , or COA ₅	2	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₂ CH ₂ CH ₁	COA ₂ , COA ₃ , COA ₄ , or COA ₅	2	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
15	CH ₁	COA ₂ , COA ₃ , COA ₄ , or COA ₅	3	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₁	COA ₂ , COA ₃ , COA ₄ , or COA ₅	3	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₂ CH ₁	COA ₂ , COA ₃ , COA ₄ , or COA ₅	3	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₂ CH ₂ CH ₁	COA ₂ , COA ₃ , COA ₄ , or COA ₅	3	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₁	COA ₂ , COA ₃ , COA ₄ , or COA ₅	0	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₁	COA ₂ , COA ₃ , COA ₄ , or COA ₅	0	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₂ CH ₁	COA ₂ , COA ₃ , COA ₄ , or COA ₅	0	Cl, F, or Br	CH ₂ CH ₃	Tc [™]
	CH ₂ CH ₂ CH ₂ CH ₁	COA ₂ , COA ₃ , COA ₄ , or COA ₅	0	Cl, F, or Br	CH ₂ CH ₃	Tc [™]

Applies when A is A₁

TABLE N

	Q	Z	n	X	E	M
5	CH ₁	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ or CH ₂ OA ₅	1	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₁	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ or CH ₂ OA ₅	1	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₂ CH ₁	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ or CH ₂ OA ₅	1	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₂ CH ₂ CH ₁	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ or CH ₂ OA ₅	1	Cl, F, or Br	CH ₂	Tc ^{nm}
10	CH ₁	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ or CH ₂ OA ₅	2	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₁	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ or CH ₂ OA ₅	2	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₂ CH ₁	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ or CH ₂ OA ₅	2	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₂ CH ₂ CH ₁	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ or CH ₂ OA ₅	2	Cl, F, or Br	CH ₂	Tc ^{nm}
15	CH ₁	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ or CH ₂ OA ₅	3	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₁	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ or CH ₂ OA ₅	3	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₂ CH ₁	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ or CH ₂ OA ₅	3	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₂ CH ₂ CH ₁	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ or CH ₂ OA ₅	3	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₁	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ or CH ₂ OA ₅	0	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₁	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ or CH ₂ OA ₅	0	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₂ CH ₁	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ or CH ₂ OA ₅	0	Cl, F, or Br	CH ₂	Tc ^{nm}
	CH ₂ CH ₂ CH ₂ CH ₁	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ or CH ₂ OA ₅	0	Cl, F, or Br	CH ₂	Tc ^{nm}

Applies when A is A_n.

TABLE O

Q	Z	n	X	E'	M
CH ₃	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ , or CH ₂ OA ₅	1	Cl, F, or Br	CH ₂ CH ₃	Tc ¹⁰⁰
CH ₂ CH ₃	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ , or CH ₂ OA ₅	1	Cl, F, or Br	CH ₂ CH ₃	Tc ¹⁰⁰
CH ₂ CH ₂ CH ₃	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ , or CH ₂ OA ₅	1	Cl, F, or Br	CH ₂ CH ₃	Tc ¹⁰⁰
CH ₂ CH ₂ CH ₂ CH ₃	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ , or CH ₂ OA ₅	1	Cl, F, or Br	CH ₂ CH ₃	Tc ¹⁰⁰
CH ₃	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ , or CH ₂ OA ₅	2	Cl, F, or Br	CH ₂ CH ₃	Tc ¹⁰⁰
CH ₂ CH ₃	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ , or CH ₂ OA ₅	2	Cl, F, or Br	CH ₂ CH ₃	Tc ¹⁰⁰
CH ₂ CH ₂ CH ₃	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ , or CH ₂ OA ₅	2	Cl, F, or Br	CH ₂ CH ₃	Tc ¹⁰⁰
CH ₂ CH ₂ CH ₂ CH ₃	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ , or CH ₂ OA ₅	2	Cl, F, or Br	CH ₂ CH ₃	Tc ¹⁰⁰
CH ₃	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ , or CH ₂ OA ₅	3	Cl, F, or Br	CH ₂ CH ₃	Tc ¹⁰⁰
CH ₂ CH ₃	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ , or CH ₂ OA ₅	3	Cl, F, or Br	CH ₂ CH ₃	Tc ¹⁰⁰
CH ₂ CH ₂ CH ₃	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ , or CH ₂ OA ₅	3	Cl, F, or Br	CH ₂ CH ₃	Tc ¹⁰⁰
CH ₂ CH ₂ CH ₂ CH ₃	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ , or CH ₂ OA ₅	3	Cl, F, or Br	CH ₂ CH ₃	Tc ¹⁰⁰
CH ₃	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ , or CH ₂ OA ₅	0	Cl, F, or Br	CH ₂ CH ₃	Tc ¹⁰⁰
CH ₂ CH ₃	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ , or CH ₂ OA ₅	0	Cl, F, or Br	CH ₂ CH ₃	Tc ¹⁰⁰
CH ₂ CH ₂ CH ₃	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ , or CH ₂ OA ₅	0	Cl, F, or Br	CH ₂ CH ₃	Tc ¹⁰⁰
CH ₂ CH ₂ CH ₂ CH ₃	CH ₂ OA ₂ , CH ₂ OA ₃ , CH ₂ OA ₄ , or CH ₂ OA ₅	0	Cl, F, or Br	CH ₂ CH ₃	Tc ¹⁰⁰

- 41 -

TABLE P

	Q	Z	R ₁	n	R ₂	X	M
5	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₃	1	H	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₃	1	CH ₂ CH ₂ CH ₃	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₃	1	methoxybenzyl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₃	1	trityl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₃	1	H	Cl or F	Tc [™]
10	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₃	1	CH ₂ CH ₂ CH ₃	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₃	1	methoxybenzyl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₃	1	trityl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₂ CH ₃	1	H	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₂ CH ₃	1	CH ₂ CH ₂ CH ₃	Cl or F	Tc [™]
15	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₂ CH ₃	1	trityl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₂ CH ₃	1	methoxybenzyl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₂ CH ₂ CH ₃	1	methoxybenzyl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₂ CH ₂ CH ₃	1	H	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₂ CH ₂ CH ₃	1	CH ₂ CH ₂ CH ₃	Cl or F	Tc [™]
20	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₂ CH ₂ CH ₃	1	trityl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₂ CH ₂ CH ₃	1	methoxybenzyl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₃	2	H	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₃	2	CH ₂ CH ₂ CH ₃	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₃	2	methoxybenzyl	Cl or F	Tc [™]
25	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₃	2	trityl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₃	2	methoxybenzyl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₃	2	trityl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₃	2	H	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₃	2	CH ₂ CH ₂ CH ₃	Cl or F	Tc [™]
30	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₂ CH ₃	2	H	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₂ CH ₃	2	CH ₂ CH ₂ CH ₃	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₂ CH ₃	2	methoxybenzyl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₂ CH ₃	2	trityl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₂ CH ₂ CH ₃	2	methoxybenzyl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₂ CH ₂ CH ₃	2	CH ₂ CH ₂ CH ₃	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₂ CH ₂ CH ₃	2	H	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	CO ₂ R ₁	CH ₂ CH ₂ CH ₂ CH ₃	2	trityl	Cl or F	Tc [™]

TABLE Q

	Q	Z	R ₁	n	R ₂	X	M
5	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₃	1	H	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₃	1	CH ₂ CH ₂ CH ₃	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₃	1	methoxybenzyl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₃	1	trityl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₃	1	methoxybenzyl	Cl or F	Tc [™]
10	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₃	1	trityl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₃	1	H	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₃	1	CH ₂ CH ₂ CH ₃	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₂ CH ₃	1	H	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₂ CH ₃	1	CH ₂ CH ₂ CH ₃	Cl or F	Tc [™]
15	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₂ CH ₃	1	methoxybenzyl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₂ CH ₃	1	trityl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₂ CH ₂ CH ₃	1	methoxybenzyl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₂ CH ₂ CH ₃	1	CH ₂ CH ₂ CH ₃	Cl or F	
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₂ CH ₂ CH ₃	1	H	Cl or F	
20	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₂ CH ₂ CH ₃	1	trityl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₃	2	H	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₃	2	CH ₂ CH ₂ CH ₃	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₃	2	methoxybenzyl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₃	2	trityl	Cl or F	Tc [™]
25	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₃	2	methoxybenzyl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₃	2	trityl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₃	2	CH ₂ CH ₂ CH ₃	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₃	2	H	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₂ CH ₃	2	H	Cl or F	Tc [™]
30	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₂ CH ₃	2	CH ₂ CH ₂ CH ₃	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₂ CH ₃	2	trityl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₂ CH ₃	2	methoxybenzyl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₂ CH ₂ CH ₃	2	methoxybenzyl	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₂ CH ₂ CH ₃	2	CH ₂ CH ₂ CH ₃	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₂ CH ₂ CH ₃	2	H	Cl or F	Tc [™]
	A ₁ , A ₂ , A ₃ , or A ₄	COR ₁	CH ₂ CH ₂ CH ₂ CH ₃	2	trityl	Cl or F	Tc [™]

TABLE R

Q	Z	R ₁	n	R ₂	X	M
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₃	3	H	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₃	3	CH ₂ CH ₂ CH ₃	Cl or F	Tc [™]
5 A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₃	3	methoxybenzyl	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₃	3	trityl	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₃	3	methoxybenzyl	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₃	3	trityl	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₃	3	CH ₂ CH ₂ CH ₃	Cl or F	Tc [™]
10 A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₃	3	H	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₂ CH ₃	3	H	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₂ CH ₃	3	CH ₂ CH ₂ CH ₃	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₂ CH ₃	3	methoxybenzyl	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₂ CH ₃	3	trityl	Cl or F	Tc [™]
15 A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₂ CH ₂ CH ₃	3	methoxybenzyl	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₂ CH ₂ CH ₃	3	H	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₂ CH ₂ CH ₃	3	CH ₂ CH ₂ CH ₃	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₂ CH ₂ CH ₃	3	trityl	Cl or F	Tc [™]
20 A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₃	0	H	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₃	0	CH ₂ CH ₂ CH ₃	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₃	0	methoxybenzyl	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₃	0	trityl	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₃	0	methoxybenzyl	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₃	0	trityl	Cl or F	Tc [™]
25 A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₃	0	CH ₂ CH ₂ CH ₃	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₃	0	H	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₂ CH ₃	0	H	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₂ CH ₃	0	CH ₂ CH ₂ CH ₃	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₂ CH ₃	0	methoxybenzyl	Cl or F	Tc [™]
30 A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₂ CH ₃	0	trityl	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₂ CH ₂ CH ₃	0	methoxybenzyl	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₂ CH ₂ CH ₃	0	H	Cl or F	Tc [™]
A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₂ CH ₂ CH ₃	0	CH ₂ CH ₂ CH ₃	Cl or F	Tc [™]
35 A ₁ , A ₂ , A ₃ or A ₄	COR ₁	CH ₂ CH ₂ CH ₂ CH ₃	0	trityl	Cl or F	Tc [™]

EXAMPLES

General Experimental For Examples 1 to 13

Reagents used in the syntheses were purchased from Aldrich (Milwaukee, WI) or Fluka (Ronkonkoma, NY), and were used without further purification unless otherwise indicated. Anhydrous Na_2SO_4 was used as a drying agent. Reaction yields are reported without attempts at optimization. Thin layer chromatography was performed on EM Science (Gibbstown, NJ) precoated (0.2 mm) silica gel 60 plates, and the spots were detected with iodine vapor and/or UV light. Silica gel 60 (70-230 mesh), obtained from EM Science (Gibbstown, NJ), was used for column chromatography. ^1H NMR spectra were obtained on a Bruker spectrometer (Bruker AC 300). All samples prepared for NMR analysis were dissolved in CDCl_3 , purchased from Aldrich. Chemical shifts are reported as δ values with chloroform or TMS as the internal reference. Coupling constants are reported in Hz. The multiplicity is defined by s (singlet), d (doublet), t (triplet), brs (broad signal), dt (doublet of triplet) and m (multiplet). IR spectra were recorded with a Mattson Polaris FT-IR spectrometer and are reported in cm^{-1} . Melting points were determined on a Meltemp apparatus (Cambridge, MA), and are uncorrected. Elemental analyses were performed by Atlantic Microlabs (Norcross, GA). High resolution mass spectrometry was performed by the Nebraska Center for Mass Spectroscopy, University of Nebraska (Lincoln, NE).

The compound reference numbers used in the examples and Tables correspond to the compounds depicted in the reaction schemes.

EXAMPLE 1

Preparation Of Compounds 1.5a And 1.5b

Oxalyl chloride (2 mmol, 1 mL from 2M solution in CH_2Cl_2) was added to tropane acid 1.3 (1 mmol) in CH_2Cl_2 (10 mL) at room temperature under N_2 . The resulting mixture was stirred for 1.5 hours and concentrated in vacuo at 30°C to obtain a viscous oil which was dried in a vacuum for 15 minutes. The acid chloride obtained was dissolved in CH_2Cl_2 (10 mL) and cooled to -10°C and amine 1.4 (1 mmol, 470 mg) in CH_2Cl_2 (10 mL) was added, followed by Et_3N (3 mmol, 0.42 mL), under N_2 . The resulting solution was stirred at room temperature for 6 hours. Water (20 mL) was then added to the reaction mixture and the product was extracted into CH_2Cl_2 (3 x 20

mL). CH_2Cl_2 layers were combined, dried (Na_2SO_4) and concentrated in vacuo to obtain an oil that was chromatographed on silica ($\text{EtOAc}:\text{MeOH}:\text{NH}_4\text{OH}$ 8.5:1:0.5) to obtain the title compound as a viscous oil.

1.5a: yield 59%; IR 1640 cm^{-1} ; ^1H NMR (CDCl_3) δ 1.59 (m, 3H), 2.05-2.5 (m, 9H), 2.7-2.9 (m, 4H), 3.1-3.2 (m, 4H), 3.3-3.5 (m, 3H), 3.5 and 3.6 (s, 2H each), 3.72 and 3.74 (s, 3H each), 6.36 (brs, 1H), 6.8 (d, 2H, $J = 6$ Hz), 6.84 (d, 2H, $J = 6$ Hz), 7.02-7.21 (m, 8H).

1.5b: yield 66%; IR 1636 cm^{-1} ; ^1H NMR (CDCl_3) δ 1.5-1.7 (m, 3H), 2.05-2.5 (m, 9H), 2.7-2.9 (m, 4H), 3.1-3.2 (m, 4H), 3.3-3.5 (m, 3H), 3.5 and 3.6 (s, 2H each), 3.72 and 3.74 (s, 3H each), 6.4 (brs, 1H), 6.8-6.9 (m, 6H), 7.02-7.25 (m, 6H).

EXAMPLE 2

Preparation Of Compounds 1.6a And 1.6b

$\text{BH}_3 \cdot \text{THF}$ (5 mmol, 5 mL of 1M solution in THF) was added to compound 1.5 (1 mmol) in THF (10 mL) under N_2 and the resulting mixture was heated at reflux for 12 hours. The reaction mixture was cooled to 0°C and 1N HCl was added dropwise until there was no more gas evolution, then the mixture was concentrated in vacuo. 1N HCl (10 mL) was added to the viscous oil obtained and the resulting mixture was stirred at 50°C for 30 minutes. The reaction mixture was cooled to 0°C and basified with concentrated NH_4OH . The product was extracted into CH_2Cl_2 and purified by chromatography on silica ($\text{EtOAc}:\text{MeOH}:\text{NH}_4\text{OH}$ 8.5:1:0.5) to give the title compounds.

1.6a: yield 19%; IR 1661 cm^{-1} ; ^1H NMR (CDCl_3) δ 1.4-1.9 (m, 5H), 2.05-3.1 (m, 18H), 3.0-3.15 (m, 1H), 3.26-3.28 (m, 1H), 3.48-3.51 (m, 1H), 3.67 and 3.681 (s, 2H each), 3.72 and 3.73 (s, 3H each), 6.8 (m, 4H), 7.02-7.21 (m, 8H).

1.6b: yield 23%; IR 1659 cm^{-1} ; ^1H NMR (CDCl_3) δ 1.4-1.9 (m, 5H), 2.05-3.1 (m, 18H), 3.0-3.15 (m, 1H), 3.26-3.28 (m, 1H), 3.48-3.51 (m, 1H), 3.57 and 3.61 (s, 2H each), 3.72 and 3.73 (s, 3H each), 6.75-6.8 (m, 4H), 6.87-6.90 and 6.99-7.04 (m, 2H each), 7.12-7.18 (m, 4H).

EXAMPLE 3**Preparation Of Compounds 1.11a and 1.11b**

Oxalyl chloride (2 mmol, 1 mL from 2M solution in CH_2Cl_2) was added to tropane acid 1.3 (1 mmol) in CH_2Cl_2 (10 mL) at room temperature under N_2 . The
5 resulting mixture was stirred for 1.5 h and concentrated in vacuo at 30°C to obtain a viscous oil, which was dried in a vacuum for 15 minutes. The acid chloride obtained was dissolved in CH_2Cl_2 (10 mL) and cooled to -10°C and amine 1.9 (1 mmol, 197 mg) in CH_2Cl_2 (10 mL) was added, followed by Et_3N (2 mmol, 0.28 mL) under N_2 . The resulting solution was stirred at room temperature for 6 hours. Water (20 mL) was
10 then added to the reaction mixture and the product was extracted into CH_2Cl_2 (3 x 20 mL). The CH_2Cl_2 layers were combined, dried (Na_2SO_4) and concentrated in vacuo to produce an oil that was chromatographed on silica ($\text{EtOAc}:\text{MeOH}:\text{NH}_4\text{OH}$ 8.5:1:0.5) to obtain the title compound as a viscous oil.

1.11a: yield 63%; IR 1656 cm^{-1} ; ^1H NMR (CDCl_3) δ 1.55-1.78 (m, 3H),
15 -2.05-2.6 (m, 9H), 3.1-3.4 (m, 5H), 3.69 (s, 2H), 3.79 (s, 3H), 6.84 (d, 2H, $J=6$ Hz), 7.09 (d, 2H, $J=6$ Hz), 7.18 (d, 2H, $J=6$ Hz), 7.24 (d, 2H, $J=6$ Hz), 9.8 (brs, 1H).

1.11b: yield 59%; IR 1653 cm^{-1} ; ^1H NMR (CDCl_3) δ 1.59-1.76 (m, 3H),
1.97-2.4 (m, 6H), 2.4 -2.5 (m, 3H), 3.09 (m, 1H), 3.2-3.38 (m, 4H), 3.68 (s, 2H),
3.78 (s, 3H), 6.8-6.9 (m, 4H), 7.08-7.13 (m, 2H), 7.2 (d, 2H, $J=10$ Hz), 9.8 (brs,
20 1H).

EXAMPLE 4**Preparation Of Compounds 1.13a and 1.13b**

$\text{BH}_3\cdot\text{THF}$ (5 mmol, 5 mL of 1M solution in THF) was added to compound 1.11 (1 mmol) in THF (10 mL) under N_2 and the resulting mixture was heated at
25 reflux for 12 hours. The reaction mixture was cooled to 0°C and 1N HCl was added dropwise until there was no more gas evolution, then the mixture was concentrated in vacuo. 1N HCl (10 mL) was added to the viscous oil obtained and the resulting mixture was stirred at 90°C for 30 minutes. The solution was then cooled to 0 $^\circ\text{C}$ and basified with conc. NH_4OH . The product was extracted into CH_2Cl_2 and purified by
30 chromatography on silica ($\text{EtOAc}:\text{MeOH}:\text{NH}_4\text{OH}$ 8.5:1:0.5) to give the title compound.

- 47 -

1.13a: yield 79%; IR 1608 cm⁻¹; ¹H NMR (CDCl₃) δ 1.5-1.8 (m, 5H), 2.05-2.2 (m, 4H), 2.23 (s, 3H), 2.34-2.39 (m, 2H), 2.47-2.52 (m, 2H), 2.65 (dd, 1H, J₁ = 5.3, J₂ = 7.8), 3.03 (td, 1H, J₁ = 4, J₂ = 8.8), 3.25 (m, 2H), 3.5 (s, 2H), 3.78 (s, 3H), 6.84 (d, 2H, J = 6 Hz), 7.09 (d, 2H, J = 6 Hz), 7.18 (d, 2H, J = 6 Hz), 7.24 (d, 2H, J = 6 Hz).

1.13b: yield 83%; IR 1600 cm⁻¹; ¹H NMR (CDCl₃) δ 1.59-1.76 (m, 3H), 1.97-2.4 (m, 6H), 2.4-2.5 (m, 3H), 3.09 (m, 1H), 3.2-3.38 (m, 4H), 3.68 (s, 2H), 3.78 (s, 3H), 6.8-6.9 (m, 4H), 7.08-7.13 (m, 2H), 7.2 (d, 2H, J = 10 Hz).

EXAMPLE 5

10 Preparation Of Compounds 1.14a and 1.14b

Amine 1.9 (12.5 mmol, 2.46 g) in CH₂Cl₂ (15 mL) was added dropwise to a stirred solution of chloroacetyl chloride (12.5 mmol, 1 mL) in CH₂Cl₂ (15 mL), followed by Et₃N (12.5 mmol, 1.7 mL) at -78°C under N₂. The reaction mixture was allowed to warm to room temperature and stirred for 1 hours. Water (20 mL) was then added and the organic layer was separated and washed with 1N HCl (20 mL), brine (20 mL) and water (20 mL). The organic layer was concentrated in vacuo and dried in vacuo for 30 minutes. The oil was dissolved in EtOAc (50 mL) and hexane (100 mL). The turbid solution obtained was concentrated to half the volume and stored in a freezer for 4 hours. The solid formed was collected by suction filtration to give compound 1.12, which was used for further reactions without additional purification.

Amine 1.13 (1 mmol), chloro compound 1.12 (2 mmol, 548 mg) and Et₃N (2 mmol, 0.28 mL) in acetonitrile (10 mL) were heated at reflux for 24 hours. The reaction mixture was concentrated in vacuo and the product was partitioned between water (20 mL) and CH₂Cl₂ (20 mL). The oil obtained by concentrating the organic phase was chromatographed on silica (2% MeOH:CH₂Cl₂ and 10% MeOH:CH₂Cl₂) to produce the title compound as a yellow oil.

1.14a: yield 53%; IR 1654 cm⁻¹; ¹H NMR (CDCl₃) δ 1.4-1.8 (m, 5H), 2.05-2.9 (m, 14H), 2.92-3.5 (m, 7H), 3.52 (s, 2H), 3.95 (s, 2H), 3.76 (s, 6H), 6.8-6.85 (m, 4H), 6.9 (d, 2H, J = 6 Hz), 7.15-7.25 (m, 6H), 8.4 (brs, 1H).

1.14b: yield 66%; IR 1650 cm^{-1} ; ^1H NMR (CDCl_3) δ 1.38-1.76 (m, 5H), 2.0-2.81 (m, 14H), 2.88-3.46 (m, 7H), 3.58 (s, 2H), 3.68 (s, 2H), 3.77 (s, 6H), 6.79-6.85 (m, 4H), 6.9-7.03 (m, 2H), 7.18-7.25 (m, 4H), 8.4 (brs, 1H).

EXAMPLE 6

5 Preparation Of Compounds 1.15a and 1.15b

LAH (1.5 eq) was added to a solution of compound 1.14 (1 mmol) in THF (10 mL) under N_2 and the resulting mixture was heated at reflux for 12 hours. Usual work up, followed by chromatography of the resulting product on a chromatotron (EtOAc:MeOH: NH_4OH 8.5:1:0.5), gave the title compound.

10 1.15a: yield 63%. IR 1609 cm^{-1} ; ^1H NMR (CDCl_3) δ 1.5-1.8 (m, 5H), 2.05-2.3 (m, 5H), 2.3 (s, 3H), 2.3-2.6 (m, 7H), 2.7-2.9 (m, 5H), 3.1 (td, 1H, $J_1 = 4$, $J_2 = 8.8$), 3.35-3.45 (m, 2H), 3.59 (s, 2H), 3.65-3.7 (m, 2H), 3.76 (s, 6H), 6.8-6.85 (m, 4H), 7.15-7.25 (m, 8H).

15 1.15b: yield 53%. IR 1603 cm^{-1} ; ^1H NMR (CDCl_3) δ 1.4-1.7 (m, 5H), 1.95-2.29 (m, 5H), 2.25-2 (m, 10H), 2.7-2.9 (m, 5H), 3.0 (td, 1H, $J_1 = 4$, $J_2 = 8.8$), 3.2 (m, 1H), 3.35 (m, 1H), 3.6 and 3.65 (s, 2H each), 3.7 and 3.77 (s, 3H each), 6.7-6.8 (m, 4H), 6.9-6.96 and 7.01-7.06 (m, 2H each), 7.16-7.22 (m, 4H).

EXAMPLE 7

General procedure for compounds 1.7, 1.16 and 1.17

20 Substrate 1.6, 1.14 or 1.15 (1 mmol) was dissolved in TFA (7.5 mL) and anisole (0.25 mL) at 0°C and $\text{Hg}(\text{OAc})_2$ (636 mg, 2 mmol) was added. The resulting mixture was stirred for 30 min and concentrated in vacuo to obtain a viscous oil which was dried in vacuo for 30 minutes. Dry ether (10 mL) was then added to the above oil and the resulting suspension was sonicated for 5 minutes. The colorless solid that
25 formed was collected by suction filtration, dried in vacuo for 20 minutes and dissolved in absolute EtOH (10 mL). H_2S gas was passed through the solution for 20 minutes and the reaction mixture was filtered through a pad of celite. The filtrate was concentrated in vacuo to obtain the trifluoroacetate salt of the title compound, which was used for further reactions without additional purification.

EXAMPLE 8

Preparation of 2b-{oxo[N,N'-bis-(2'-mercaptoethyl)-ethylenediaminato)] rhenium (V)-methylamino}-3b-(4-chlorophenyl)tropane (1.22)

A solution of compound 1.16a (428 mg, 1 mmol) in MeOH (10 mL) was added to a solution of $\text{Bu}_4\text{NReOCl}_4$ (588 mg, 1 mmol) in MeOH (2 mL) under N_2 at 0°C . Et_3N (0.5 mL, 4 mmol) was then added, and the resulting mixture was stirred at room temperature for 12 hours. The reaction mixture was concentrated in vacuo. The residue obtained was chromatographed on silica ($\text{EtOAc}:\text{MeOH}:\text{NH}_4\text{OH}$ 9.5:0.4:0.1) to obtain a purple solid, which was recrystallized ($\text{MeOH}:\text{CH}_2\text{Cl}_2$) to give pinkish needles. Yield 43%; mp 158°C ; IR (KBr) 967 cm^{-1} .

EXAMPLE 9**Radiolabeling with Tc-99m**

A sample of ligand (1.7a, 1.7b, 1.16a, 1.16b or 1.17; 0.2-0.4 μmol) was dissolved in 100 μL EtOH and 100 μL HCl (1 N). 500 μL HCl (1 N) and 1 mL Sn-glucoheptonate solution (containing 136 μg SnCl_2 and 200 μg Na-glucoheptonate, pH 6.67) and 50 μL EDTA solution (0.1 N) were successively added. [$^{99\text{m}}\text{Tc}$]Pertechnetate (100-200 μL ; ranging from 1-20 mCi) saline solution was then added. The reaction was heated for 30 minutes at 100°C , cooled to room temperature and neutralized with a sat. NaHCO_3 solution. After extracting the complex from the aqueous reaction medium with ethyl acetate (1 x 3 mL, 2 x 1.5 mL) and passing it through a small column of Na_2SO_4 , ethyl acetate was removed under a flow of N_2 . The residue was dissolved in 200 μL EtOH and purified by HPLC (PRP-1 column, 250 x 4.1 mm, $\text{CH}_3\text{CN}/3,3\text{-dimethylglutarate}$ buffer, 5 mM, pH 7, volume ratio 8:2, flow rate 1 mL/min). The retention times for the mixtures of 1.19a were 10.5 to 11.5 minutes (radiochemical yield 88%, radiochemical purity >98%). All the complexes displayed stability at 4 and 24 hours after preparation. Little change in radiochemical purity was observed. Identical labeling and HPLC conditions were used for the preparation of mixtures of 1.19b, 1.20a, and 1.20b (retention times of 10.6 and 12, 9.4 and 10.1, 8.0 and 8.2 and 7.8 and 8.9 minutes respectively) with radiochemical yields of 70, 88 and 82%, respectively, and radiochemical purities of >98%. For 21,

- 50 -

the radiochemical yield was 80%, with a purity of 97% (PRP-1 column, CH₃CN/3,3-dimethylglutarate buffer, 5 mM, pH 7, vol. ratio 6:4).

EXAMPLE 10

Evaluation

5 10a. Partition coefficients

Partition coefficients were measured by mixing each Tc-99m compound with 3 g each of 1-octanol and buffer (pH 7.0 or 7.4, 0.1 M phosphate) in a test tube. The test tube was vortexed for 3 minutes at room temperature, then centrifuged for 5 minutes. Two weighed samples (0.5 g each) from the 1-octanol and buffer layers were
10 counted in a well counter. The partition coefficient was determined by calculating the ratio of cpm/g of octanol to that of buffer. Samples from the octanol layer were repartitioned until consistent partition coefficient values were obtained. The measurement was repeated 3 times.

10b. Biodistribution in rats

15 Male Sprague-Dawley rats (225-300 g) allowed free access to food and water were used for in vivo biodistribution studies. Kung, 1984, *supra*; Kung, 1985, *supra*. While under ether anesthesia, 0.2 mL of a saline solution containing 1.19a, 1.20a or 1.21 (50-100 μ Ci) was injected directly into the femoral vein of rats, and the rats were sacrificed by cardiac excision at various time points post-injection. The organs of
20 interest were removed and weighed, and the radioactivity was counted with an automatic gamma counter (Packard 5000). The percentage dose per organ was calculated by a comparison of the tissue counts to suitably diluted aliquots of the injected material. Total activities of blood and muscle were calculated under the assumption that they were 7% and 40% of the total body weight, respectively.

25 Regional brain distribution in rats was obtained after an injection of 1.19a, 1.20a or 1.21. Samples from different brain regions (cortex, striatum, hippocampus, and cerebellum) were dissected, weighed and counted, and the percentage dose per gram of sample was calculated by comparing the sample counts with the count of the diluted initial dose. The uptake ratio of each region was obtained by dividing the
30 percentage dose per gram of that region by that of the cerebellum. For blocking studies, rats were injected with either β -CIT or haloperidol (iv, 1 mg/Kg) 5 min prior

to injection of 1.19a. The rats were dissected and brain tissue samples were counted as described above. The specific uptake of the compound was expressed as ratio of ST/CB (% dose/g of striatum divided by the same of cerebellum).

10c. SPECT and MRI imaging in a baboon

5 A baboon (~15 kg) was the subject of a SPECT imaging study. Prior to imaging, the animal was fasted, immobilized with ketamine (10-20 mg/kg, i.m.) and xylazine (2-3 mg/kg, i.m.), intubated and maintained on a 1.5-2.0% isofluorane/98.5% oxygen mixture (flow rate of 200-500 cc/min). The animal was injected with glycopyrrolate (10 µg/kg, s.c.), an anticholinergic drug that does not cross the
10 blood-brain barrier, in order to decrease digestive and respiratory secretions. Body temperature was maintained using a hot water circulating heating pad and was monitored with a rectal thermometer. The animal's head was immobilized using a vacuum-packed bean-bag device that hardens upon evacuation when molded around the head. No-carrier-added [^{99m}Tc]TRODAT-1 (1.19a; 9 mCi) was administered as an
15 intravenous bolus in the saphenous vein of the baboon. Immediately after injection, sequential 5 minute per frame dynamic SPECT scans were acquired on a triple-headed Picker Prism 3000 camera (FWHM: 7 mm) equipped with fan beam collimators for 2 hours. The acquisition parameters were a 20% energy window at 140 KeV, 120 projection angles over 360 degrees, a 128 x 128 matrix, and a zoom factor of 1.78 in a
20 slice thickness of 2 mm. The projection data was reconstructed with a count dependent 3-D Wiener filter. Chang's first order correction method was used to compensate for attenuation. Magnetic resonance images (MRI) of the baboon brain were acquired with a 1.5 Tesla machine (GE Medical Systems, Milwaukee, WI). The spoiled GRASS acquisition parameters included a repetition time (TR) of 5 msec and a flip angle of 35
25 degrees, which produced 1 mm thick slices. The data were reinterpolated in 256 x 256 matrices with cubic voxels of 2 mm per side to match the SPECT images. The SPECT images of [^{99m}Tc]TRODAT-1 (1.19a) at 60-90 minutes post-injection were summed and reformatted to match the MRI scans. Both data sets were imported into a locally developed software package for co-registration. The program simultaneously displayed
30 three orthogonal views of either the MRI, the SPECT scans (coronal, transaxial and sagittal views), or the fused images of both sets.

EXAMPLE 11**Experimental For Reaction Schemes Depicted In Figures 1 and 2.**

Syntheses of the 3 β -p-chloro and p-fluorophenyl tropane ester, 1.2a and 1.2b, respectively, were carried out according to the procedure described previously (Meltzer, 1993, *supra*) and the corresponding carboxylic acids 1.3a and 1.3b were made following a literature procedure (Carroll, 1992, *supra*) and are shown in Figure 1. The corresponding acyl chlorides of these carboxylic acids were prepared by the action of oxalyl chloride at room temperature intercepted with amine 1.4 to obtain amide 1.5. Diborane reduction of these amides in THF furnished corresponding tertiary amide 1.6. The removal of the 4-methoxybenzyl groups of protected dithiols compound 1.6 was achieved by treating the substrate with Hg(OAc)₂ in TFA followed by the removal of mercury as its sulfide.

The synthetic strategy employed for the preparation of compound 1.16 is shown in Figure 2. Acyl halide 1.3 was converted to secondary amide 1.11 by reacting it with amine 1.9 in the presence of triethyl amine. Secondary amine 1.13 was prepared by diborane reduction of amide 1.11, and was converted to amide 1.14 by alkylations with alkyl chloride 1.12. The amide functions of compound 1.14 were reduced with LAH to yield compound 1.15. Amine 1.15 and amide 1.14 were deprotected with Hg(OAc)₂ to obtain trifluoroacetate salts of dithiols 1.16 and 1.17. Since the instability of the disulfides 1.7, 1.16 and 1.17 prevented the purification of these dithiols, they were obtained as their triflate salts, and used directly without further characterization for the preparation of rhenium (22) and technetium (1.19a, 1.19b, 1.20a, 1.20b and 1.21) complexes.

The radiolabeling of 1.7, 1.16 and 1.17 with sodium [^{99m}Tc]pertechnetate was successfully achieved by using stannous(II) glucoheptonate as the reducing agent to produce 1.19a, 1.19b, 1.20a, 1.20b and 1.21 in good yield (80%) and radiochemical purity (>95%).

EXAMPLE 12**Evaluation And Results Comparing Compounds Of The Invention Having the N₂S₂ Ligand In The 2 β -Position Of The Tropane Core With Other Compounds And Prior Art Compounds**

5 The novel series of compounds differ from those previously reported in that the substitution of the bis-aminethanethiol ligand is attached at the 2 β -position of the tropane core structure. The corresponding Tc-99m labeled agent displayed a three- to fourfold increase in initial brain uptake (0.1% for N-substituted compound (Meegalla, 1995, *supra*) vs. 0.3-0.4% in brain at 2 min post injection) and concomitantly retained
10 the specific uptake in the striatum area of the brain. This observation suggests that, in this series of compounds, the 3 β -p-fluoro- is slightly less favorable than the corresponding 3 β -p-chlorophenyl derivative. As previously reported for the same series of tropane derivatives, the 3 β -p-fluoro- derivative displayed a lower brain uptake, which may be due to its lower binding affinity to dopamine transporters.
15 Carroll, 1995, *supra*.

12a. Biodistribution comparison

The major criteria for determining the potential usefulness of in vivo dopamine transporter imaging agents are based on an animal biodistribution study. In this case, rats were used as an animal model. After an intravenous injection of the Tc-99m
20 labeled compounds, the values of initial brain uptake (% dose/whole organ) at 2 minutes post intravenous injection are used to measure the ability to penetrate the intact blood-brain barrier. Compounds displaying higher brain uptake are the better agents (minimum requirement > 0.1% dose in brain). The second criteria is the specific uptake in the striatum region of the brain, where dopamine transporters are located.
25 The uptake value (% dose/gram) of the striatum (ST) is divided by the background area, cerebellum (CB; essentially devoid of dopamine transporter); the ratio of ST/CB is an indicator for specific uptake (minimum requirement for ST/CB > 1.5). Five structurally similar tropane derivatives were examined in this biological study. (Tables 1.1 to 1.4). Compounds 1.19a and 1.20c displayed high initial uptake and high
30 specific retention in brain.

- 54 -

12b. Partition coefficients evaluation

One of the key properties for these potential dopamine transporter imaging agents is their neutrality and lipophilicity. The [^{99m}Tc] labeled complexes, 1.19a, 1.20a, 1.20c and 1.21, displayed excellent medium range lipophilicity (partition coefficients between 1-octanol and pH 7.0 buffer of 99-1818). It is noteworthy that, contrary to the lowered lipophilicity commonly observed with the addition of an amide group, complex 1.21, containing an amide functional group, exhibited an almost tenfold higher partition coefficient compared to the corresponding reduced compound, 1.19a.

The lipophilicity, as measured by the partition coefficient (1-octanol/pH 7.0 buffer), displayed very unpredictable values. Most striking is the value for 1.21, which contains an amide inside the chelating ring (partition coefficient = 1818). The partition coefficient value is very important for the evaluation of potential brain imaging agents, because they must be neutral and lipophilic in order to penetrate the intact blood-brain barrier. Generally, the optimal range of partition coefficient values for good brain uptake are between 100-1000.

12c. Brain uptake

Biodistribution studies of 1.19a, 1.20a, 1.20c and 1.21 in rats were performed after an intravenous injection of a tracer dose. The results showed a distribution pattern reflecting regional perfusion (i.e., high uptake in muscle, kidney, liver, brain and skin; Tables 1.1 and 1.2). However, the brain uptake is moderate, ranging from 0.43-0.11% dose/organ at two minutes for the five complexes. The complex containing an amide group, 1.21, showed the lowest brain uptake (Table 1.1) despite its high lipophilicity (P.C. = 1818). Increasing the lipophilicity of these compounds does not appear to improve brain uptake in rats. The most significant finding of this initial biodistribution study is that the brain uptake of these complexes, except 1.21, was highly concentrated in the striatal area, where the dopamine transporters are located, compared to a region with no dopamine neurons (i.e., the cerebellar region); therefore, at 60 minutes after an intravenous injection, the ratios of striatum to cerebellum (ST/CB) were found to be 2.66, 2.18, and 2.82 for 1.19a, 1.20a and 1.20c, respectively. However, complex 21 showed little specific uptake (ST/CB = 1.17) at 60 minutes post intravenous injection. The initial biodistribution study suggested that [^{99m}Tc]TRODAT-1 (1.19a) is a good

imaging agent candidate in this series of complexes. It displayed the highest initial brain uptake, and high retention in the target area (*i.e.*, striatum) at later time points; therefore, a more detailed biodistribution study was carried out. Specific uptake of [^{99m}Tc]TRODAT-1 (1.19a) at different time points displayed a prolonged retention, and the ST/CB ratio reached a maximum value of 4.07 at 4 hours after injection (Table 1.3).

Blocking studies in rats were performed at 60 minutes post-injection to characterize further the uptake and binding, and [^{99m}Tc]TRODAT-1 (1.19a) did indeed show binding to dopamine transporter sites. In this series of regional brain uptake studies in rats, the ST/CB ratio at 60 minutes post-injection was 2.66 (Fig. 1.1). The specific uptake of [^{99m}Tc]TRODAT-1 (1.19a) in rat striatum could be blocked by pretreating rats with a dose of β -CIT (1 mg/kg, iv), a known dopamine transporter ligand. The specific binding, as indicated by ST/CB, was reduced to 1.0 after pretreatment with β -CIT. The specific binding was not reduced by pretreatment with haldol (1 mg/kg, iv), an agent with a mixed pharmacological profile (binding to various CNS receptors but not to the dopamine transporter); no blocking effect was observed. The ST/CB ratio (2.6) was identical to that in control rats (Fig. 5). The results suggested that uptake in the rat striatum was specifically related to the dopamine transporter in rat brain.

To evaluate further the potential of [^{99m}Tc]TRODAT-1 (1.19a) as a dopamine transporter imaging agent, a SPECT imaging study was carried out in a female baboon. To facilitate the identification of anatomical localization, the coronal, transaxial and sagittal SPECT images (1.34 mm thick) obtained 60-90 minutes post injection were coregistered with the MRI images of the same baboon. The fused images displayed excellent consistence with the expected localization of this agent in caudate and putamen areas, where the dopamine transporters are known to be located. The images also showed good correlation with PET imaging agent [¹¹C]CFT and SPECT imaging agent [¹²³I] β -CIT, reported previously. In vitro binding studies of Re complex 1.22 in rat striatal homogenates displayed good binding affinity (K_i = 14 nM, using [¹²⁵I]IPT (Kung, 1995, *supra*) as the ligand; K_d = 0.2 nM, data not shown); while the bis-ethanethiol, 1.16a, displayed a comparable affinity (K_i = 7 nM). However, upon intravenous co-injection of the bis-ethanethiol ligand into rats (200 mg/dose, which is

equivalent to 1 mg/Kg), the specific uptake (Table 1.2) was not blocked by the competing agent, which suggests that the free thiol compound may not be able to penetrate the intact blood-brain barrier and compete with the binding of [^{99m}Tc]TRODAT-1 (1.19a) as a dopamine transporter in the brain. Although the
5 binding affinity of the corresponding Re complex, 1.22, is not as potent as other iodinated tropane derivatives, the brain uptake and retention of [^{99m}Tc]TRODAT-1 (1.19a) appears to be sufficient for in vivo SPECT imaging in nonhuman primates.

The initial brain uptake at 2 minutes after intravenous injection in rat brain is the key indicator for evaluating the compound's penetration of the blood-brain barrier.
10 For compounds with high first pass extraction, the brain uptake values at 2 minutes are in the range of 2-3% dose/whole brain after iv injection in rats. Comparing the four structurally similar compounds (Table 1.4), only 1.19a displayed significant uptake; the other three compounds, 1.21, 1.24 and 1.25, showed at least 300% lower uptake.

This observation is very surprising and not consistent with what one would
15 -predict by their partition coefficient. Based on this novel finding, compounds containing an amide in the N₂S₂ chelating ring system are specifically removed from further development. The prior art, technepine (Madras, 1996, *supra*), used a N₂S₂ chelating ring system containing an amide group (technepine), which provides less favorable biological properties.

20 For dopamine transporter imaging agents, the target area of the brain is the striatum, where dopamine transporters are highly concentrated. The cerebellum region is suitable for use as the background region, because it has no dopamine transporters. The specific uptake is measured by the ratio of % dose/gram of striatum divided by % dose/gram of cerebellum (ST/CB ratio)--the higher the value, the better the specific
25 uptake, and the more promising as a dopamine transporter imaging agent. Again, the data in Table 1.1 shows that ST/CB ratio for 1.19a is the best among this group of compounds. The specific uptake of these agents in rat brain clearly displays the novel finding that, among the structurally similar compounds containing a N₂S₂ chelating group, only 1.19a displays the selective localization in the striatum, where dopamine
30 transporters are located. Single photon emission computed tomography (SPECT) images of the selected and claimed agent displayed a high contrast in the target area (striatum) of a baboon (nonhuman primate) brain. The data clearly demonstrate that the

- 57 -

new technology can be reduced to practice and is potentially useful for human imaging study of dopamine transporter in brain.



Based on the novel findings regarding biodistribution discussed above, the specific chemical compounds (1.19a and 1.20a) not containing amide groups and with
5 an A₂ moiety are particularly useful dopamine transporter imaging agents.

EXAMPLE 13

Evaluation Of Stereoisomeric Compounds

It is possible that tropane derivatives containing a bis-aminoethanethiol group will form stereoisomers, which requires the separation and characterization of these
10 isomers (Table 1.5 a, b, c). Initial evaluation of the stereoisomers suggests that Peak A and Peak B displayed different brain uptake and specific localization in striatum area: Peak A showed higher initial brain uptake (0.5 vs. 0.28% dose/organ, at 2 minutes post-injection for Peak A and Peak B, respectively), but Peak B had a higher ratio (ST/CB 2.72 vs. 3.79 at 60 min post-injection for Peak A and Peak B, respectively).
15 Correlation of dopamine transporter uptake as measured by SPECT imaging and the actual neuronal integrity requires extensive kinetic modeling studies to validate and estimate the potential clinical utility. Optimized imaging protocol and reproducibility of SPECT imaging of this new agent remain to be investigated.

Table 1.1. Brain uptake of six Tc-99m labeled tropane derivatives (% dose/organ)



Compound	2 min	60 min	ST/CB Ratio at 60 min. ^a	P.C. ^b
1.19a. TRODAT-1	0.43 ± 0.16	0.12 ± 0.001	2.66 ± 0.01	227
1.20a	0.37 ± 0.09	0.098 ± 0.014	2.18 ± 0.32	99
1.20c	0.41 ± 0.03	0.18 ± 0.01	2.82 ± 0.19	262
1.21	0.11 ± 0.02	0.07 ± 0.014 ^c	1.17 ± 0.010	1818

^aStriatal/Cerebellum (ST/CB) ratio: % dose per gram of striatum/% dose per gram of cerebellum

^bP.C.: measured between 1-octanol/pH 7.0 phosphate buffer

^cData were from rats sacrificed at 30 minutes

Table 1.2. Biodistribution in rats post intravenous injection of [99mTc]TRODAT-1, 1.19a^a

Organ	2 minutes	60 minutes	60 minutes ^b
Blood	4.94 ± 0.46	2.14 ± 0.17	6.29 ± 1.12
Heart	1.47 ± 0.16	0.19 ± 0.02	0.25 ± 0.05
Muscle	10.84 ± 1.95	10.28 ± 1.36	10.37 ± 0.48
Lung	6.82 ± 0.37	1.86 ± 0.36	1.76 ± 0.12
Kidney	5.13 ± 0.75	3.06 ± 0.14	1.76 ± 0.32
Spleen	0.42 ± 0.16	0.45 ± 0.05	0.51 ± 0.06
Liver	16.62 ± 2.11	17.67 ± 3.42	20.35 ± 0.99
Skin	2.66 ± 0.35	3.96 ± 0.22	4.11 ± 0.29
Brain	0.43 ± 0.16	0.12 ± 0.00	0.12 ± 0.01

Regional Brain Distribution (% does/g)

Region	2 min (ST/CB)	60 min (ST/CB)	60 min ^b (ST/CB)
Cerebellum	0.284 ± 0.066	0.057 ± 0.003 (1.00)	0.059 ± 0.007 (1.00)
Striatum	0.266 ± 0.066	0.151 ± 0.002 (2.66)	0.156 ± 0.018 (2.65)
Hippocampus	0.268 ± 0.090	0.096 ± 0.015 (1.69)	0.104 ± 0.011 (1.77)
Cortex	0.347 ± 0.140	0.094 ± 0.012 (1.65)	0.090 ± 0.009 (1.53)
Remainder	0.269 ± 0.076	0.076 ± 0.005 (1.34)	0.079 ± 0.006 (1.34)

^a % does/organ, average of 3 rats ± SD

^b Biodistribution in rats post iv injection of [99mTc]TRODAT-1 with excess ligand (100 mg/does; % does/organ, average of 3 rats ± SD)





- 60 -

Table 1.3. Biodistribution in rats post intravenous injection of [99mTc]TRODAT-1, 1.19a*

	2 min	30 min	60 min	120 min	240 min	360 min
ST/CB Ratio	0.93 ± 0.23	2.04 ± 0.18	2.66 ± 0.01	3.90 ± 1.33	4.07 ± 0.54	2.97 ± 0.14

- 5 * Striatal/Cerebellum (ST/CB) ratio: % dose per gram of striatum/% dose per gram of cerebellum

Table 1.4 Biodistribution in rats (brain uptake, % dose/organ) after an intravenous injection of [^{99m}Tc]TRODAT-1 and related compounds (% dose/organ, average of 3 rats \pm SD)



Organ	2 min	30 min	ST/CB ratio (30 min)	Partition coefficient
TRODAT-1(1.19a)	0.425 \pm 0.120	0.232 \pm 0.021	2.0	227
(1.21)	0.11 \pm 0.02	0.070 \pm 0.014	1.17	1818
(1.24)	0.028 \pm 0.007	0.022 \pm 0.002	-	1.28
(1.25)	0.040 \pm 0.007	0.013 \pm 0.002	-	1.07

- 62 -

Table 1.5. Biodistribution in rats (brain uptake, % dose/organ) after an intravenous injection of [^{99m}Tc]TRODAT-1 (1.19a) (racemic) and stereoisomers (Peak A and Peak B) (% dose/organ, average of 3 rats \pm SD)

Table 1.5a. Biodistribution in rats after an intravenous injection of peak A (1.19a) (% dose/organ, average of 3 rats \pm SD)

Organ	2 min	60 min
Blood	1.98 \pm 0.19	1.00 \pm 0.15
Heart	1.76 \pm 0.09	0.21 \pm 0.00
Muscle	33.61 \pm 4.31	14.98 \pm 0.49
Lung	9.68 \pm 0.51	3.06 \pm 0.28
Kidney	5.47 \pm 1.04	2.04 \pm 0.21
Spleen	0.27 \pm 0.04	0.46 \pm 0.18
Liver	9.55 \pm 2.19	17.75 \pm 1.81
Skin	2.73 \pm 0.39	3.56 \pm 0.65
Brain	0.50 \pm 0.06	0.21 \pm 0.01

Regional brain distribution (% dose/g)

Region	2 min	60 min	Ratio @ 60 min
Cerebellum	0.289 \pm 0.017	0.086 \pm 0.007	1.00
Striatum	0.318 \pm 0.063	0.235 \pm 0.009	2.72
Hippocampus	0.287 \pm 0.082	0.138 \pm 0.003	1.61
Cortex	0.387 \pm 0.047	0.139 \pm 0.007	1.61
Remainder	0.283 \pm 0.047	0.119 \pm 0.007	1.38

Table 1.5b. Biodistribution in rats after an intravenous injection of peak B (1.19a)
 (% dose/organ, avg. 3 rats \pm SD)

Organ*	2 min	60 min
Blood	4.02 \pm 0.20	1.89 \pm 0.21
Heart	1.28 \pm 0.15	0.19 \pm 0.06
Muscle	41.46 \pm 11.33	8.60 \pm 2.51
Lung	6.00 \pm 1.11	1.23 \pm 0.89
Kidney	4.47 \pm 0.69	1.87 \pm 0.80
Spleen	0.27 \pm 0.03	0.41 \pm 0.24
Liver	9.07 \pm 1.66	18.71 \pm 2.54
Skin	3.43 \pm 0.62	4.11 \pm 0.62
Brain	0.28 \pm 0.01	0.12 \pm 0.02

Regional Brain Distribution (% dose/g)

Region	2 min	60 min	Ratio @ 60 min
Cerebellum	0.167 \pm 0.019	0.047 \pm 0.010	1.00
Striatum	0.155 \pm 0.019	0.177 \pm 0.008	3.79
Hippocampus	0.137 \pm 0.003	0.083 \pm 0.012	1.77
Cortex	0.199 \pm 0.012	0.083 \pm 0.016	1.78
Remainder	0.149 \pm 0.007	0.069 \pm 0.009	1.48

- 64 -

Table 1.5c. Brain uptake in rats after an intravenous injection of the Racemate (1.19a) (% dose/organ, average of 3 rats \pm SD)

Organ	2 min	60 min
Brain	0.43 \pm 0.16	0.12 \pm 0.00

5 Regional brain distribution (% dose/g)

Region	2 min	60 min	Ratio @ 60 min
Cerebellum	0.284 \pm 0.066	0.057 \pm 0.003	1.00
Striatum	0.266 \pm 0.066	0.151 \pm 0.002	2.66
Hippocampus	0.268 \pm 0.090	0.096 \pm 0.015	1.69
Cortex	0.347 \pm 0.140	0.094 \pm 0.012	1.65
Remainder	0.269 \pm 0.076	0.076 \pm 0.005	1.34

General Experimental For Examples 14 To 17

Reagents used in the syntheses were purchased from Aldrich (Milwaukee, WI) or Fluka (Ronkonkoma, NY), and were used without further purification unless otherwise indicated. Anhydrous Na_2SO_4 was used as a drying agent. Reaction yields are reported without attempts at optimization. Thin layer chromatography was performed on EM Science (Gibbstown, NJ) precoated (0.2 mm) silica gel 60 plates, and the spots were detected with iodine vapor and/or UV light. Silica gel 60 (70-230 mesh), obtained from EM Science (Gibbstown, NJ), was used for column chromatography. ^1H NMR spectra were obtained on a Bruker spectrometer (Bruker AC 300). All samples prepared for NMR analysis were dissolved in CDCl_3 , purchased from Aldrich. Chemical shifts are reported as δ values with TMS as the internal reference. Coupling constants are reported in Hz. The multiplicity is defined by s (singlet), t (triplet), td (triplet of doublet), dt (doublet of triplet) and m (multiplet). IR spectra were recorded with a Mattson Polaris FT-IR spectrometer and are reported in cm^{-1} . Melting points were determined on a Meltemp apparatus (Cambridge, MA) and are uncorrected. The compound reference numbers used in the Examples and Tables correspond to the compounds depicted in Figures 8-11.

EXAMPLE 14

Preparation of 2.2

A mixture of nortropane derivative 2.1 (1 g, 3.9 mmol), KI (664 mg, 4 mmol), K_2CO_3 (1.4 g, 10 mmol) and bromopropanol (0.37 mL, 4 mmol) in dioxane (25 mL) was heated at reflux under N_2 for 12 hours. The reaction mixture was allowed to cool to room temperature and then filtered. The filtrate was partitioned between water and CH_2Cl_2 . The CH_2Cl_2 layer was concentrated in vacuo to obtain a viscous oil, which was purified on silica (2% MeOH: CH_2Cl_2 drop of NH_3) to obtain the title compound as a colorless oil. Yield 46%; IR (CHCl_3) 3330, 1739; ^1H NMR 1.45-1.8 (5H, m), 1.95-2.2 (m, 2H), 2.37-2.5 (m, 3H), 2.85-2.89 (m, 1H), 2.98 (td, $J_1 = 5.1$, $J_2 = 12.8$, 1H), 3.45 (s, 3H), 3.57-3.63 (m, 2H), 3.69-3.78 (m, 2H), 7.11 and 7.19 (d, $J = 8.55$, 2H each).

- 66 -

EXAMPLE 15**Preparation of 2.3**

A solution of alcohol, 2.1 (337 mg, 1 mmol) and Et₃N (0.14 mL, 1 mmol) in CH₂Cl₂ was cooled to -10°C under N₂ and MsCl 9 0.07 mL, 1 mmol) was added over
5 5 minutes. The resulting solution was stirred for 20 minutes. and water (10 mL) was added and allowed to warm to room temperature. The CH₂Cl₂ layer was separated and concentrated in vacuo at 25°C to obtain a viscous oil which was dried in vacuo for 30 minutes. The mesylate obtained was dissolved in dry acetone (10 ml) and anhydrous LiBr (108 mg, 1.2 mmol) was added. The resulting mixture was heated at reflux for 5
10 hours under N₂. The reaction mixture was allowed to cool to room temperature and concentrated in vacuo to obtain a viscous oil which was purified on silica (1% MeOH: CH₂Cl₂) to obtain the title compound as a viscous oil. 62%; IR (CHCl₃) 1740; ¹H NMR 1.58-2.15 (m, 7H), 2.38 (t, J=6.18, 2H), 2.55 (dt, J₁=2.88, J₁= 12.36, 1H), 2.7-3.9 (m, 2H), 3.36-3.37 (m, 1H), 3.5-3.68 (m, 6H), 7.16 and 7.23 (d, J=8.7, 2H
15 each).

EXAMPLE 16**Preparation of 2.4**

A solution of bromo compound 2.3 (1.4 g, 3.6 mmol), N,N'-bis-(2-S-4-methoxybenzyl-2-mercapto)ethyl-ethylenediamine (3.3 g, 7.9 mmol), KI
20 (770 mg, 3.6 mmol), K₂CO₃ (1.4 g, 10.1 mmol) in dioxane (50 mL) was heated at reflux for 15 hours. The reaction mixture was allowed to cool to room temperature and filtered. The filtrate was concentrated in vacuo to obtain a viscous oil, which was partitioned in between water and CH₂Cl₂. The CH₂Cl₂ layer was concentrated in vacuo to obtain an oil which was purified on silica (EtOAc: MeOH: NH₄OH; 9: 0.9: 0.1).
25 21%; IR (neat) 1746; ¹H NMR 1.4-1.7 (m, 4H), 2-2.4 (m, 6H), 2.41-2.7 (m, 12H), 2.75 (t, J = 6.8, 2H), 2.85-2.93 (m, 2H), 3.34-3.36 (m, 2H), 3.45 (s, 3H), 3.63-3.69 (m, 5H), 3.77 (s, 6H), 6.82 (d, J = 8.7, 4H), 7.14-7.26 (m, 8H).

EXAMPLE 17**Preparation of 2.7a**

Substrates 2.5a (1 mmol) was dissolved in TFA (7.5 mL) and anisole (0.25 mL) at 0°C and Hg(OAc)₂ (636 mg, 2 mmol) was added. The resulting mixture was stirred for 30 minutes. and concentrated in vacuo to obtain a viscous oil which was dried in vacuo for 30 minutes. Dry ether (10 mL) was then added to the above oil and the resulting suspension was sonicated for 5 minutes. The colorless solid formed was collected by suction filtration and dried in vacuo for 20 minutes and dissolved in absolute EtOH (10 mL). H₂S gas was passed through the solution for 20 minutes and the reaction mixture was filtered through a pad of celite. Filtrate was concentrated in vacuo and redissolved in CH₂Cl₂ (10 mL) and washed with saturated Na₂CO₃ (10 mL). The CH₂Cl₂ layer was concentrated in vacuo to obtain 2.5a as a viscous oil.

Bu₄NReOCl₄ (588 mg, 1 mmol) was dissolved in MeOH (5 mL) under Ar and cooled to 0°C. Dithiol 2.5a (485 mg, 1 mmol) in MeOH (5 mL) was then added followed by Et₃N (0.56 mL, 4 mmol). The resulting solution was stirred at room temperature for 12 hours and concentrated in vacuo. The residue obtained was subjected to preparative TLC (CH₂Cl₂:MeOH:NH₄OH 9:0.9:0.1) to obtain stereoisomeric mixture of 2.5a. 23%; mp mixture 95-110°C (sub.). IR (KBr) 1743, 941; ¹H NMR 2.8-3.2 9 (m), 3.2-3.45 (m), 3.49 and 3.52 (s each), 3.52-3.7 (m), 4-4.25 (m), 7.14 (d, J=8.7), 7.15 (d, J=8.7), 7.34 (m). Radiochemistry was achieved by Figure 9. The corresponding rhenium complex, 2.6, was prepared as surrogate for chemical analysis. Figure 10.

- 68 -

Table 2.1a. Biodistribution in rats after intravenous injection of peak A of (2.6a)
(% dose/organ, avg. of 3 rats \pm SD)

5	Organ	2 min	30 min
	Blood	2.41 \pm 0.33	1.16 \pm 0.06
	Heart	0.79 \pm 0.03	0.22 \pm 0.02
	Muscle	7.78 \pm 0.32	10.41 \pm 1.26
	Lung	15.63 \pm 2.31	9.65 \pm 1.37
	Kidney	2.97 \pm 0.09	1.25 \pm 0.11
	Spleen	0.42 \pm 0.10	0.42 \pm 0.05
10	Liver	14.29 \pm 2.56	20.87 \pm 2.23
	Skin	1.59 \pm 0.68	5.69 \pm 0.73
	Brain	0.25 \pm 0.04	0.13 \pm 0.02

- 69 -

Table 2.1b. Biodistribution in rats after intravenous injection of peak B of (2.6a)
 (% dose/organ, avg. of 3 rats \pm SD) * n = 1

Organ	2 min	30 min
Blood	3.96 \pm 0.70	1.82 \pm 0.43
Heart	0.70 \pm 0.21	0.24 \pm 0.08
Muscle	9.92 \pm 1.04	8.09 \pm 1.686
Lung	19.16 \pm 2.06	12.51 \pm 1.46
Kidney	2.03 \pm 0.45	1.24 \pm 0.18
Spleen	0.42 \pm 0.10	0.67 \pm 0.17
Liver	19.56 \pm 3.21	28.57 \pm 2.94
Skin	1.25 \pm 0.17	3.25 \pm 0.76
Brain	0.19 \pm 0.041	0.094 \pm 0.026

Regional brain distribution (% dose/g)

Region	2 min	30 min	Ratio v. CB
Cerebellum	0.13 \pm 0.01	0.041 \pm 0.009	—
Striatum	0.10 \pm 0.03	0.057 \pm 0.014	1.4
Hippocampus	0.090 \pm 0.01	0.054 \pm 0.012	1.3
Cortex	0.14 \pm 0.03	0.064 \pm 0.016	1.6
Remainder	0.10 \pm 0.02	0.052 \pm 0.015	1.3

- 70 -

Table 2.1c. Brain uptake in rats after intravenous injection of the Racemate of (2.6a) (2.5; % dose/organ, avg. of 3 rats \pm SD)

Organ	2 min	30 min
Brain	0.27 ± 0.02	0.11 ± 0.02

5 **Regional brain distribution (% dose/g)**

Region*	2 min	30 min	Ratio v. CB
Cerebellum	0.161 ± 0.015	0.048 ± 0.004	—
Striatum	0.159 ± 0.025	0.086 ± 0.010	1.8
Hippocampus	0.139 ± 0.016	0.063 ± 0.008	1.4
Cortex	0.183 ± 0.014	0.072 ± 0.003	1.5
Remainder	0.146 ± 0.017	0.062 ± 0.007	1.4

General Experimental For Examples 18 To 28

Reagents used in the syntheses were purchased from Aldrich (Milwaukee, WI) or Fluka (Ronkonkoma, NY), and were used without further purification unless otherwise indicated. Anhydrous Na_2SO_4 was used as a drying agent. Reaction yields are reported without attempts at optimization. Thin layer chromatography was performed on EM Science (Gibbstown, NJ) precoated (0.2 mm) silica gel 60 plates, and the spots were detected with iodine vapor and/or UV light. Column chromatography was performed on silica gel 60 (70-230 mesh) obtained from EM Science (Gibbstown, NJ). The spectra of ^1H and ^{13}C were obtained using a Bruker spectrometer. All samples prepared for NMR analysis were dissolved in CDCl_3 purchased from Aldrich. Chemical shifts are reported as δ values with chloroform or TMS as the internal reference. Coupling constants are reported in Hz. The multiplicity is defined by s (singlet), d (doublet), t (triplet), brs (broad signal), dt (doublet of triplet) and m (multiplet). IR spectra were recorded with a Mattson Polaris FT-IR spectrometer and are reported in cm^{-1} . Melting points were determined on a Meltemp apparatus (Cambridge, MA), and are uncorrected. Elemental analyses were performed by Atlantic Microlabs (Norcross, GA). HRMS was performed by the Nebraska Center for Mass Spectroscopy, University of Nebraska (Lincoln, NE).

Compounds 3.7, 3.8, 3.10 and 3.12 were prepared according to the literature methods. Satisfactory elemental analyses (within 0.4%) could not be obtained for the thiols and dithiols and hence HRMS data for those compounds are reported. The compound reference numbers used in the examples and Tables correspond to the compounds depicted in the reaction schemes.

EXAMPLE 18**25 Preparation of N-[(2-(4'-methoxybenzylthio)-2-methylpropyl)] 2-(4'-methoxybenzylthio)-2-methyl-propionamide (3.3)**

2-(4'-methoxybenzylthio)-2-methylpropionic acid (2.4 g, 10 mmol) and SOCl_2 (7 mL) in CHCl_3 (50 mL) were heated at reflux for 3 hours. The reaction mixture was allowed to cool to room temperature and concentrated *in vacuo*. The resulting oil, 3.1, was dried under a high vacuum, redissolved in CH_2Cl_2 (20 mL) and cooled to -20°C . A solution of 2-(4'-methoxybenzylthio)-2-methylpropanamine, 3.2, and Et_3N (1.7 mL)

- 72 -

in CH₂Cl₂ (20 mL) was then added, and the resulting mixture was stirred at room temperature for 12 hours. Water (50 mL) was added and the product, 3.3, was extracted with CH₂Cl₂ (2 x 25 mL). The CH₂Cl₂ layer was dried (Na₂SO₄) and concentrated *in vacuo* to obtain a viscous oil which was chromatographed on silica (50% EtOAc:hexane) to obtain the title compound, 3, as a waxy solid. Yield 63%; IR (CHCl₃) 1664 cm⁻¹; ¹H NMR (300 Mhz) D 1.33 (s, 12H), 2.56 (s, 2H), 3.69 (s, 4H), 3.76 (s, 6H), 6.80 and 7.25 (D, J = 8.67 Hz, 4H each); HRMS (FAB) m/z 447.1902 calculated for C₂₃H₃₃NO₃S₂, M⁺ +1, 448.1994.

EXAMPLE 19

10 Preparation of N,N-di[(2-(4'-methoxybenzylthio)-2-methylpropyl)] amine (3.4)

BH₃•THF (100 mL, 1M solution in THF) was added to a solution of compound 3.3 (Example 18 compound) (4.4 g, 10 mmol) in THF (100 mL), and the resulting mixture was heated at reflux under N₂ for 12 hours. The reaction mixture was cooled in an ice bath, and water (20 mL) was carefully added. The resulting solution was concentrated *in vacuo* to obtain a viscous oil that was suspended in 6N HCl (50 mL). This mixture was heated at reflux for 1 hour. After the reaction mixture was cooled in an ice bath, it was basified with concentrated NH₄OH, and the product, 3.4, was extracted with CH₂Cl₂ and purified on silica (EtOAc). Yield 63%; m.p: 58-60°C; IR (CHCl₃) 1609 cm⁻¹; ¹H NMR (300 MHz) D 1.35 (s, 12H), 2.59 (s, 4H), 3.71 (s, 4H), 3.78 (s, 6H), 6.81, and 6.24 (D, J = 9.92 Hz, 4H each); HRMS (FAB) m/z 433.2109 calculated for C₂₄H₃₅O₂S₂N, M⁺ +1, 434.2198. Anal. calculated for C₂₄H₃₅O₂S₂N: C 66.51; H 8.06; Found: C 66.12; H 8.62.

EXAMPLE 20

25 Preparation of N,N-di[(2-(4'-methoxybenzylthio)-2-methylpropyl)]-methylamine (3.5)

NaBH₃CN (500 mg, 8 mmol) was added to a solution of 3.4 (Example 19 compound) (2 g, 5 mmol) and methanol (2 mL, 37% aq.) in CH₃CN. The resulting mixture was stirred for 15 minutes, and glacial acetic acid was added dropwise until the solution tested neutral on wet pH papers. The mixture was stirred for 45 minutes and the solvents were removed. 2N KOH (10 mL) was added to the residue, and the

- 73 -

resulting mixture was extracted with ether (3 x 10 mL). The ether extracts were combined, washed with 0.2N KOH (10 mL) then extracted with 1N HCl (2 x 20 mL). The acid extracts were combined, neutralized with solid KOH and re-extracted with ether (3 x 10 mL). Ether layers were combined and concentrated *in vacuo* to obtain a
5 viscous oil, 3.5, which was purified on silica (EtOAc). Yield 73%; oil; IR (CHCl₃) 1604 cm⁻¹; ¹H NMR (300 MHz) D 1.38 (s, 12H), 2.56 (s, 3H), 2.66 (s, 4H), 3.74 (s, 4H), 3.77 (s, 6H), 6.83, and 7.25 (D, J = 8.67 Hz, 4H each); HRMS (FAB) m/z 447.2265 calculated for C₂₅H₃₇O₂S₂N, M⁺ +1, 448.2361.

EXAMPLE 21

10 Preparation of N,N-di[(2-mercapto)-2-methylpropyl]-methylamine (3.6)

Amine 3.5 (Example 20 compound) (2.6 g, 6 mmol) and anisole (1.5 mL) in TFA (45 mL) were cooled to 0°C, and Hg(OAc)₂ (1.91 g, 6 mmol) was added. This mixture was stirred at 0°C for 15 minutes and concentrated *in vacuo* at room temperature. The residue was dried under a high vacuum for 30 minutes and dry ether
15 (50 mL) was added. The resulting solid was collected by suction filtration and redissolved in ethanol (100 mL). Hydrogen sulfide was then bubbled through the ethanol solution for 15 minutes, and the black precipitate that formed was filtered through a thick pad of celite. The filtrate was concentrated *in vacuo* to obtain a colorless oil that was dried under a high vacuum for 30 minutes. 1N HCl (20 mL) and
20 ether (20 mL) were added to the above oil, and the resulting mixture was vigorously stirred for 15 minutes and transferred to a separating funnel. The aqueous layer was separated and basified with concentrated NH₄OH, and the resulting colorless product was extracted with CH₂Cl₂ (20 x 2 mL). The CH₂Cl₂ layer was dried (Na₂SO₄) concentrated *in vacuo* to obtain a viscous oil, 3.6, which was stored under a blanket of
25 argon. Yield 66%; oil; IR (CHCl₃) 1604 cm⁻¹; ¹H NMR (300 MHz) D 1.3 (s, 12H), 2.17 (brs, 2H), 2.5 (s, 3H), 2.63 (s, 4H); HRMS (EI) m/z 207.1115 calculated for C₉H₂₁NS, M⁺ -2, 205.0955.

EXAMPLE 22**Preparation of N,N-di[(2'-mercaptoethyl)]-2-methylpropylamine (3.9)**

Ethylene sulfide (2 g, 22 mmol), isobutyl amine (1.4 mL, 14 mmol) and toluene (5 mL) were heated at 110°C in a sealed tube for 8 hours. Upon cooling, the solution was filtered to remove colorless solid formed during the reaction and the filtrate obtained was concentrated in vacuo. The product, 3.9, was obtained by fractional distillation. Yield 23%; bp 78-80°C (4 Hgmm); IR (neat) 2964, 2799, 2551 cm⁻¹; ¹H NMR (300 MHz) δ 0.82 (d, J = 9 Hz, 6H), 1.64 (brs, 3H), 2.03 (d, J = 9 Hz, 2H), 2.54 (m, 8H); HRMS (EI) m/z calculated for C₈H₁₉NS₂, M+ -.

10 EXAMPLE 23**Preparation of N,N-di[(2-mercaptoethyl)]-2-aminoethyl-4-morpholine (3.11)**

Ethylene sulfide (5 g, 38 mmol), 4-(2-aminoethyl)morpholine (7.6 mL, 76 mmol) and toluene (30 mL) were heated at 110 °C in a sealed tube overnight. Upon cooling, the solution was filtered to remove colorless solid formed during the reaction and the filtrate obtained was concentrated in vacuo. The product was purified by flash column chromatography on silica (5% ethanol/ethyl acetate) to obtain the titled compound, 3.11. ¹H NMR (300 MHz) δ 1.95 (s, 2H), 2.43-2.45 (m, 6H), 2.65-2.75 (m, 10H), 3.68 (m, 4H). Anal. calculated for C₁₀H₂₂OS₂N₂: C 37.15; H 7.48; N 8.66 Found: C 37.42; H 7.33; N 7.29.

20 EXAMPLE 24**General procedure for the preparation of trityl compounds (3.15-3.18)**

Tritylthiol (Ph₃CSH) (1 g, 3.6 mmol) in THF (5 mL) was added over 5 minutes to a pentane washed NaH (60% dispersion, 145 mg, 3.6 mmol) in THF (5 mL) at 0°C, and the resulting mixture was stirred at room temperature for 10 minutes. It was then cooled to 0°C and treated with 1,2-dibromoethane (0.31 mL, 3.6 mmol). After stirring at room temperature for 30 minutes, the reaction mixture was concentrated and partitioned between EtOAc (20 mL) and water (10 mL). The EtOAc layer was dried over Na₂SO₄ and concentrated *in vacuo* to obtain a yellow oil that solidified on standing.

- 75 -

1,4-dioxane (25 mL), Na_2CO_3 (1.15g, 10.8 mmol), NaI (543 mg, 3.6 mmol), and nortropane (3.13 or 3.14) (671 mg, 2.64 mmol) were sequentially added to the bromo compound obtained above (1 g, 3.6 mmol) and the contents were heated at reflux for 18 hours. The reaction mixture was concentrated and partitioned between CH_2Cl_2 (50 mL) and water (20 mL). The CH_2Cl_2 layer was separated, dried over Na_2SO_4 and concentrated *in vacuo* to obtain a brownish yellow oil that was purified by flash chromatography on silica (10% EtOAc:hexane).

a. N-[2'-(triphenylmethylmercapto)ethyl]-3b-(4"-fluorophenyl) tropane-2b-carboxylic acid methyl ester (3.15)

Yield 51%; mp 49-51°C; IR (CHCl_3) 1743 cm^{-1} ; ^1H NMR (300 MHz) d 1.43 (m, 3H), 1.92 (m, 2H), 2.17 (m, 1H), 2.28 (m, 2H), 2.45 and 2.62 (m, each 1H), 2.93 (m, 2H), 3.3 and 3.5 (m, each 1H), 3.43 (s, 3H), 7.3, and 7.5 (m, 19 H); HRMS (FAB) m/z 565.2450 calculated for $\text{C}_{36}\text{H}_{36}\text{O}_2\text{NSF}$, $\text{M}^+ + 1$, 566.2263. Anal. calculated for $\text{C}_{36}\text{H}_{36}\text{O}_2\text{NSF}$: C 76.46; H 6.37. Found: C 76.27; H 6.07.

b. N-[2'-(triphenylmethylmercapto)ethyl]-3b-(4"-chlorophenyl) tropane-2b-carboxylic acid methyl ester (3.16)

Yield (1.2 g) 57.4%; mp 120-122°C; IR (CHCl_3) 1739 cm^{-1} ; ^1H NMR (300 MHz) d 1.47 (m, 3H), 1.92 (m, 2H), 2.17 (m, 1H), 2.28 (m, 2H), 2.45 and 2.62 (m, each 1H), 2.93 (m, 2H), 3.3 and 3.5 (m, each 1H), 3.43 (s, 3H), 7.3, and 7.5 (m, 19H); HRMS (EI) m/z 581.2155 calculated for $\text{C}_{36}\text{H}_{36}\text{O}_2\text{NSCl}$, $\text{M}^+ - \text{Tr}$, 338.0983; FAB 581.2155 calculated for $\text{C}_{36}\text{H}_{36}\text{O}_2\text{NSCl}$, $\text{M}^+ + 1$, 582.2233. Anal. calculated for $\text{C}_{36}\text{H}_{36}\text{O}_2\text{NSCl}$: C 74.35; H 6.19. Found: C 74.01; H 6.53.

c. N-[2'-(Triphenylmethylmercapto)propyl]-3b-(4"-fluorophenyl) tropane-2b-carboxylic acid methyl ester (3.17)

Yield 45.9%; mp 72-74°C; IR (CHCl_3) 1743 cm^{-1} ; ^1H NMR (300 MHz) d 1.5 (m, 5H), 2.12 (m, 6H), 2.55 (dt, $J_1 = 2.88$, $J_2 = 12.27$, 1H), 2.88 (t, $J = 4.2$, 1H), 2.95 (td, $J_1 = 4.83$, $J_2 = 12.27$, 1H) 3.32 and 3.59 (m, each 1H), 3.43 (s, 3H), 6.9-7.4 (m, 19 H); HRMS (FAB) m/z 579.2607 calculated for $\text{C}_{37}\text{H}_{38}\text{O}_2\text{NSF}$, $\text{M}^+ + 1$, 579.2693. Anal. calculated for $\text{C}_{37}\text{H}_{38}\text{O}_2\text{NSF}$: C 76.55, H 6.55. Found: C 76.10; H 6.74.

- 76 -

d. **N-[2'-(Triphenylmethylmercapto)propyl]-3b-(4"-chlorophenyl) tropane-2b-carboxylic acid methyl ester (3.18)**

Yield 41%; a foam; IR (CHCl₃) 1743 cm⁻¹; ¹H NMR (300 MHz) δ 1.5 (m, 5H), 2.12 (m, 6H), 2.55 (dt, J₁ = 2.88, J₂ = 12.27, 1H), 2.88 (t, J = 4.2, 1H),
5 2.95 (td, J₁ = 4.83, J₂ = 12.27, 1H) 3.32 and 3.59 (m, each 1H), 3.43 (s, 3H), 6.9-7.4 (m, 19 H); HRMS (FAB) m/z 595.2311 calculated for C₃₇H₃₈O₂NSCl, M⁺ + 1, 596.2316. Anal. calculated for C₃₇H₃₈O₂NSCl: C 74.62, H 6.38. Found: C 74.23; H 6.74.

EXAMPLE 25

10 **General procedure for the preparation of mercapto compounds (3.19-3.22)**

A trityl compound (3.15-3.18) (1 mmol) was dissolved in CF₃COOH (6.5 mL), and anisole (0.2 mL) at 0°C and Hg(OAc)₂ (382 mg, 1.2 mmol) were added. The resulting mixture was stirred at 0°C for 30 minutes. The reaction mixture was
then concentrated *in vacuo* to obtain a brownish red oil that was dried under high
15 vacuum for 1 hour. Anhydrous ether (50 mL) was added to the above oil, and the mixture was kept under sonication for 15 minutes. The resulting mixture was magnetically stirred for an additional 30 minutes. The colorless precipitate that formed was collected by suction filtration, dried under a high vacuum for 15 minutes and redissolved in ethanol (50 mL). Hydrogen sulfide gas was bubbled through the ethanol
20 solution for 15 minutes, and the black precipitate that formed was filtered through a thick pad of celite. The filtrate was concentrated *in vacuo* to obtain a colorless oil which was dried in a high vacuum for 30 minutes. 1N HCl (20 mL) and ether (20 mL) were added to this oil, and the resulting mixture was vigorously stirred for 15 minutes and transferred to a separating funnel. The aqueous layer was separated and
25 basified with concentrated NH₄OH, and the resulting colorless product was extracted with CH₂Cl₂ (20 x 2 mL). The CH₂Cl₂ layer was dried (Na₂SO₄) concentrated *in vacuo*.

a. **N-[2'-(mercapto)ethyl]-3b-(4"-fluorophenyl)tropane-2b-carboxylic acid methyl ester (3.19)**

30 Yield 68%; MP 46-48°C; IR (CHCl₃) 1743 cm⁻¹; ¹H NMR (300 MHz) δ (m, 3H), 1.92 (m, 2H), 2.17 (m, 1H), 2.28 (m, 2H), 2.45 and 2.62 (m, each 1H), 2.93

- 77 -

(m, 2H), 3.3 and 3.5 (m, each 1H), 3.43 (s, 3H), 7.3 and 7.5 (m, 19 H); HRMS (FAB) m/z 323.1355 calculated for $C_{17}H_{22}O_2NSF$, $M^+ + 1$, 324.1596. Anal. calculated for $C_{17}H_{22}O_2NSF$: C 63.15; H 6.88. Found: C 62.55; H 6.38.

5 b. **N-[2'-(mercapto)ethyl]-3b-(4"-chlorophenyl)tropane-2b-carboxylic acid methyl ester (3.20)**

Yield (263 mg) 77.5%; mp 69-71 °C; IR ($CHCl_3$) 1743 cm^{-1} ; 1H NMR (300 MHz) δ 1.7 (m, 4H), 2.05 (m, 3H), 2.17 (m, 3H), 2.60 (dt, $J_1=2.97$, $J_2=12.39$, 1H), 2.94 (m, 2H), 3.39 and 3.64 (m, each 1H), 3.52 (s, 3H), 7.22 (m, 4 H); HRMS (FAB) m/z 339.1060 calculated for $C_{17}H_{22}O_2NSCl$, $M^+ + 1$, 340.1141. Anal. calculated for $C_{17}H_{22}O_2NSCl$: C 60.17; H 6.48. Found: C 56.72; H 5.83.

10 c. **N-[2'-(mercapto)propyl]-3b-(4"-fluorophenyl)tropane-2b-carboxylic acid methyl ester (3.21)**

Yield 71%; waxy solid; IR ($CHCl_3$) 1741 cm^{-1} ; 1H NMR (300 MHz) δ 1.49 and 2.09 (m, each 6H), 2.53 (dt, $J_1 = 2.88$, $J_2 = 12.27$, 1H), 2.86 (t, $J = 4.2$, 1H), 15 2.95 (td, $J_1 = 4.83$, $J_2 = 12.27$, 1H), 3.32 and 3.59 (m, each 1H), 3.43 (s, 3H), 6.9 and 7.1 (m, each 2H); HRMS (FAB) m/z 337.1512 calculated for $C_{18}H_{24}O_2NSF$, $M^+ + 1$, 338.1579.

20 d. **N-[2'-(mercapto)propyl]-3b-(4"-chlorophenyl)tropane-2b-carboxylic acid methyl ester (3.22)**

Yield 66%; waxy solid; IR ($CHCl_3$) 1741 cm^{-1} ; δ 1.7 (m, 6H), 2.05 (m, 3H), 2.17 (m, 3H), 2.60 (dt, $J_1 = 2.97$, $J_2 = 12.39$, 1H), 2.94 (m, 2H), 3.39 and 3.64 (m, each 1H), 3.52 (s, 3H) and 7.22 (m, 4H); HRMS (FAB) m/z 353.1216 calculated for $C_{18}H_{24}O_2NSCl$, $M^+ + 1$, 354.1211.

EXAMPLE 26

25 **Radiolabeling with [^{99m}Tc] Described For Ligand Mixture 3.20 And 3.7 (3.25)**

A lyophilized sample of a mixture of 3.20 (3 μ mol) and 3.7 (2 μ mol) was dissolved in 200 μ L CH_3CN , and 100 μ L 1N-HCl and 1 mL Sn-glucosheptonate were successively added. [^{99m}Tc]Pertechnetate (1 mL; ranging from 1 to 90 mCi) saline solution was then added. The reaction was allowed to stand at room temperature for 30 30 minutes. After extracting the complex from the aqueous reaction medium with ethyl acetate (2 x 1.5 mL) and drying the organic solution over Na_2SO_4 , ethyl acetate was

- 78 -

removed with a flow of N₂. The residue was dissolved in 200 microlitre ethyl acetate and purified by HPLC on a PRP-1 column (250 x 4.1 mm) with CH₃CN/DMGA buffer (5 mM, pH 7; 8:2) as eluent and a flow rate of 1 mL/minute. The retention time of 3.25 was 16.6 min (radiochemical yield 40%, radiochemical purity > 95%). All the
5 complexes displayed stability at 4 and 24 h after preparation; little change in radiochemical purity was observed. Identical labeling procedures were used for the preparation of the labeled complexes 3.24 to 3.34, with radiochemical yields of 46, 40, 36, 46, 20, 10, 33, 22, 10, 5 and 21%, respectively (radiochemical purities were all > 95%).

10 EXAMPLE 27

Evaluation

27a. Partition coefficients

The partition coefficient was measured by mixing the Tc-99m compound with 3 g each of 1-octanol and buffer (pH 7.0 or 7.4, 0.1 M phosphate) in a test tube. The
15 test tube was vortexed for 3 min at room temperature, then centrifuged for 5 minutes. Two weighed samples (0.5 g each) from the 1-octanol and buffer layers were counted in a well counter. The partition coefficient was determined by calculating the ratio of cpm/g of octanol to that of buffer. Samples from the octanol layer were repartitioned until consistent partition coefficient values were obtained. The measurement was
20 repeated 3 times.

The complexes with gem-dimethyl groups, [^{99m}Tc] 3.26 and 3.27, displayed a much higher partition coefficient than those without, [^{99m}Tc] 3.24 and 3.25. In addition, the partition coefficient of the complex containing the fluorine atom, [^{99m}Tc] 3.24 and 3.26, is always lower than the corresponding complex with the chlorine atom.
25 It is apparent that the partition coefficient of [^{99m}Tc] 3.25 appears to be the best among this series of three plus one Tc complexes.

The lipophilicities of [^{99m}Tc] 10-13 (described in Example 26) were measured by partition between n-octanol and buffer (Table 3.1).

27b. *In vitro* autoradiography

30 Male Sprague-Dawley rats (200-250 mg) were sacrificed by decapitation, and the brains were removed, placed in OTC embedding medium (Miles Laboratory,

- 79 -

Elkhart, IN) frozen in powdered dry ice. After equilibration to -15°C , 20 μm coronal sections were sliced on a cryostat (Hacker Instruments, Fairfield, NJ), thaw mounted onto gelatin-coated slides, desiccated at 4°C for 3 hours and kept at -70°C until use. Prior to the experiment, the slides were dried at room temperature and preincubated for 30 minutes in buffer containing 50 mM Tris-HCl (pH 7.4, 120 mM NaCl). The slides were then incubated for 2 hours in preincubation buffer and the [$^{99\text{m}}\text{Tc}$] compound 3.25 (385,000 cpm/200 μL) in a coplan jar, washed for 1 hour in cold Tris buffer, with one change of buffer, dipped in ice-cold water to remove buffer salts and allowed to dry at room temperature. Nonspecific binding was determined in the presence of 1 μM IPT. These slides were simultaneously exposed to DuPont x-ray film in an autoradiographic cassette for 18 hours. The exposed film was developed with a Kodak automatic film processor.

27c. *In vivo* biodistribution

Male Sprague-Dawley rats (225-300 g) that were allowed free access to food and water were used for *in vivo* biodistribution studies. (Kung, 1984, *supra*; Kung, 1985, *supra*). While under halothane anesthesia, 0.2 mL of a saline solution containing 3.24 to 3.34 (50-100 MCi) was injected directly into the femoral vein of rats, and they were sacrificed by cardiac excision at various time points post-injection. The organs of interest were removed and weighed, and the radioactivity was counted with an automatic gamma counter (Packard 5000). The percentage dose per organ was calculated by a comparison of the tissue counts to suitably diluted aliquots of the injected material. Total activities of blood and muscle were calculated under the assumption that they were 7% and 40% of the total body weight, respectively.

Regional brain distribution in rats was obtained after an injection of 3.24 to 3.34. Samples from different brain regions (cortex, striatum, hippocampus, and cerebellum) were dissected, weighed and counted, and the percentage dose per gram of sample was calculated by comparing the sample counts with the count of the diluted initial dose. The uptake ratio of each region was obtained by dividing the percentage dose per gram of that region by that of the cerebellum. For blocking studies, rats were injected with either β -CIT or haloperidol (iv, 1 mg/Kg) 5 min prior to injection of 3.25. The rats were dissected and brain tissue samples were counted as described above.

- 80 -

The brain uptakes of these complexes appeared to be similar and were all relatively low (0.1% dose/organ or less at 2 minutes post-injection) despite the different lipophilicities measured by partition coefficient between n-octanol and phosphate buffer (Tables 3.1). Slow washout from the brain was observed for all these complexes. Interestingly, only complexes 3.24 and 3.25, without any gem-dimethyl groups, displayed specific uptake in striatum, where dopamine transporters are highly concentrated; striatum to cerebellum ratio (ST/CB) was 1.93 and 2.2 at 30 minutes post-injection for [^{99m}Tc] 3.24 and 3.25, respectively. The cerebellum area, which does not contain dopamine transporters, was used as the background region for comparison.

Biodistribution of a [^{99m}Tc] compound 3.25 at 2, 30, 60, and 120 minutes post intravenous injection indicated that the complex followed the initial blood flow and localized in organs with high blood flow, such as muscle, liver, and kidney. The [^{99m}Tc] complex 3.25 cleared from muscle, while liver accumulation increased with time (Table 2). Accumulation of radioactivity was highest in all brain regions at 2 minutes post intravenous injection and declined gradually over the 120 minute period. The washout was slowest from the striatal region, followed by cortex, and hippocampus. Maximum regional contrast ratio observed for striatum(ST)/cerebellum(CB) was 2.2 and 3.5 at 30 and 60 minutes post-injection, respectively (Table 3). Therefore, additional blocking studies in rats were performed at this time point to further characterize the uptake of this [^{99m}Tc] compound. In this series of regional brain uptake studies in rats, the ST/CB ratio at 60 minutes after injection was 2.6 (Fig. 1). The specific uptake of the [^{99m}Tc] compound 3.25 in striatum could be blocked by pretreating rats with a dose of RTI-55 (N-methyl-2b-carbomethoxy-3b-(4-iodophenyl)tropane) (1 mg/kg, iv), a dopamine transporter ligand (ST/CB = 1.0); but not with haloperidol (1 mg/kg, iv), an agent with a mixed pharmacological profile (binding to various CNS receptors but not to the dopamine transporter); no blocking effect was observed (ST/CB = 2.6; Fig. 1). The results suggested that the uptake in the striatum of rat brain was specifically related to the dopamine transporter.

In vitro autoradiography of rat brain sections incubated with a [^{99m}Tc] compound 3.25 exhibited elevated labeling in striatum, major islands of Calleja and

olfactory tubercle regions, where dopamine neurons are known to be concentrated. See Malison, R. T. *et al. J. Nucl. Med.* 1995, in submission; Mozley, P. D. *et al. J. Nucl. Med.* 1995, in press; Neumeyer, J. L. *et al. J. Med. Chem.* 1994, 37, 1558-1561.

EXAMPLE 28

5 Experimental For Reaction Schemes Depicted in Figures 12-14

The aminobisethanethiol ligand with gem-dimethyl groups, 3.6, was synthesized according to a previously reported procedure (Ohmomo, 1992, *supra*), as shown in Figure 12. The aminobisethanethiol ligand without gem-dimethyl groups, 3.7, was synthesized according to the literature (Kolb, 1994, *supra*). The N-ethyl substituted aminobisethylthiols, 3.8, were prepared according to the procedure
10 employed for the synthesis of 7, using N-ethyl bischloroethyl amine as the starting material. The other N-substituted bisethanethiols, 3.9 to 3.12, were prepared by bis-alkylation of benzyl-, iso-butyl-, morpholinoethyl- and (N,N-bisethylamino)ethyl-amine with ethylene sulfide, respectively. (Corbin, 1984,
15 *supra*).

The syntheses of thiol tropane ligands 3.19 to 3.22 are shown in Scheme 13. Demethylated tropane derivatives 3.13 and 3.14 were prepared from cocaine in 4 steps, as previously reported (Meltzer, 1993, *supra*). N-alkylation was achieved by reacting them with S-trityl protected 2-bromoethanethiol and 3-bromopropanethiol (Dhar, 1994,
20 *supra*), and the resulting alkylated products, 3.15-3.18, were successfully deprotected with Hg(OAc)₂ to produce free thiols 3.19-3.22. Although the bis-alkylation of amines with ethylene sulfide generally produced the expected bis-ethanethiols in poor yields, it provided a very short route for obtaining the required dithiols quickly for the initial studies. No attempts were made to improve the yields of these reactions. The vacuum
25 distillation yielded fairly pure dithiols but further reduced the yields. The dithiols seem to have only moderate stability and tend to produce a white solid, presumably disulfides, over time. However, the monothiols, 3.15-3.18, seem to have fairly good stability when stored at a low temperature under N₂. As is evident from the X-ray crystallographic structure of Re-complex 3.23, none of the reaction conditions
30 employed in preparation of monothiols 3.15-3.18 and the Re complex altered the stereochemistry at the C-2 position of tropane ring.

- 82 -

Labeling with [^{99m}Tc] was carried out by reacting the appropriate ligands in a molar ratio of 1:1.5 (aminobisethanethiol:tropanethiol ligand) with sodium [^{99m}Tc]pertechnetate, in the presence of tin(II) glucoheptonate as a reducing agent at room temperature, with yields of about 40% (Figure 14).

5 Byproducts were labeled complexes in which either the tridentate ligand aminobisethylthiol or the monothiol is complexed to a TcO-core to form neutral binuclear complex $\text{Tc}_2\text{O}_2[\text{RN}(\text{CH}_2\text{CH}_2\text{S})_2]_3$ (Ravert, 1983, *supra*) and ionic complexes (Spies, 1990, *supra*).

The labeled compounds were purified by HPLC and final radiochemical purity
10 of > 95% was obtained. All of the [^{99m}Tc] complexes 3.24-3.34 displayed good in vitro stability. The lipophilicities of 3.24-3.34 were measured by partition between n-octanol and buffer (Table 3.1). The complexes with gem-dimethyl groups, 3.26 and 3.27, displayed a much higher partition coefficient than the analogous complexes, 3.24 and 3.25, without gem-dimethyl groups. In addition, the partition coefficients of the
15 complexes containing the fluorine atom, 3.24, 3.26 and 3.28, are always lower than those of the corresponding complexes with the chlorine atom. In the series of alkyl substituted NS_2 -ligand complexes, 3.25, 3.30 and 3.31, the partition coefficient follows an expected trend; the PC increases with the size of alkyl substituent (the PC's for N-methyl, N-ethyl and N-i-butyl are 307, 369 and 881, respectively). Having a hetero
20 atom in the substitution group at the NS_2 -part (3.33, 3.34) did not follow any general trend in partition coefficient.

Coinjections of Tc-99m and Re-3.23 into HPLC under various elution-conditions appeared to confirm that they have a similar retention time. It is likely that the Tc-99m complexes have the same chemical structures as those of the corresponding
25 Re-complexes. Compounds 3.25 and 3.23 behaved similarly under identical HPLC conditions (coinjection), suggesting that 3.23 is indeed a good surrogate for 3.25. The retention time of 3.25 is similar to that of 3.23; on a C-18 column (Partisil 10-ODS-3, 250 x 4.6 mm) with $\text{MeOH}/\text{NH}_4\text{HCO}_3$ (0.1M, pH 7, ratio 8:2, flow rate 1 mL/min) as the eluent, the retention times were 14.9 and 15.3 min for 3.25 and 3.23, respectively
30 (Fig. 17). On a Chiralpak AD column (250 x 4.6 mm) with hexane/EtOH (1:1, flow rate 1 mL/min) as the eluent, the retention times were 10.4 and 10.9 min for 3.25 and 3.23, respectively. On a PRP-1 column (Hamilton 250 x 4.1 mm) with

- 83 -

CH₃CN/dimethylglutarate buffer (5 mM, pH 7, ratio 9:1, flow rate 1 ml/min) as the eluent, the retention times were 10.2 and 9.8 minutes for 3.25 and 3.23, respectively. Whether the ^{99m}Tc complex has indeed the same chemical structure as Re complex 3.23 (methyl anti to the Re=O) cannot be determined definitively at this point. Under
5 the applied conditions, only one of the two possible isomers (anti or syn) can be detected. If the other isomer is indeed present, the ratio must be > 98:2 and the compounds must behave very similarly.

In vivo biodistribution studies of various Tc-^{99m} labeled complexes, 3.24-3.34, were evaluated in male Sprague-Dawley rats. The brain uptakes of these
10 complexes appeared to be similar and were all relatively low (0.1% dose/organ or less at 2 min post-injection) despite the different lipophilicities measured by partition coefficient between n-octanol and phosphate buffer (Table 3.1). Slow washout from the brain was observed for all these complexes. Interestingly, only complexes without any gem-dimethyl groups displayed specific uptake in striatum, where dopamine
15 transporters are highly concentrated. Furthermore, only complexes with smaller R groups on the NS2-ligand showed any specific brain uptake; striatum to cerebellum ratio (ST/CB) was 1.93, 2.2 and 1.97 at 30 minutes post-injection for 3.24, 3.25 and 3.30, respectively. Increasing the chain length in the tropane thiol ligand from two to three carbons (compounds 3.28 and 3.29) did not change the brain uptake dramatically,
20 but the ST/CB ratio was decreased (1.71 and 1.72, respectively). The cerebellum area, which does not contain dopamine transporters, was used as the background region for comparison.

Biodistribution showed that 3.25 had the highest ST/CB ratio (2.2) after 30 minutes post intravenous injection. Therefore 3.25 was studied further in rats. The
25 study at 2, 30, 60 and 120 min post intravenous injection indicated that the complex followed the initial blood flow and localized in organs with high blood flow, such as muscle, liver and kidney. The Tc-^{99m} complex cleared from muscle, while liver accumulation increased with time (Table 3.2). Accumulation of radioactivity was highest in all brain regions at 2 minutes post intravenous injection and declined
30 gradually over the 120 minute period. The washout was slowest from the striatal region, followed by cortex and hippocampus. Maximum regional contrast ratio observed for striatum/cerebellum (ST/CB) was 3.5 at 60 minutes post-injection (Table

- 84 -

3.3). Therefore, additional blocking studies in rats were performed at 60 minutes post-injection to further characterize the uptake of this Tc-99m compound. In this series of regional brain uptake studies in rats, the ST/CB ratio at 60 min post-injection was 2.6 (Fig. 15). The specific uptake of 3.25 in striatum could be blocked by pretreating rats with a dose of β -CIT (1 mg/kg, iv), a dopamine transporter ligand (ST/CB = 1.0); but not with haldol (1 mg/kg, iv), an agent with a mixed pharmacological profile (binding to various CNS receptors but not to the dopamine transporter); no blocking effect was observed. The ST/CB ratio (2.6) was identical to that in control rats (Fig. 15). The results suggested that uptake in the rat striatum was specifically related to the dopamine transporter. In addition, in vitro autoradiography of a rat brain coronal section incubated with 3.25 clearly demonstrated a regional distribution pattern of intense labeling in caudate putamen and olfactory tubercle, areas known to have a high density of dopamine transporters (Fig. 16).

EXAMPLE 29

15 Comparison Study Of Technetrim And Rhenium Complexes

To further characterize the chemical structure of the technetium complexes, the corresponding ReO(III) complex, Re-3.25, was prepared and characterized (Kung, *J. Amer. Chem. Soc.*, in submission; Meegalla, 1995, *supra*). The non-radioactive rhenium is chemically close to technetium-99, but without the usual hazards associated with the handling of radioactive material. X-ray crystallography of the heterodimeric complex, Re-3.25, displayed an expected structure, with a pyramidal Re=O core and a N-methyl group at the *anti* position to the Re=O functionality. *In vitro* binding studies with rat striatal homogenates displayed excellent binding affinity ($K_i = 0.3$ nM, using [125 I]-IPT as the ligand; $K_d = 0.2$ nM).

25 In vitro binding studies of Re complex 3.23 with rat striatal homogenates displayed excellent binding affinity ($K_i = 0.3$ nM, using [125 I]-IPT as the ligand; $K_d = 0.2$ nM). Kung, 1995, *supra*. The major drawback of this series of agents is that the brain uptake (0.1% dose/organ in rat brain at 2 min post intravenous injection) is too low to be useful for human imaging study. New complexes that produce at least 30 0.5% dose/organ in rat brain must be obtained before any are further developed as dopamine transporter imaging agents. Nevertheless, this series of [99m Tc] mixed ligand

- 85 -

complexes (aminobisethanethiol and monothiol complexed to a TcO^{3+} center core) is the first example of technetium labeled agents displaying specific regional uptake in rat brain that reflects receptor distribution.

Table 3.1. Partition coefficient, brain uptake and striatum/cerebellum ratios of various Tc-99m complexes

Complex	Retention Time(min)/ Partition Coefficient	Brain Uptake (% dose)		Striatum/Cerebellum Ratios (30 min)	
		2 min	30 min		
3.26	17.6'/1800	0.08 ± 0.03	0.05 ± 0.002	1.0	(n=3)
3.24	11.6'/97	0.09 ± 0.01	0.063 ± 0.003	1.93	(n=3)
3.27	27.4'/2000	0.051 ± 0.009	0.046 ± 0.002	1.0	(n=3)
3.25	16.6'/307	0.100 ± 0.068	0.07 ± 0.003	2.2	(n=12)
3.28	14.5'/99	0.082 ± 0.014	0.045 ± 0.008	1.71	(n=3)
3.29	12.5'/125	0.12 ± 0.03	0.063 ± 0.013	1.72	(n=3)
3.30	10.8'/369	0.097 ± 0.003	0.058 ± 0.006	1.97	(n=3)
3.31	14.8'/881	0.080 ± 0.009	0.051 ± 0.006	0.97	(n=3)
3.32	23.6'/146	0.048 ± 0.021	0.046 ± 0.20	0.72	(n=3)
3.33	9.8'/86	0.062 ± 0.008	0.046 ± 0.009	0.47	(n=3)
3.34	14.5'/92	0.11 ± 0.02	0.061 ± 0.011	0.53	(n=6)

15 * Retention times of the complexes were measured by HPLC on a PRP-1 column (250x4.1 mm) eluted with acetonitrile-5 mM dimethylglutaric acid buffer, pH 7 (80:20), flow rate: 1 mL/min.

Retention times of the complexes were measured by HPLC on a PRP-1 column (250x4.1 mm) eluted with acetonitrile-5 mM dimethylglutaric acid buffer, pH 7 (90:10), flow rate: 1 mL/min.

Table 3.2. Biodistribution of 3.25 in rats (intravenous injection; % dose/organ \times standard deviation, n=3-6)

5

10

Organ	2 min	30 min	60 min	120 min
Blood	4.72 \pm 1.37	2.75 \pm 0.62	2.83 \pm 0.42	2.31 \pm 0.27
Heart	1.46 \pm 0.37	0.30 \pm 0.04	0.22 \pm 0.23	0.12 \pm 0.013
Muscle	23.30 \pm 3.82	16.70 \pm 3.62	13.63 \pm 0.99	4.33 \pm 1.20
Lung	6.41 \pm 2.04	2.09 \pm 0.47	1.26 \pm 0.06	0.69 \pm 0.061
Kidney	5.67 \pm 0.94	3.10 \pm 0.68	2.87 \pm 0.43	2.74 \pm 0.096
Spleen	0.36 \pm 0.07	0.61 \pm 0.10	0.50 \pm 0.09	0.58 \pm 0.009
Liver	13.51 \pm 0.36	29.61 \pm 2.22	32.15 \pm 3.00	35.37 \pm 1.52
Skin	2.94 \pm 0.36	4.71 \pm 1.27	4.57 \pm 0.65	2.30 \pm 0.082
Brain	0.10 \pm 0.02	0.06 \pm 0.02	0.046 \pm 0.002	0.025 \pm 0.002

Table 3.3. Regional brain distribution of 3.25 in rat brain (% dose/g)

Region	2 min	30 min	60 min	120 min
Cerebellum	0.066 ± 0.017	0.027 ± 0.006	0.018 ± 0.001	0.011 ± 0.002
Striatum	0.054 ± 0.010	0.060 ± 0.011	0.063 ± 0.001	0.031 ± 0.003
Hippocampus	0.046 ± 0.005	0.028 ± 0.008	0.025 ± 0.003	0.011 ± 0.000
Cortex	0.060 ± 0.009	0.038 ± 0.007	0.026 ± 0.002	0.015 ± 0.003
ST/CB ratio	0.82	2.2	3.5	2.8

- 89 -

EXAMPLE 30**Kit Formulation For Compound 1.19a**

A kit would contain: compound 1.19a (180-250 mg); stannous chloride (100-200 mg); sodium glucoheptonate (200-400 mg); disodium EDTA (300-350 mg); 2.0 N hydrochloric acid (200-250 mL); and ethanol (100-200 mL).

Preparation of compound 1.19a using kit formulation:

Vial A (reaction vial): 200 micrograms 1.19a

Vial B: 2N HCl solution

Vial C: SnCl₂/glucoheptonate, pH 6.7

10 Stannous chloride anhydrous (100 mg/mL)

Sodium glucoheptonate (200 mg/mL)

Vial D: 0.05 mL EDTA

0.1 M Sodium EDTA

Vial E: Sterile sodium phosphates, injection, USP (Abbott, lot 10-288-
15 DK)


One sterilized empty vial and one ethanol (absolute) vial.

Mix 1.95 mL of ethanol with 0.05 mL of 2N HCl in the sterilized empty vial. Add 0.1 mL of the mixture to Vial A and shake well. Add 0.2 mL of the solution from Vial B to Vial A and 1 mL of the solution from Vial C to Vial A. Add 0.05 mL
20 of the solution for Vial D to Vial A. Add Tc-99m solution (0.1-0.5 mL) to Vial A. Place Vial A in the autoclave at 112°C for about 30 minutes. Following autoclaving, cool the reaction vial (A) to room temperature. When the compound is to be used for analysis, draw as much as the solution from vial A with a 5 mL syringe which is
25 radiochemical purity of the residual aliquot in Vial A by TLC.

- 90 -

What is claimed is:



1. A compound of the formula




5 wherein





X is selected from the group consisting of H, C₁-C₄ alkyl, F, Cl, Br, and I;Q is selected from the group consisting of H, C₁-C₄ alkyl, R, A₁, A₂, A₃, A₄, A₅, A₆, A₇, and A₈;

Z is selected from the group consisting of R, CONRR₁, COR₁, CO₂R₁, CO₂R₂,
 10 CO₂A₁, CO₂A₂, CO₂A₃, CO₂A₄, CO₂A₅, CO₂A₆, CO₂A₇, CO₂A₈, COA₁, COA₂, COA₃,
 COA₄, COA₅, COA₆, COA₇, COA₈, CH₂OA₁, CH₂OA₂, CH₂OA₃, CH₂OA₄, CH₂OA₅,
 CH₂OA₆, CH₂OA₇, CH₂OA₈, CH₂NHA₁, CH₂NHA₂, CH₂NHA₃, CH₂NHA₄,
 CH₂NHA₅, CH₂NHA₆, CH₂NHA₇, CH₂NHA₈, A₁, A₂, A₃, A₄, A₅, A₆, A₇, and A₈;


Y is -(CH₂)_n;15 R is H, C₁-C₃ alkyl;R₁ is H, C₁-C₃ alkyl;R₂ is a heterocyclic amine,A₁ isA₂ is

20

A₃ is

A₄ isA₅ isA₆ isA₇ is

5 -

A₈E is C₁-C₂ alkyl;

n is 0, 1, 2, 3, 4, 5;

M is selected from the group consisting of Tc and Re;

10 R₃ is selected from the group consisting of H, CR₄, substituted or unsubstituted C₁-C₃ alkoxy, substituted or unsubstituted C₆-C₂₄ aryl, and substituted or unsubstituted phenylalkoxy; and

R₄ is selected from the group consisting of H and C₁-C₃ alkyl, optionally substituted with a substituted or unsubstituted phenyl group;

15 provided that, one of Q and Z, and only one of Q and Z, includes a moiety selected from the group consisting of A₁, A₂, A₃, A₄, A₅, A₆, A₇, and A₈.

2. The compound of claim 1 wherein said Q moiety is R.

- 92 -

2. The compound of claim 2 wherein R is H or CH₃.
3. The compound of claim 3 wherein Z is A₁, A₂, A₃, or A₄.
4. The compound of claim 3 wherein Z is CH₂OA₁, CH₂OA₂, CH₂OA₃, or CH₂OA₄.
5. The compound of claim 1 wherein said Q moiety includes a compound selected from the group A₁-A₈.
6. The compound of claim 1 wherein said Z moiety includes a compound selected from the group A₁-A₈.
7. The compound of claim 1 wherein X is Cl, F, or Br.
8. The compound of claim 1 wherein Z is CO₂CH₃.
9. The compound of claim 1 wherein X is Cl; Q is CH₃; Z is A₁; and n is 1.
10. The compound of claim 1 wherein X is Br; Q is CH₃; Z is A₁; and n is 1.
11. The compound of claim 1 wherein X is F; Q is CH₃; Z is A₁; and n is 1.
12. The compound of claim 1 wherein X is Cl; Q is CH₃; Z is A₂; n is 1; and M is Tc.
13. The compound of claim 1 wherein X is Br; Q is CH₃; Z is A₂; n is 1; and M is Tc.

- 93 -

14. The compound of claim 1 wherein X is F; Q is CH₃, Z is A₂; n is 1; and M is Tc.
15. The compound of claim 1 wherein X is Cl; Q is CH₃, Z is A₃; and n is 0.
- 5 16. The compound of claim 1 wherein X is Br; Q is CH₃, Z is A₃; and n is 0.
17. The compound of claim 1 wherein X is F; Q is CH₃, Z is A₃; and n is 0.
18. The compound of claim 1 wherein X is Cl; Q is CH₃, Z is A₄; n is 0; and M is Tc.
- 10 19. The compound of claim 1 wherein X is Br; Q is CH₃, Z is A₄; n is 0; and M is Tc.
20. The compound of claim 1 wherein X is F; Q is CH₃, Z is A₄; n is 0; and M is Tc.
- 15 21. The compound of claim 1 where X is C₁-C₄ alkyl, F, Cl, Br, or I; Q is H or C₁-C₄ alkyl; Z is A₁, A₂, A₃, or A₄; R₃ is H; and M is Tc.
22. The compound of claim 1 where X is C₁-C₄ alkyl, F, Cl, Br, or I; R₃ is H; Q is A₁, A₂, A₃, or A₄; Z is CO₂R₁ or CO₂R₂; and M is Tc.
23. The compound of claim 1 where X is Cl; Q is A₁; R₃ is H; and Z is CO₂R₂ or CO₂CH₃.
- 20 24. The compound of claim 1 where X is Br; Q is A₁; R₃ is H; and Z is CO₂R₂ or CO₂CH₃.

- 94 -

25. The compound of claim 1 where X is F; Q is A₁; R₃ is H; and Z is CO₂R₂ or CO₂CH₃.

26. The compound of claim 1 where X is Cl; Q is A₂; Z is CO₂R₂ or CO₂CH₃; and M is Tc.

5 27. The compound of claim 1 where X is Br; Q is A₂; Z is CO₂R₂ or CO₂CH₃; and M is Tc.

28. The compound of claim 1 where X is F; Q is A₂; Z is CO₂R₂ or CO₂CH₃; and M is Tc.

29. The compound of claim 1 where X is Cl; Q is A₃; R₃ is H; and Z is
10 CO₂R₂ or CO₂CH₃.

30. The compound of claim 1 where X is Br; Q is A₃; R₃ is H; and Z is CO₂R₂ or CO₂CH₃.

31. The compound of claim 1 where X is F; Q is A₃; R₃ is H; and Z is CO₂R₂ or CO₂CH₃.

15 32. The compound of claim 1 where X is Cl; Q is A₄; Z is CO₂R₂ or CO₂CH₃; and M is Tc.

33. The compound of claim 1 where X is Br; Q is A₄; Z is CO₂R₂ or CO₂CH₃; and M is Tc.

34. The compound of claim 1 where X is F; Q is A₄; Z is CO₂R₂ or
20 CO₂CH₃;
and M is Tc.

35. The compound of claim 1 where X is C₁-C₄ alkyl, F, Cl, Br, or I; Q is A₇ or A₈; Z is CO₂R₁ or CO₂R₂; and E is C₁-C₂ alkyl.


37. The compound of claim 1 where X is Cl; Q is A₇; Z is CO₂CH₃; E is C₁-C₂ alkyl; and M is Tc.

38. The compound of claim 1 where X is F; Q is A₇; Z is CO₂CH₃; E is C₁-C₂ alkyl; and M is Tc.

39. The compound of claim 1 where X is Br; Q is A₇; Z is CO₂CH₃; E is C₁-C₂ alkyl; and M is Tc.

40. A diagnostic method for monitoring neuronal functions in a mammal comprising:

(a) introducing into a mammal a compound having the formula:



10 -

wherein

X is selected from the group consisting of H, C₁-C₄ alkyl, F, Cl, Br, and I;

Q is selected from the group consisting of H, C₁-C₄ alkyl, R, A₁, A₂, A₃, A₄,

A₅, A₆, A₇, and A₈;

15 Z is selected from the group consisting of R, CONRR₁, COR₁, CO₂R₁, CO₂R₂, CO₂A₁, CO₂A₂, CO₂A₃, CO₂A₄, CO₂A₅, CO₂A₆, CO₂A₇, CO₂A₈, COA₁, COA₂, COA₃, COA₄, COA₅, COA₆, COA₇, COA₈, CH₂OA₁, CH₂OA₂, CH₂OA₃, CH₂OA₄, CH₂OA₅, CH₂OA₆, CH₂OA₇, CH₂OA₈, CH₂NHA₁, CH₂NHA₂, CH₂NHA₃, CH₂NHA₄, CH₂NHA₅, CH₂NHA₆, CH₂NHA₇, CH₂NHA₈, A₁, A₂, A₃, A₄, A₅, A₆, A₇, and A₈;


20 Y is -(CH₂)_n;





R is H, C₁-C₃ alkyl;

R₁ is H, C₁-C₃ alkyl;




R₂ is a heterocyclic amine,

A₁ is



A₂ isA₃ isA₄ isA₅ is

5

A₆ isA₇ isA₈E is C₁-C₂ alkyl;

n is 0, 1, 2, 3, 4, 5;

M is selected from the group consisting of Tc and Re;

10

- 97 -

R_3 is selected from the group consisting of H, CR_4 , substituted or unsubstituted C_1 - C_5 alkoxy, substituted or unsubstituted C_6 - C_{24} aryl, and substituted or unsubstituted phenylalkoxy; and

- R_4 is selected from the group consisting of H and C_1 - C_5 alkyl, optionally substituted with a substituted or unsubstituted phenyl group;

provided that, one of Q and Z, and only one of Q and Z, includes a moiety selected from the group consisting of A_1 , A_2 , A_3 , A_4 , A_5 , A_6 , A_7 , and A_8 .

41. The method of claim 40 wherein said diagnostic imaging is performed using single photon emission computed tomography.

42. The compound of claim 1 dissolved or dispersed in a pharmaceutically acceptable carrier or diluent.

43. A diagnostic kit comprising:

- a) a lyophilized composition comprising a compound of the formula



I

15

wherein

X is selected from the group consisting of H, C_1 - C_4 alkyl, F, Cl, Br, and I;






Q is selected from the group consisting of H, C_1 - C_4 alkyl, R, A_1 , A_2 , A_3 , A_4 , A_5 , A_6 , A_7 , and A_8 ;

- Z is selected from the group consisting of R, $CONRR_1$, COR_1 , CO_2R_1 , CO_2R_2 , CO_2A_1 , CO_2A_2 , CO_2A_3 , CO_2A_4 , CO_2A_5 , CO_2A_6 , CO_2A_7 , CO_2A_8 , COA_1 , COA_2 , COA_3 , COA_4 , COA_5 , COA_6 , COA_7 , COA_8 , CH_2OA_1 , CH_2OA_2 , CH_2OA_3 , CH_2OA_4 , CH_2OA_5 , CH_2OA_6 , CH_2OA_7 , CH_2OA_8 , CH_2NHA_1 , CH_2NHA_2 , CH_2NHA_3 , CH_2NHA_4 , CH_2NHA_5 , CH_2NHA_6 , CH_2NHA_7 , CH_2NHA_8 , A_1 , A_2 , A_3 , A_4 , A_5 , A_6 , A_7 , and A_8 ;



- 98 -

Y is $-(CH_2)_n$;R is H, C_1 - C_3 alkyl; R_1 is H, C_1 - C_3 alkyl; R_2 is a heterocyclic amine,


5

 A_1 is A_2 is A_3 is A_4 is A_5 is

10

 A_6 is A_7 is

- 99 -



E is C₁-C₂ alkyl;

n is 0, 1, 2, 3, 4, 5;

M is selected from the group consisting of Tc and Re;

- 5 R₃ is selected from the group consisting of H, CR₄, substituted or unsubstituted C₁-C₃ alkoxy, substituted or unsubstituted C₆-C₂₄ aryl, and substituted or unsubstituted phenylalkoxy; and

 R₄ is selected from the group consisting of H and C₁-C₃ alkyl, optionally substituted with a substituted or unsubstituted phenyl group;

- 10 provided that, one of Q and Z, and only one of Q and Z, includes a moiety selected from the group consisting of A₁, A₂, A₃, A₄, A₅, A₆, A₇, and A₈; and
 (b) a reducing agent.

44. The kit of claim 43 wherein said reducing agent is selected from the group consisting of stannous glucoheptonate, stannous chloride, stannous mannitol,
 15 sodium bisulfite, and combinations thereof.

45. The kit of claim 43 wherein X is Cl, F, or Br; Q is CH₃, Z is A₁ or A₂; and n is 1.

46. The kit of claim 43 wherein X is Cl, F, or Br; Q is CH₃, Z is A₃ or A₄; and n is 0.

- 20 47. The kit of claim 44 wherein X is Cl, F, or Br; Q is CH₃, Z is A₁ or A₂; and n is 1.

48. The kit of claim 44 wherein X is Cl, F, or Br; Q is CH₃, Z is A₃ or A₄; and n is 0.

- 100 -


49. The kit of claim 43 wherein X is Cl, F, or Br; Q is CH₃, Z is CH₂OA₁, or CH₂OA₂; and n is 1.

50. The kit of claim 43 wherein X is Cl, F, or Br; Q is CH₃, Z is CH₂OA₃, or CH₂OA₄; and n is 0.

51. The kit of claim 44 wherein X is Cl, F, or Br; Q is CH₃, Z is CH₂OA₁, or CH₂OA₂; and n is 1.

52. The kit of claim 44 wherein X is Cl, F, or Br; Q is CH₃, Z is CH₂OA₃, or CH₂OA₄; and n is 0.

53. A compound of the formula



10

wherein

X is selected from the group consisting of H, F, Cl, Br, and I;

Y is selected from the group consisting of R, A₁, A₂, A₃, A₄, and A₅;


Z is selected from the group consisting of H, CO₂R₁, COR₁, CNR₁, CNOR₁,
 15 CO₂A₁, CO₂A₂, CO₂A₃, CO₂A₄, CO₂A₅, COA₁, COA₂, COA₃, COA₄, COA₅, CNA₁,
 CNA₂, CNA₃, CNA₄, CNA₅, CNOR₁A₁, CNOR₁A₂, CNOR₁A₃, CNOR₁A₄, CNOR₁A₅,
 A₁, A₂, A₃, A₄, and A₅;

R is C₁-C₄ alkyl;

R₁ is C₁-C₄ alkyl;


20

A₁ is




R₂ is selected from CH₃ and CH₂CH₃;


A₂ is




A₃ is



A₄ is



A₅ is



5

n is 1, 2, 3, or 4;

M is selected from the group consisting of Tc and Re;

R₃ is selected from the group consisting of H, CR₄, CO₂R₄, CHOR₄, CH₂NHR₄, C(O)NH₄, substituted or unsubstituted C₁-C₃ alkoxy, substituted or unsubstituted C₆-C₂₄ aryl, and substituted or unsubstituted phenylalkoxy; and

10

R₄ is selected from the group consisting of H and C₁-C₃ alkyl, optionally substituted with a substituted or unsubstituted phenyl group;

provided that, one of Y and Z, and only one of Y and Z, includes a moiety selected from the group consisting of A₁, A₂, A₃, A₄, and A₅.

1/22




Fig. 1

2/22




Fig. 2

3/22




Fig. 3

4/22




Fig. 4

5/22




Fig. 5

6/22




Fig. 6

7/22




Fig. 7

8/22




Fig. 8

9/22




Fig. 9




Fig. 10

10/22






Fig. 11


11/22



	R_1	R_2
3.6	CH_3	CH_3
3.7	CH_3	H
3.8	Et	H
3.9	i-Bu	H
3.10		H
3.11		H
3.12		H

Fig. 12

12/22




	X
3.13	F
3.14	Cl




	X	n
3.15	F	2
3.16	Cl	2
3.17	F	3
3.18	Cl	3

	X	n
3.19	F	2
3.20	Cl	2
3.21	F	3
3.22	Cl	3

Fig. 13

13/22



	R_1	R_2
3.6	CH_3	CH_3
3.7	CH_3	H
3.8	Et	H
3.9	i-Bu	H
3.10		H
3.11		H
3.12		H

	X	n
3.19	F	2
3.20	Cl	2
3.21	F	3
3.22	Cl	3




	R_1	R_2	X	n
3.24	CH_3	H	F	2
3.25	CH_3	H	Cl	2
3.26	CH_3	CH_3	F	2
3.27	CH_3	CH_3	Cl	2
3.28	CH_3	H	F	3
3.29	CH_3	H	Cl	3
3.30	Et	H	Cl	2
3.31	i-Bu	H	Cl	2
3.32		H	Cl	2
3.33		H	Cl	2
3.34		H	Cl	2

Fig. 14

14/22




Fig. 15




Fig. 16

15/22




Fig. 17

16/22




Fig. 18

17/22




Fig. 19

18/22




Fig. 20

19/22




Fig. 21




Fig.22

21/22




Fig. 23




Fig. 24

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/16908

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 51/00; A61M 36/14

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both: national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/1.11, 1.56, 1.85; 534/10, 14, 15; 206/223, 569, 570; 546/1, 4, 5, 10, 124, 132

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, MEDLINE, CAPLUS, USPATFULL, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	CLARKE et al. Compounds Affecting the Central Nervous System. 4. 3 β -Phenyltropane-2-carboxylic Esters and Analogs. Journal of Medicinal Chemistry, Vol. 16, No. 11, pages 1260-1267, especially page 1262.	1-3, 7-9, 40-44, 53 ----- 4-6, 10-39, 45-52
X --- Y	CARROLL et al. Cocaine and 3 β -(4'-Substituted phenyl)tropane-2 β -carboxylic Acid Ester and Amide Analogues. New High-Affinity and Selective Compounds for the Dopamine Transporter. J. Med. Chem. 1995, Vol. 38, No. 2, pages 379-388, especially pages 380 and 383.	1-3, 7-9, 40-44, 53 ----- 4-6, 10-39, 45-52

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* "A" document defining the general state of the art which is not considered to be of particular relevance	* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* "E" earlier document published on or after the international filing date	* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reasons (as specified)	* "Z" document member of the same patent family
* "O" document referring to an oral disclosure, use, exhibition or other means	
* "P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search	Date of mailing of the international search report
28 JANUARY 1997	25 FEB 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer

DAMERON L. JONES

Telephone No. (703) 308-1235

22/22




Fig. 25

INTERNATIONAL SEARCH REPORT

 International application No
 PCT/US96/16908

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	OHMOMO et al. New Conformationally Restricted ^{99m}Tc N_2S_2 Complexes as Myocardial Perfusion Imaging Agents. J. Med. Chem., 1992, Vol. 35, No. 1, pages 157-162, especially 157-158.	1-53
X --- Y	MELTZER et al. Substituted 3-Phenyltropane Analogs of Cocaine: Synthesis, Inhibition of Binding at Cocaine Recognition Sites, and Positron Emission Tomography Imaging. J. Med. Chem., 1993, Vol. 36, No. 7, pages 855-862, especially page 856.	1-3, 7-9, 40-44, 53 ----- 4-6, 10-39, 45-52
X --- Y	US 5,380,848 A (KUJAR ET AL) 10 January 1995 (10.01.95), see entire document, especially abstract.	1-3, 7-9, 40-44, 53 ----- 4-6, 10-39, 45-52
X --- Y	US 5,128,118 A (CARROLL ET AL) 07 July 1992 (07.07.92), see entire document, especially column 2, lines 1-20.	1-3, 7-9, 40-44, 53 ----- 4-6, 10-39, 45-52
X --- Y	WO 92/02260 A1 (RESEARCH TRIANGLE INSTITUTE) 20 February 1992 (20.02.92), see entire document, especially pages 2-3.	1-3, 7-9, 40-44, 53 ----- 4-6, 10-39, 45-52
X --- Y	WO 93/09814 A1 (RESEARCH TRIANGLE INSTITUTE) 27 May 1993 (27.05.93), see entire document, especially pages 3 and 4.	1-3, 7-9, 40-44, 53 ----- 4-6, 10-39, 45-52
X --- Y	WO 94/04146 A1 (PRESIDENT AND FELLOWS OF HARVARD COLLEGE) 03 March 1994 (03.03.94), see entire document, especially pages 8-9.	1-3, 7-9, 40-44, 53 ----- 4-6, 10-39, 45-52

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/16908

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/1.11, 1.56, 1.85; 534/10, 14, 15; 206/223, 569, 570; 546/1, 4, 5, 10, 124, 132